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Preterm birth (PTB) is associated with an increased incidence of many neurodevelopmental 
disorders. The mechanisms underlying this association are unclear, but insults associated 
with PTB such as hypoxia, inflammation and stress can affect brain development. In this 
thesis I examine the effects of these insults on the mouse brain at times with 
neurodevelopmental relevance to PTB. 
Mice when born are roughly equivalent in terms of brain development to a human at 24 
weeks of gestation and mature to term equivalence by postnatal day (P) 10. As such, this 
course of postnatal brain development in mice provides an opportunity to study insults 
associated with PTB at timepoints neurodevelopmentally relevant to PTB in humans. 
DNA methylation is crucial to the fine spatial and temporal control of gene expression 
associated with normal brain development. Altered DNA methylation (5-methylcytosine; 
5mC) has been shown in the brains of individuals with autism spectrum disorders, 
schizophrenia and other neurodevelopmental disorders. Additionally, preterm birth is 
associated with altered DNA methylation at several key genes associated with 
neurodevelopment. However, many of these studies cannot distinguish 5mC and 5-
hydroxymethylation (5hmC), which is generated from 5mC by the Ten-eleven translocation 
(TET) enzymes. The TET enzymes are highly susceptible to environmental perturbations and 
are therefore a good candidate for epigenetic dysregulation associated with PTB related 
insults. 
I hypothesised that common PTB-related insults such as inflammation and/or hypoxia would 
affect the expression of the TET enzymes and this would be associated with altered DNA 
hydroxymethylation. To test this hypothesis, I used a forebrain slice culture model and 
showed that hypoxia results in increased expression of the TET enzymes. Previous studies 
have shown that DNA hydroxymethylation accumulates at classic hypoxic response genes 
following hypoxia in the cancer environment. I tested the applicability of this to brain 
development and found significant accumulation of 5hmC in these areas following hypoxia, 
demonstrating the relevance of this mechanism to neonatal hypoxia. 
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Early life stress is also thought to be important in PTB. To test effects of stress on brain 
development, I developed a novel paradigm of early life stress in mice (modified maternal 
separation or MMS). MMS consists of separating a pup from its mother for 1.5 hours/ day 
from P4-P6. During this separation period the pup is moved into a supine position, from 
where it will struggle to return to the prone position and the process is repeated. I 
hypothesised that MMS would affect the transcriptome and DNA methylome in the perinatal 
period and result in altered behaviour in adulthood. Using 3’ mRNA sequencing and DNA 
methylation immunoprecipitation-sequencing I found subtle alterations in gene expression 
and profound alterations in DNA methylation in the hypothalamus immediately following 
MMS. In adulthood, I demonstrated that pups exposed to MMS have a hyperactivity 
phenotype in the elevated plus and open field mazes but do not display hyperactivity under 
habitual conditions. At 4 months of age, there were no changes in candidate gene expression 
in the hypothalamus, but there were changes in the expression of genes associated with 
stress signalling in the hippocampus following MMS. Finally, there were no persistent 
changes in DNA methylation in candidate regions in the hypothalamus. 
I also showed an NFkB signature in the hypothalamic transcriptome following MMS. NFkB 
signalling is classically associated with inflammation, I therefore hypothesised that 
inflammation, induced by LPS, would potentiate subsequent MMS. Using 
immunohistochemistry, I found no difference in specific cell populations in the cortex or 
hippocampus. I then performed 3’ mRNA sequencing to assess the transcriptome wide effect 
of LPS and MMS in the cortex. I showed enrichment of NFkB binding sites among differentially 
expressed genes in MMS but there was no additional effect of prior LPS exposure. Finally, I 
sought to explore whether LPS and/or MMS affected synaptic pruning in the hippocampus, 
however there was no evidence for altered expression of genes associated with synaptic 
pruning. 
In summary, in this thesis I show that LPS, hypoxia and early life stress can affect mouse brain 
development. These results further the knowledge around how insults associated with PTB 





Worldwide approximately 11% of all live births occur before term. When a baby is born 
preterm it is at a much higher risk of atypical brain development. This can include a learning 
disability or a diagnosis of, among others, autism spectrum disorder and schizophrenia in 
later life. The reason for this is not well understood but it is thought that factors such as 
inflammation, hypoxia (or too little oxygen) and stress, which are all common in babies born 
preterm may play a role. One possibility is that these factors could affect the ‘epigenome’ of 
cells within the baby’s brain and this might play a role in the increased risk of atypical brain 
development. The epigenome is the name for a collective of molecular signposts on DNA that 
are involved in deciding which proteins are made and when, in this thesis I focus on an 
epigenetic mark called DNA methylation. During a process as complex as brain development, 
the manufacturing of proteins needs to be very well controlled, and as such, things that affect 
DNA methylation may affect the way the brain develops. As DNA methylation is involved in 
the control of which bits of DNA make proteins, it is extremely diverse between tissues. This 
means that DNA methylation in tissues we can measure in human studies such as blood or 
saliva, have limited relevance to the epigenome of parts of the brain. Therefore, to better 
understand how factors such as inflammation, hypoxia and stress can affect DNA methylation 
of a preterm baby’s brain we need to use models.  
Mice are born with very immature brains in comparison to the human brain of a baby born 
at term. When they are born, mice are at a similar stage of brain development to a human at 
24 weeks of pregnancy and mature to a similar stage of brain development to a full-term 
human baby, by their 10th day of life. This means we can use new-born mice to investigate 
factors associated with preterm birth (PTB) during a time in which similar processes in brain 
development are occurring. 
There are several ways to investigate brain development in mice. One way is a method called 
organotypic slice culture. In this method, slices of brain are cut and kept alive by giving them 
the nutrients they need. This method has the advantage of using fewer mice and being able 
to use more precise conditions, so processes can be measured without other influencing 
factors. I used this system to show that hypoxia results in an increased production of RNA 
(the precursor of protein in the cell) relating to the TET enzymes. These are a group of 
proteins which convert DNA methylation to another epigenetic mark, called DNA 
hydroxymethylation. These two marks have different properties, and this indicates these 
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marks may be important to the hypoxia response within the brain. I also used another model 
in which I isolated two types of cells called oligodendrocyte precursor cells (OPCs) and 
microglia. I kept these cells alive in groups without the presence of other brain cells and 
showed that hypoxia results in a reduced ability of OPCs to produce mature myelinating 
oligodendrocytes, which are important to normal brain function and often affected by PTB. I 
also show that LPS (lipopolysaccharide; used to mimic infection) and hypoxia can make 
microglia produce specific types of proteins which are involved in inflammation. 
There are many mouse models to study stress in early life, but they do not always accurately 
replicate the stress associated with PTB. I developed a new model, which I adapted from a 
commonly used model called maternal separation. In my model, called modified maternal 
separation (MMS), mice on their 4th day of life are repeatedly but gently turned on to their 
back for 1.5 hours on 3 consecutive days. I showed this model is not associated with changes 
in growth or blood glucose levels, which other models of early life stress are associated with. 
I also show MMS is associated with many changes in DNA methylation in the hypothalamus, 
a region of the brain important in the stress response. Next I demonstrated that mice 
exposed to MMS displayed hyperactive behaviour in a new stressful environment as adults 
and that this hyperactivity was not representative of normal hyperactivity during the course 
of a typical day. 
Finally, I tested to see if MMS would be affected by prior administration of LPS. To investigate 
this, I used a technique called 3’ mRNA sequencing, which measures what types of mRNA 
(the type of RNA which will form a template for a protein synthesis) are present. I did this in 
the cortex, a region commonly affected by PTB. However, there was little differences in which 
mRNA was present here when LPS preceded MMS compared to MMS alone. 
In conclusion, in this thesis I present results which contribute to the wider understanding of 
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Preterm birth (PTB) is associated with various adverse neurodevelopmental outcomes, but 
many of the underlying mechanisms are unknown. In this thesis I explore the effect of early 
life insults, which are associated with PTB, on mouse brain development. I examine how 
perinatal hypoxia, inflammation, exogenous glucocorticoids and stress can affect the 
epigenome, as well as various physiological and biochemical processes integral to brain 
development. 
1.1 Epidemiology of PTB 
PTB is clinically defined as birth prior to 37 weeks of gestation 1. In 2010, PTB accounted for 
11.1% of all live births reported worldwide, with complications directly resulting from PTB 
accounting for approximately 1 million deaths per year 2. Seventy five percent of all deaths 
in the perinatal period occur among those born preterm 3, and in 2010 the UK reported infant 
mortality as 1.6 and 24.3 per 1000 live births for term and preterm births respectively 4.  
In recent decades, mortality associated with PTB has decreased with improved neonatal care, 
but with this there has been an increased diagnosis of neurodevelopmental disorders among 
those born preterm 5,6. Neurodevelopmental outcome following PTB has improved since the 
1990’s 7, but PTB remains the single largest early life risk factor for poor long-term 
neurodevelopmental outcome 8–10. PTB is associated with an increased prevalence of 
neurodevelopmental disorders including cerebral palsy (CP) 11, autism spectrum disorders 
(ASD) 12–14 and schizophrenia 15,16. PTB is also predictive of cognitive ability at school age, with 
those born at earlier gestational ages typically receiving lower scores 17.  
Despite the social and economic burdens associated with PTB there is still relatively little 
known about its aetiology. Cervical length is a major risk factor, with near universal screening 
now in place 18. There may also be a genetic component, as the daughters of mothers who 
have given birth preterm are themselves more likely to undergo preterm labour 19.  
Moreover, in a large genome wide association study (GWAS), single nucleotide 
polymorphisms (SNPs) in several genes (Early B-Cell Factor 1, Selenocysteine-specific 
elongation factor, Type-2 angiotensin II receptor and WNT4) have been associated with 
gestational duration 20. Environmental factors such as socio-economic status, stress, 
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smoking, poor diet and drug use have also been implicated in the onset of PTB 21,22. Infection, 
both maternal and intra-uterine, is also strongly associated with the onset of PTB 23,24.  
1.2 PTB and neurodevelopmental disorders 
Neurodevelopmental disorders are those which have origins during early brain development 
and, as mentioned earlier, PTB is associated with an increased risk for many 
neurodevelopmental disorders. In this section I will discuss this with particular attention paid 
to ASD and schizophrenia. 
1.2.1 Autism Spectrum Disorders (ASD) 
ASD diagnoses in England have increased dramatically over the last 50 years 25, likely as a 
consequence of broadening diagnostic criteria and increased clinical awareness. ASDs are 
highly heterogeneous in their aetiology, phenotype and severity. The DSM V criteria for ASD 
reflects this with three levels of severity, and many syndromic and non-syndromic forms have 
been described. ASD can be broadly defined as persistent difficulties in both verbal and non-
verbal social interactions 26,27. There is a higher prevalence of ASD in males 28, with a 
prevalence amongst 8-year old boys and girls in the UK of 3.8 and 0.8 per 1000 respectively 
29.  
Many syndromic forms of ASD are monogenic and inherited in a mendelian fashion 30,31. De 
novo mutations in either the germline or somatic cells during early development also 
contribute to a small proportion of ASD cases 32. There is also clear evidence for a large 
polygenic component to ASD 33,34. 
Environmental factors also play a role in the aetiology of ASD. It has been shown in many 
studies across different populations and ethnicities that PTB is associated with an increased 
prevalence of ASD in offspring 12–14,35–37. Perinatal infection has also been heavily linked to 
ASD 38–41  and in particular maternal influenza infection during pregnancy has been associated 
with an increased ASD in offspring, 42 but it should be noted this has not been replicated in 
other studies 43.  
1.2.2 Schizophrenia 
Schizophrenia is a neurodevelopmental disorder, characterized by positive (e.g. 
hallucinations and delusions) and negative (e.g. avolition and alogia) symptoms which 
typically first occur during late adolescence 44. Schizophrenia has an incidence of 5 per 1000 
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in the general population 45, and there is a marked increase in prevalence amongst those 
born preterm 15,16,46. Similarly to ASD, some studies have suggested a link between early life 
inflammation (particularly maternal influenza) and risk of schizophrenia in later life 40,41,47,48. 
Increased levels of circulating maternal cytokines are also associated with an increased risk 
of schizophrenia in offspring 49,50. Although the mechanisms linking maternal infection with 
the development of schizophrenia in offspring remain unclear, studies suggest a reallocation 
of resources may be involved 51–53. 
Positive associations from genome wide association studies (GWAS) in individuals with 
schizophrenia are enriched for genes associated with astrocytes and oligodendrocytes 54. As 
will be discussed later, oligodendrocytes are particularly vulnerable to PTB related brain 
injury, particularly hypoxia. In term born infants, perinatal hypoxia doubles the risk of 
psychiatric disease 55. Schmidt-Kastner et al showed that 55% of genes associated with 
schizophrenia (through GWAS) have also been linked to hypoxia response mechanisms 56. 
Therefore, neonatal hypoxia is also a plausible mechanism in the aetiology of schizophrenia. 
1.2.3 Encephalopathy of prematurity  
Encephalopathy of prematurity commonly results from PTB, consisting of both white matter 
injury (WMI) and grey matter injury 57. WMI typically occurs in the deep white matter of the 
periventricular area and can result from many clinical factors such as hypoxia/ischemia, 
infection or nutritional deficiencies 58. The degree of WMI is predictive of 
neurodevelopmental outcome 59 and a spectrum of WMI occurs following PTB. This includes 
three principal pathologies: diffuse non-necrotic lesions, focal macroscopic lesions and focal 
microscopic lesions 60. Microscopic lesions have a similar distribution to macroscopic lesions 
suggesting similar underlying mechanisms 60. However, unlike macroscopic and diffuse 
lesions, traditional 3T MRI techniques are unable to identify microscopic necrotic lesions, but 
they can be seen with higher powered 12T imaging 61. Diffuse WMI is the most common form 
of WMI seen in infants born preterm and a significant contributor to this is impaired 
oligodendrocyte maturation 62. 
CP is a neurodevelopmental disorder with characteristic motor symptoms. Periventricular 
leukomalacia (PVL) is a core neuropathological feature 63,64 which consists of focal necrotic 
lesions in the deep white matter combined with more diffuse, less severe lesions 65. It is 
estimated that 2-3.5 per 1000 neonates will develop CP 66 and PTB is a major risk factor. In a 
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large epidemiological study from Norway, with data from almost 1.8 million births of various 
gestational ages over 34 years, there was an 8.5% incidence of CP in those with a gestational 
age at birth of 23-27 weeks, which decreased in an age dependent manner to 0.1% in those 
born at term 11.  
Around 10% of CP cases are thought to be directly associated with fluctuating oxygenation 
at birth 67 and the multiple-hit hypothesis proposes that a number of distinct insults acting in 
synchrony may lead to the development of CP 68. Hypomyelination as a result of 
oligodendrocyte cell death is a core feature of CP. Cells of the oligodendrocyte lineage are 
especially vulnerable to PTB related insults as their maturation coincides with the time in 
which PTB occurs 69 and hypomyelination is also frequently seen in PTB associated brain 
injury without CP 70,71.  
There is extensive neurogenesis during the 3rd trimester 72 and cortical migration of 
GABAergic interneurons occurs until after term equivalent age 73, the routes of which may be 
disrupted by deep white matter injury associated with PTB. 
1.2.4 Common features of neurodevelopmental disorders 
The aetiology of non-syndromic neurodevelopmental disorders is often unknown and there 
is a large symptomatic overlap between disorders, with central diagnostic criteria such as low 
IQ and social difficulties listed for many disorders 74,75. This leads to some diagnostic 
subjectivity and individuals therefore often have multiple diagnoses 76,77. Many 
neurodevelopmental disorders are also associated with common risk factors, as discussed 
earlier PTB and maternal infection are associated with a marked increase of both ASD and 
schizophrenia. There is evidence similar mechanisms may underlie ASD and schizophrenia, 
with mounting evidence for synaptic involvement in both disorders. I will now discuss some 
common features of neurodevelopmental disorders, focusing primarily on ASD and 
schizophrenia. 
1.2.4.1 Synaptic components of neurodevelopmental disorders 
1.2.4.1.1 ASD 
During the early postnatal period there is a rapid increase in the number of synapses within 
the brain, which peaks around 2 years of age. Henceforth, synapse number gradually 
decreases until mid-late adolescence, from which point synapse number remains relatively 
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constant 80. The process of selective glial mediated synaptic loss is termed “synaptic pruning” 
and alterations in this as well as neurogenesis have long been hypothesised to be involved in 
the pathophysiology of many neurodevelopmental disorders 81,82. 
ASD is associated with an increased synapse number in the cortex 83,84 and amygdala 85. 
Cortical transcriptomes from post-mortem tissue of individuals with ASD show strong signs 
of synaptic and microglial alterations 33,86. In individuals with ASD, brain size is slightly below 
average at birth, then significantly increased at 1 year before normalising in adulthood 87. In 
post-mortem tissue from individuals with ASD there is differential DNA methylation at 
several loci associated with synaptic pruning (e.g. C1q, CR3, C3 and tumour necrosis factor 
(TNF)) 88. The Shank family of proteins interact with PSD95 (post-synaptic density protein 95) 
at the synapse 89. Mutations within these proteins are associated with ASD in humans 90 and 
Shank3 haploinsufficiency produces an ASD like phenotype in mice which can be rescued with 
the HDAC (histone deacetylase) inhibitor Romidepsin 91. The post-synaptic proteins 
neuroligin 3 and 4, as well as their presynaptic ligand neurexin 1 have also been linked to ASD 
92.  
1.2.4.1.2 Schizophrenia 
Deficits in synaptic pruning have been hypothesised to underlie schizophrenia for decades 
93,94. In post-mortem tissue from individuals with schizophrenia there is a decreased synaptic 
density in the prefrontal cortex  and hippocampus 95, as well as a decreased abundance of 
synaptic proteins in the hippocampus 96. Microglia induced pluripotent stem cells (iPSCs) 
derived from individuals with schizophrenia also show increased levels of synaptic pruning 
compared to control individuals 97. 
Many genes and physiological processes that are thought to play a role in schizophrenia also 
have roles in synaptic pruning. As mentioned previously, viral infection during pregnancy may 
be associated with an increased incidence of schizophrenia in offspring, and in mouse models 
neonatal, toll-like receptor 3 (TLR3) activation (which models viral infection) reduces spine 
density in a manner dependent on DISC1 (disrupted in schizophrenia 1) 98,99. A variant of the 
C4 gene (part of the complement pathway) confers an increased risk of schizophrenia in 
humans. In mice, C4 is present at the synapse and has an important role in synaptic pruning 
100. C4A expression is increased in the cortex of individuals with schizophrenia and ASD 33. 
CSMD1 (CUB and Sushi multiple domains 1) is an inhibitor of C4 and is highly expressed in 
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the brain 101. A SNP within the CSMD1A gene is associated with schizophrenia and various 
cognitive attributes 102,103. 
1.3 Methods and models to study human brain development following PTB 
Understanding the patterns of human brain development following PTB presents a number 
of problems. First and foremost, the brain is a largely inaccessible organ which precludes the 
use of brain specific biopsies or samples taken during routine clinical practice (with the 
exception of CSF). I will now briefly discuss commonly used methods and models for the 
investigation of human brain development. 
1.3.1 Humans 
Brain development in humans is studied primarily using various non-invasive parameters 
such as epidemiology, behavioural studies and imaging modalities, such as magnetic 
resonance imaging (MRI), magnetic resonance spectroscopy (MRS) and ultrasound. These 
techniques have given crucial insights into typical brain development and how it is affected 
by PTB. However, they alone are unable to provide a full picture of the physiological and 
biochemical response to PTB. This necessitates the use of experimental models such as iPSCs, 
organoids and animal models. 
1.3.2 Animal models 
There are many animal models available to study how PTB and early life adversity affect brain 
development. Simple organisms such as zebrafish are useful to study fundamental, well 
conserved characteristics of brain development as they have short reproduction cycles 
(hatching occurs 3-4 days after fertilisation) and are transparent during the early stages of 
nervous system formation. Rodents are mammals, with short gestational cycles (birth occurs 
~21 days after fertilisation) and many conserved neurodevelopmental processes making 
them an attractive model. Large animal models are also used as they have a higher degree of 
similarity to the human brain but have long gestational cycles (birth occurs ~114 days post-
fertilisation in the pig for instance). 
1.3.2.1 Rodents 
Rodents, particularly mice and rats, are the most commonly used animal to study brain 
development due to genetic tractability, short gestational cycles and the presence of many 
well conserved processes in brain development. Compared to humans, mice are born 
relatively immature in terms of brain development. The bioinformatic mapping of gene 
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expression patterns across both human and mouse development indicates that mice when 
born have roughly equivalent gene expression patterns to a human at about 24 weeks of 
gestation and become comparable to term born humans by postnatal day (P)10 121. As such, 
insults immediately following birth occur at neurodevelopmentally comparable timepoints 
to preterm birth in humans. 
1.3.2.2 Large animals 
Large animal models such as pigs and sheep have longer periods of gestation and higher 
degrees of neural complexity compared to rodents. Due to this long period of gestation and 
the cost associated with their maintenance, large animal models are useful for evidence of 
efficacy before trials in non-human primates (such as a baboon model 122) and humans. For 
instance, an ex utero incubation system has been successfully trialed in preterm sheep 123.  
1.3.3 Primary culture systems 
Primary culture systems are useful as the conditions in which cells grow can be accurately 
controlled with fewer variables than in vivo experimentation. They also allow experiments 
which would be unethical in living animals and as cells from an individual can be used in 
multiple treatment groups, culture systems help to reduce the number of animals used in 
scientific experimentation. However, they fail to account for many complexities of tissue 
resident cells and as such are best used in combination with in vivo experimentation. I will 
now briefly review some common culture models for the study of brain development. 
1.3.3.1 Rodent primary cell culture 
The heterogeneity of cell types in the brain makes it difficult to ascribe physiological function 
or mechanism to specific cell types. Primary cell culture is often used to look at cell type 
specific effects of pharmacological agents and environmental perturbations. In neonatal 
animals, brain tissue can be dissociated and specific cell types extracted using various 
techniques, before culturing. 
Since the specific growth factors and nutrients needed to enable cell growth are often 
unknown, animal serum is commonly used in media for the culture of primary cells. As serum 
content is undefined and variable from batch to batch, this is a central point of variability in 
these systems. Further studies, such as the one by Bohlen et al 124, in which a protocol for the 




1.3.3.2 Rodent Organotypic brain slice culture 
An alternative culture system which retains the complex cytoarchitecture of the brain while 
providing a controlled culture system is organotypic brain slice culture. In this paradigm, the 
brain is isolated from a neonatal animal and cut into 300µm sections, which can then be 
cultured for an extended period on a semi-permeable membrane at the media/air interface. 
This system has been used for high throughput drug screening 125 as well as investigations of 
neurodegeneration 126, myelination/remyelination 127 and electrophysiological activity 128. It 
is however a lower throughput approach than primary culture models (which can be scaled 
for use in 96 or 384 well formats). Therefore, organotypic brain slice culture systems are an 
intermediary between primary cell culture and in vivo experimentation. 
1.3.3.3 Human iPSCs and organoids 
The widespread use of animal models, whilst adding critical information to the field, has not 
resulted in a marked improvement in outcome for infants born preterm. In recent years, 
iPSCs and human organoid models have emerged which provide much translational promise. 
Human cortical organoids can produce electrical patterns similar to those seen in preterm 
infants 129 and work in organoids has already identified the protein unfolding response as a 
promising therapeutic target for neonatal hypoxia 130. However, organoids do not 
recapitulate the entire cellular heterogeneity of the brain and questions remain over the 
reproducibility of these systems. Also, the brain does not develop in isolation and these 
systems cannot account for systemic influences on brain development such as sensory input. 
1.4 Epigenetics  
There is no consensus definition of the term “Epigenetics”, but Adrian Bird’s proposed 
definition of “the structural adaptation of chromosomal regions so as to register, signal or 
perpetuate altered activity states” 131 is a common modern definition. For the purpose of this 
thesis, I will focus on modifications to genomic cytosine (see Figure 1.1), which do not alter 




Figure 1.1 Cytosine can be converted to 5-methylcytosine (5mC) by the DNMT enzymes. This 
mark when present within the promoter regions of a gene is classically associated with 
repression of transcription. Until recently this was thought to be a permanent modification, 
with no known removal mechanism other than passive DNA demethylation (lack of 
maintenance on the de novo strand during DNA replication). However recently the TET 
enzymes were shown to catalyse the hydroxymethylation of 5mC to form 5-
hydroxymethylcytosine (5hmC), and subsequently 5-formylcyosine (5fC) and 5-
carboxylcytosine (5caC). 5fc and 5caC can then be removed and an unmodified cytosine 
replaced through thymine DNA glycosylase (TDG) and the base excision repair (BER) pathway.  
1.4.1 DNA Methylation 
DNA methylation typically occurs at the 5th carbon of cytosine residues when accompanied 
by a guanine residue in the sequence Cytosine phosphate Guanine (CpG) 132, to produce 5-
methylcytosine (5mC). Roughly 10% of these CpG sites genome wide are present in clusters 
called CpG islands (CGI), which are often located in the promoter regions of key 
developmentally regulated genes 132–134. Although CGIs are generally unmethylated, the 
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presence of 5mC in these areas is typically associated with repression of gene transcription 
132. DNA methylation is highly conserved from plants through to mammals and is widely 
viewed as a key mechanism in the fine spatial and temporal control of gene expression during 
development 132. Low levels of 5mC are generally associated with pluripotency, where less 
than 30% of CpGs may be methylated as opposed to terminally differentiated cells where up 
to 85% of CpGs may be methylated 135–137. The enzymes DNA methyltransferase (DNMT) 3A 
and 3B are responsible for de novo DNA methylation 138, while DNMT1 is responsible for the 
maintenance of 5mC on the complimentary strand during DNA replication 139. 
1.4.2 DNA Hydroxymethylation and the Ten-Eleven Translocation Enzymes 
The Ten-Eleven Translocation (TET) enzymes were first proposed to produce 5-
hydroxymethylcytosine (5hmC) from 5mC by Tahiliani et al 140. The three TET proteins (TET1-
3) are part of a large group of α-ketoglutarate dependent dioxygenase enzymes which 
include other epigenetic modifiers such as the jumonji-containing domain histone 
demethylases and the proline hydroxylase (PHD) proteins (involved in the cellular response 
to hypoxia 141). This group of enzymes uses the tricarboxylic acid (TCA) cycle metabolite α-
ketoglutarate and oxygen as essential substrates and Fe2+ as an essential co-factor 22,142. 
TET1 and TET2 have overlapping functions 143, whilst TET3 is important during 
reprogramming within the oocyte 144,145 but is also important at later developmental stages 
within the retina 146. These are the only enzymes which are known to produce 5hmC and its 
subsequent metabolized forms of 5-formylcytosine (5fC) and 5-carboxylocytosine (5caC) 
147,148. 5hmC, 5fC and 5caC are present in the genome at decreasing quantities (with 5hmC 
being the most prevalent). This is due to a conformational change which occurs during the 
act of 5hmC production, resulting in reduced TET affinity for the subsequent derivatives 149. 
1.4.3 Dynamics of DNA Methylation and Hydroxymethylation 
Both 5mC and 5hmC are dynamically present in the brain throughout development in rodents 
and humans 110,163,164 and, as will be discussed later, are altered in many neurodevelopmental 
disorders. A gradual increase in 5hmC is seen at developmentally primed genes through brain 
development, with particular enrichment at Fragile X Mental Retardation Protein (FMRP) 
binding sites 163,165. In mouse embryonic stem cells 5hmC is found both intragenically at sites 
of active transcription genes and at extended promoters of polycomb repressed genes 166. In 
the adult brain 5hmC is present throughout gene bodies at much higher levels than in ESCs 
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and for the most part absent at transcription start sites, where 5hmC is typically enriched in 
ESCs 163.  5mC and 5hmC are present in cell type specific patterns and can be used to predict 
neuronal subtype 167. There is also minimal 5hmC on the X chromosome in both male and 
female rodents and humans 163. 
5mC is a stable modification, meaning it is covalently bound to cytosine and produces distinct 
effects on chromatin architecture and transcription. 5hmC is also associated with distinct 
effects on the genome. However only a few 5hmC binding partners have been characterized 
to date. Spruijt et al 168 demonstrated the ubiquitin like with PHD and ring finger domains 2 
(UHRF2) protein binds and recruits other complexes to 5hmC. Mellen et al showed that 
methyl CpG binding protein 2 (MeCP2) can also bind to 5hmC with high affinity 169.  
1.5 Epigenetics and neurodevelopmental disorders  
Several neurodevelopmental disorders are associated with genetic alterations in epigenetic 
proteins. Rett syndrome is caused by mutations of the DNA methylation reader MeCP2 176; 
ICF (Immunodeficiency, Centromeric region instability, Facial anomalies) syndrome is 
associated with a mutation in the de novo DNA methyltransferase DNMT3b 177 and fragile X 
syndrome is associated with an expanded CGG repeat in the promoter of the FMR1 gene, 
which results in its hypermethylation and subsequent silencing 178. Also, the imprinting 
disorders Angelman syndrome and Prader-Willi syndrome are caused in most cases by 
mutations or deletions within imprinted genes (reviewed by Rangasamy et al. 2013 179). These 
are examples of syndromic neurodevelopmental disorders and, as discussed previously with 
respect to ASD, can be classified by their known aetiology and characteristic symptoms. 
Much of the research on epigenetic alterations in neurodevelopmental disorders focuses on 
these syndromic forms, but as mentioned previously these account for a small percentage of 
overall individuals with a diagnosed neurodevelopmental disorder. In the next section, I will 
discuss the evidence for epigenetic alterations in both in cases of non-syndromic 
neurodevelopmental disorders and following PTB. 
1.5.1 Epigenetic alterations following PTB 
Cruickshank et al examined blood at birth and at 18 years of age, from infants born extremely 
preterm (less than 31 weeks of gestation) and compared DNA methylation profiles to term 
born infants. Differences were found at birth but not at 18 years of age 180. Similar results 
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have been shown in other studies, comparing infants born preterm and at term 181–183. 
However, as discussed earlier, DNA methylation is highly dynamic throughout development. 
As these studies are comparing DNA from infants born at different ages, it is therefore not 
necessarily surprising to see differences. 
To address this,  Sparrow et al analyzed DNA taken from buccal cells of infants born preterm 
at term equivalent age (i.e. 40 weeks from conception) and term born controls. Here, altered 
DNA methylation was seen at several genes with important functions in neural development 
184. However, this differential methylation is not present at largely 1 year of age 185. One of 
the differentially methylated proteins in the Sparrow et al study was soluble light chain 7a5 
(SLC7A5), an amino acid transporter present, among other areas, in endothelial cells and 
therefore at the blood brain barrier (BBB) 184. Tărlungeanu et al demonstrated that SLC7A5 
deletion from endothelial cells results in abnormal behaviours in mice, which were improved 
with intraventricular administration of BCAAs (branched chain amino acids). In this study they 
also identified individuals with ASD who had mutations within the SLC7A5 gene 186. Therefore, 
considering SLC7A5 has been shown to be differentially methylated in infants born preterm 
and to have a role in neurodevelopmental disorders, it is an intriguing candidate for the 
investigation of PTB related brain injury. 
1.5.2 Epigenetic alterations in ASD 
Differential DNA methylation has been identified at many loci in post-mortem tissue of 
individuals with ASD, including in the prefrontal cortex, temporal cortex and cingulate gyrus 
88,187. Key inflammatory mediators, such as TNF have been shown to be both differentially 
methylated and expressed in post-mortem prefrontal cortices of individuals with ASD 88,188. 
Differential DNA methylation in blood 189 and buccal cell 190 derived DNA from monozygotic 
twins discordant for ASD has also been described.  
Differential acetylation genome wide of the H3K27ac histone modification is seen in 
individuals with ASD (when compared to age matched typical developing controls) in the 
prefrontal cortex, temporal cortex and cerebellum of individuals with ASD compared to 
typically developing controls 191. Genes related to synapses and ion channels 188 are 
particularly enriched among those showing differential histone acetylation 188,191,192. In a large 
cohort of Danish children, prenatal exposure to the HDAC inhibitor, Valproate, was shown to 
lead to an increased incidence of ASD in offspring 193. Moreover, mutations in the histone 
13 
 
acetyltransferase CREBBP (CREBP binding protein) are associated with altered 
neurodevelopmentally regulated behaviours 194. 
1.5.3 Epigenetic alterations in schizophrenia 
In post-mortem frontal cortical tissue from individuals with schizophrenia, there are 
widespread changes in DNA methylation, including in the promoter of DNMT1 195. Using an 
unbiased clustering algorithm to analyse the DNA methylome of these individuals, there was 
strong clustering within the schizophrenia and control groups, indicating a specific DNA 
methylation landscape in the brain of individuals with schizophrenia 195. Another study found 
DNMT1 to be overexpressed in layer I GABAergic interneurons of the prefrontal cortex in 
individuals with schizophrenia or bi-polar disorder, which was also associated with 
alterations in DNA methylation at some candidate genes 196. Another study of DNA 
methylation in post-mortem frontal cortical tissue in individuals with schizophrenia and age 
matched controls, showed differential methylation in genes associated with glutamatergic 
and GABAergic signaling 197. Using DNA isolated from blood in 689 individuals with 
schizophrenia, differential methylation has been reported at several genes central to neural 
development 198. Therefore, there is good evidence for deregulation of DNA methylation in 
frontal brain regions and in whole blood of individuals with schizophrenia. 
There is also mounting evidence also for alterations in histone modifications among 
individuals with schizophrenia and I will now briefly summarize some of these findings. In a 
GWAS of individuals with/without schizophrenia Shi et al identified a key chromosomal area, 
in which many histone modifiers and immune regulators are present, which confers an 
increased risk of schizophrenia 199. Histone deacetylase 1 (HDAC1) and HDAC2, which remove 
acetyl marks from histones, have both been implicated in schizophrenia 200,201. Tang et al 
showed alterations in the lifetime trajectory of the histone mark H3K14ac in the prefrontal 
cortex of individuals with schizophrenia 202. There is also evidence for altered histone 
methylation in the frontal cortex of individuals with schizophrenia 203.  
Therefore, there is evidence for epigenetic alterations in individuals born preterm and those 
with diagnosed neurodevelopmental disorders when compared to term born or typically 
developing individuals respectively. It is however unclear whether the changes in these marks 
occurs as a result of pathogenic processes and are therefore not the primary drivers of 
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atypical brain development or whether early life events cause fundamentally altered 
epigenetic trajectories which are causative of atypical neurodevelopment.  
This is further confused by the techniques used in these studies. As outlined previously, 5hmC 
and its subsequent derivatives have only recently been described and traditional bisulphite 
based techniques cannot discriminate between 5mC and its subsequent derivatives. In 
theory, a reduction in 5mC could be accompanied by a concomitant increase in 5hmC 
resulting in no net change when analysed using bisulphite sequencing. More in depth 
evaluation of 5mC/5hmC through the genome is needed in these studies, as has been done 
by Spiers et al 2017 204. 
As discussed previously there is a clear genetic component to neurodevelopmental disorders 
but even the most recent polygenic associations 34 cannot explain all cases, implying a clear 
role for environmental factors such as PTB. Therefore, a major outstanding question is how 
PTB related brain insults (i.e. hypoxia, inflammation, glucocorticoids and early life stress) can 
affect brain development and interact with the genetic component of neurodevelopmental 
disorders to modulate risk increased risk. I will now discuss the insights animal models have 
given into these insults, with reference to human literature. 
1.6 Insults associated with preterm birth 
1.6.1 Hypoxia 
Respiratory distress syndrome (RDS) is a condition associated with very preterm birth in 
which underdeveloped lungs are unable to produce surfactant, so that systemic hypoxia may 
occur with associated brain injury 205–208. There is no consensus as to the appropriate level of 
oxygen to administer infants born preterm and this can lead to fluctuations between hypoxia 
and hyperoxic states 209. In term born neonates, congenital heart disease (CHD) is the most 
common major complication following birth, and is associated with an increased incidence 
of neurodevelopmental disorders 210–212. CHD is also associated with decreased cerebral 
oxygenation 213,214 and impaired cortical development in fetuses 215,216. This implies that 
perinatal hypoxia exposure regardless of gestational age at birth can be a significant 
contributor to atypical neurodevelopment. 
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In mice, prolonging in utero like oxygenation is associated with decreased levels of short and 
long term oxidative stress 217. Hyperoxia in neonatal mice is associated with a decreased 
breathing rate post-hyperoxia 218 and with hypomyelination of the white matter 219.  
1.6.1.1 Hypoxia and the epigenome 
Hypoxia can affect the α-ketoglutarate dependent dioxygenase family of epigenetic 
modifiers in several ways. It can directly alter TET enzyme activity through reduced oxygen 
availability, which as discussed earlier is an essential substrate for their activity . Hypoxia can 
indirectly affect their function through disruption of the TCA cycle and resulting reduced α-
ketoglutarate (which is also an essential substrate for the α-ketoglutarate dependent 
dioxygenases) availability and increased succinate and fumarate levels (which are inhibitors 
of the α-ketoglutarate dependent dioxygenases) 220. Moreover, during hypoxia, α-
ketoglutarate can be metabolized by malate dehydrogenase and lactate dehydrogenase to L-
hydroxyglutarate or D-hydroxyglutarate both of which are also potent inhibitors of the α-
ketoglutarate dependent dioxygenases 221 (see Figure 1.2).  
 
Figure 1.2 Schematic of the TCA cycle outlining irreversible conversions in red and reversible conversions in green. 
During hypoxia the cell quickly enters NAD+ and ATP debt resulting in a flux towards succinate production, which 
can inhibit the α-ketoglutarate dependent dioxygenase enzyme activity. Also, during hypoxia α-ketoglutarate can 
be converted to L-hydroxyglutarate which is a potent inhibitor of the α-ketoglutarate dependent dioxygenases. 
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HIF-1α and HIF-2α are the core hypoxia response unit in the cell 231. The PHD proteins are 
part of the α-ketoglutarate dependent dioxygenase family and as such are sensitive to oxygen 
levels. During normoxia, there is sufficient oxygen present in the cell to catalyze the PHD 
mediated hydroxylation of HIF-1α and HIF-2α, which signals for their ubiquitylation and 
subsequent destruction. During hypoxia there is insufficient oxygen for this to occur and HIF-
1α and HIF-2α accumulate and can dimerize with HIF-1β before nuclear translocation and 
induction of expression of target genes 231–233.  
The TET enzymes are increased in expression following hypoxia across a range of cell types 
and following hypoxia there is an accumulation of 5hmC at classic hypoxia response genes 
153,234. It is, however, unknown whether neonatal hypoxia disrupts 5hmC dynamics in the 
brain during development. 
1.6.2 Inflammation 
Early life inflammation can be primary or secondary and acute or chronic in nature 235 as well 
as of maternal or neonatal origins 236. Chorioamnionitis is a, typically bacterial, infection of 
the chorion, amnion and placenta 237,238 and can occur following premature rupture of 
membranes or systemic maternal infection 238,239. It is a common cause of PTB but even in 
individuals born at term there is a 4-fold increase in risk of CP following chorioamnionitis 240. 
Sepsis is also more common in preterm infants and is associated with adverse outcome, 
which will be discussed next. 
1.6.2.1 Sepsis 
Sepsis is an infection within the sterile structures of the body. Early onset sepsis is that which 
occurs before the third postnatal day and the infection is typically of maternal origin. Late 
onset sepsis occurs after 3 days and typically comes from the environment 241,242. Over 20% 
of very low birth weight (>1500g) infants will develop late onset sepsis, which is associated 
with increased mortality and prolonged hospital stays and there is an inverse correlation with 
gestational age and incidence of late onset sepsis 243.  
The EPIPAGE study of births in France up to 32 weeks of gestation, found no effect of early 
or late onset sepsis on cognitive performance at 5 years of age, but did see an association of 
early life sepsis with a diagnosis of cerebral palsy at 5 years of age 244. An earlier study found 
an association between late onset sepsis and cognitive impairment in babies born before 32 
weeks of gestation, when followed up at 6-9 years old 245. A study examining brain 
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morphology in infants born preterm (median age of 26 weeks gestation) saw increased 
diffusivity in the left frontal lobe and right cingulum bundle at term equivalent age in babies 
with sepsis compared to those without, but no effect was seen with sepsis alone on 
behaviour at 2 years of age 246. Conversely, in a cohort of very preterm infants, culture 
confirmed infection was correlated with neurodevelopmental outcome at 9 years of age, 
whereas in a subset of infants in which sepsis was suspected but not confirmed by culture, 
there was no such correlation 247.  
1.6.2.2 Models of inflammation 
Inflammation induced by infection can be modelled in a number of ways, most of which 
consist of agonists of one or more members of the TLR family. TLR3 and TLR4 are the most 
commonly studied receptors with respect to neonatal infection induced inflammation and 
are stimulated by the agonists lipopolysaccharide (LPS) and Poly I:C respectively. TLR4 is 
localized to the cell membrane, while TLR3 is located in endosomes within the cytoplasm 248. 
LPS is a component of the bacterial cell wall and is commonly used to model bacterial 
infections. Poly I:C is a mimic of double stranded RNA and is commonly used to model viral 
infection. It should be noted that while LPS and poly I:C are used to model bacterial and viral 
infections through TLR4 and TLR3 agonism respectively, other members of the TLR family are 
associated with the inflammatory response to pathogens which are not modelled with LPS 
or poly I:C use alone (see Kawai and Akira, 2010 for a full review 249). 
Neonatal inflammation can also be modelled with the administration of individual cytokines. 
For instance, repeated systemic neonatal administration of IL1β replicates many key features 
of PTB related brain injury including hypomyelination and oligodendrocyte death 250. Using 
this model it has been shown that PSD95 251 and Wnt/β-catenin signaling 252 play a crucial 
role in the microglial response to neonatal inflammation, that neonatal inflammation 
disrupts interneuron development 253 and histamine receptor 3 antagonism may abrogate 
myelination deficits associated with neonatal inflammation 254. 
1.6.2.3 Microglia, inflammation and synaptic pruning 
Under quiescent states, microglia are the predominant immune cell within the brain. 
Following neonatal brain injury systemic immune cells can be recruited into the brain and 
contribute to inflammation 267. In vivo single cell imaging has shown that in mice microglia 
are very long lived cells, with a median life of over 15 months 268. Microglia are present mostly 
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in white matter during early postnatal development before migrating to grey matter regions 
and assuming a more diffuse presence by P14. They also have an ameboid phenotype in the 
early postnatal period compared to the ramified phenotype seen in quiescent adult states 
269. The microglial transcriptome in mice is most comparable to that of humans during early 
life and diverges rapidly with aging, perhaps implying divergent methods of maturation in 
humans and mice 270.  
In 3 month old mice, LPS challenge can alter the long term histone acetylation profile of 
microglia and alter the response to subsequent insults 271. Maternal immune activation (MIA) 
using poly I:C, is associated with a microglial transcriptomic signature which is enriched for 
genes associated with mature microglia 272. This assumption of a more mature phenotype 
associated with early life immune challenge may affect microglial mediated synaptic pruning 
during early development. This has not yet been investigated in a neonatal setting. 
1.7 Early life stress 
A variety of early life stresses, including abuse, neglect or parental mental illness are strongly 
associated with an increased prevalence of a wide range of psychiatric disorders throughout 
life in a variety of ethnicities 280. Exposure to prenatal stress such as maternal depression or 
anxiety is associated with an increased risk of preterm birth 281,282. 
Hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis is common in depression 283 
and early life stress is a major predictor of later life depression 284. Early life stress produces 
a range of HPA related dysfunctions in later life 285. These effects seem to be primarily 
predicted by early life stress and not the sequence of adverse life events which early life 
stress may cause 286.   
1.7.1 The role of the Hypothalamic-Pituitary-Adrenal (HPA) axis and hippocampus 
in stress 
The HPA axis is an integrated system which responds to environmental stress (illustrated in 
Figure 1.3). The HPA axis has various outputs and many functions but the circadian secretion 
of glucocorticoids under basal and stress conditions is one of the most important. 
Glucocorticoids are secreted from the zona fasciculata of the adrenal gland, which is 
stimulated by ACTH. ACTH is formed from its precursor, pro-opiomelanocortin, the 
production of which is stimulated in the anterior pituitary by corticotrophin releasing 
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hormone (CRH) which is released from the paraventricular nucleus of the hypothalamus. The 
ventral  hippocampus through hypothalamic input can mediate this CRH release 287. 
The hippocampus is classically associated with inhibition of the HPA axis, as hippocampal 
stimulation results in decreased glucocorticoid release in adult rats 288,289. Corticosterone has 
a dose-dependent effect on hippocampal plasticity 290 and the licking and grooming 
behaviour of a mother to a pup is associated with the complexity of dendritic branching in 
the CA1 region of the hippocampus in adulthood 291. 
In the hippocampus there is a distinct transcriptional profile associated with different forms 
of stress in adult mice i.e. acute, chronic and recovery 292. Adult mice allowed to recover from 
chronic stress have a distinct transcriptome when compared to stress naïve mice and have 
differential responses to subsequent stress 292. The HPA axis is therefore shaped by previous 
experiences and each individual stressful experience is associated with a distinct response 
and a subsequently distinct baseline. 
1.7.2 Stress associated with PTB 
Very preterm birth often necessitates long stays in the neonatal intensive care unit (NICU), 
which is associated with stressful events such as invasive procedures, excessive lighting, noise 
and sleep disturbances. The circadian secretion of glucocorticoids does not occur until 
approximately 2 months after birth 293 and the nature of the stress response in preterm 
infants in early postnatal life is not fully understood. 
In human studies neonatal stress is difficult to study as traditional biomarkers such as cortisol 
are not yet rhythmic and are highly variable 293 and objective parameters such as the number 
of invasive or painful procedures or time spent in the NICU are invariably confounded by the 
severity of a baby’s clinical condition. Nevertheless, many studies have attempted to control 
for these factors and interpret the effect of postnatal stress on outcome. The Neonatal Infant 
Stressor Scale evaluates exposure to a number of NICU associated stressors 294 and using this 
scale infants with a higher score (indicating a higher level of stress exposure) have anatomical 
differences and altered diffusion parameters on MRI at term equivalent age when compared 
to age matched controls 295. Other studies have shown that stress related to pain in very 
preterm infants was predictive of cortical thickness 296 and cortisol levels 297 at 7 years of age.  
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Surgery in children with CHD is a form of severe early life stress. Morning cortisol levels in 
children (measured at 3-5years) are significantly lower in those who have undergone surgery 
than those with the condition but did not undergo surgery in early life 298. 
1.7.3 Neonatal models of stress 
Due to the difficulty in assessing stress in preterm infants and the lack of mechanistic insight 
available, rodent models are often used. I will now briefly discuss common models of early 
life stress but first I will outline some points of note. 
There are strain specific responses to stress in mice: adult BALB/c mice show a greater HPA 
axis response to stress than C57BL/6J mice 299 but it is unclear if this pertains to the neonatal 
period. There is also moderate evidence to suggest differential behavioural and epigenetic 
responses to maternal separation in C57BL/6J and DBA2J mouse strains 300. Additionally, P1 
to P12 in rodents is associated with a stress-hyporesponsive period (SHRP), as defined by 
reduced glucocorticoid response to several stressors, including maternal separation 301 . This 
is primarily due to decreased adrenal activity in response to ACTH, but the hypothalamus and 
pituitary gland are responsive to stress during this period 302. This may be a mechanism to 
protect the developing brain from high levels of circulating glucocorticoids or to facilitate 
maternal association and bonding before fear learning.  
1.7.3.1 Maternal separation 
Interaction between the mother and infant immediately following birth is very important. 
During this time the neonate is dependent on the mother for food, water, warmth and 
protection but this time is also important in building a maternal-infant bond and preventing 
this interaction is a strong stressor. Therefore, the most used animal model of early life stress 
is maternal separation. 
1.7.3.1.1 Rodents 
In rodents, maternal separation consists of removing the pup from the home cage for 
between 3-8 hours per day from 1-14 days. Maternal separation (3 hours/day from P1-P10 
in mice) is associated with altered corticosterone levels as well as transcriptomic and DNA 
methylation changes in the hypothalamus in adulthood 303. Rat pups subjected to this model 
have shown decreased weight gain and circadian rhythm alterations in adulthood 304. Rat 
pups separated from their mother for 24 hours at P3 show a hyper-responsive HPA axis in 
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adulthood, whereas 24 hours of maternal separation on P7 results in a hypo-responsive HPA 
axis in adult animals 305. 
There are however conflicting results using rodent maternal separation models with respect 
to key adult behavioural phenotypes306,307. Whilst genetic differences between inbred 
colonies and strains as well as inter-unit differences may offer an explanation for this, there 
is also evidence that in repeated daily maternal separation models, an increase in maternal 
care upon returning pups to the dam may offset some effects of the paradigm 308. 
Additionally, pups at this age are dependent on their mother for food and water and 
therefore in cases of prolonged maternal separation, findings may be due to nutritional 
deficiencies, most importantly glucose. Indeed, blood glucose is significantly lower in pups 
following maternal separation than in control animals 309 and neonatal hypoglycaemia is 
independently associated with adverse neurodevelopmental outcome 310. It has also been 
suggested that maternal separation paradigm more accurately models maternal neglect, 
rather than stress caused by preterm birth and a NICU setting 307. 
1.7.3.1.2 Non-human primates 
In non-human primates, infants may be removed from their mothers if they show behaviour 
which will harm the infant. This may result in human hand rearing or peer-rearing in which 
the infant is fostered onto a proven mother. In Rhesus monkeys, maternal separation for the 
first month of life and peer raising for the rest of childhood results in abnormal social 
behaviours throughout life, lower basal cortisol and a delayed response to acute stressors 
311. Rhesus monkeys have also shown alterations in circadian locomotor behaviours, which 
can be modulated with melatonin administration (via drinking water) following peer-rearing 
312. In pigtailed monkeys, 10 days of maternal separation is associated with changes in the 
circadian alteration of heart rate and body temperature 313.  
1.7.3.2 Limited bedding and nesting material model 
Another model of early life stress is the limited bedding and nesting model, which as the 
name suggests comprises of greatly reducing the amount of bedding and nesting material in 
the home cage. This induces maternal stress and results in fragmented maternal care, as such 
this most accurately models maternal neglect. A variation of this is introducing a wire mesh 
to the floor of the cage which works in a similar manner. This is typically carried out from P2-
P9, and is a chronic, unrelenting form of stress (as opposed to the intermittent stress 
22 
 
associated with repeated maternal separation). Unlike maternal separation models, under 
this model neonatal animals are exposed to sensory stimuli such as ultrasonic vocalisations, 
social interaction with peers and thermal regulation, which are important in early life 314,315. 
In rats 316,317 and mice 318,319 this model is associated with elevated basal corticosterone levels 
in pups, altered social and depressive like behaviours and enhanced amygdala activity. 
Similar to maternal separation studies, this model has produced conflicting results with some 
studies suggesting offspring exposed to this model have depressive like symptoms in 
adulthood, while other studies do not see this effect 307,320.  
1.7.3.3 Other models 
One of the earliest paradigms used to induce neonatal stress was daily handling of pups for 
15 minutes 321 which produces acute HPA axis responses in the neonatal period 322 and in 
adult animals 323. Chronic unpredictable stress exposure to a mother is also used. This consists 
of combinations of stressors which may include intruder mice, introduction of scents, 
decreased bedding or nesting material or restraint stress administered at unpredictable 
intervals. The offspring of dams subjected to chronic unpredictable stress display altered 
wheel running activity as adults 324. In rats, neonatal exposure to a stressed dam for 30 
minutes/day for the first 7 days of life results in alterations in DNA methylation at both 
neonatal and adult stages 325–327. A similar model has also shown impairments in adult 
hippocampal neurogenesis as well as various behavioural alterations 328. Corticosterone 
administered maternally via drinking water has been used to look at the effects of elevated 
maternal corticosterone on murine pups. This results in alterations in the immune response 
in the neonatal period 329. Other models include combinations of maternal separation, 
hypoxia/hyperoxia and cold exposure 330 and maternal deprivation, in which animals are 
removed from their mother’s care for 24 hours 331. 
Overall these models have produced compelling evidence to suggest that early life stress is 
associated with alterations in brain development and alterations in adult behaviours. The 
variable results reported between studies and the relevance to human early life stress, 
particularly stress associated with the NICU, remains a concern. As noted earlier, the variable 
results may be due many reasons. There is significant variation with respect to the length of 
exposure and protocols used in maternal separation paradigms. The models outlined here 
also lack an active component, i.e. the animals are placed in a novel stressful environment, 
but they are not forced to engage with this environment. For instance, during maternal 
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separation paradigms this could manifest as higher levels of sleep in some pups compared to 
others which could result in a variable level of stress exposure. These models also do not 
accurately recapitulate stress associated with the NICU, which is associated with sleep 
deprivation, excessive lighting and so on. 
 
Figure 1.3 The HPA axis is shown, along with the machinery for the regulation of circadian rhythms. The 
superchiasmatic nucleus (SCN) of the hypothalamus receives input from light stimuli via the retino-
hypothalamic tract. This acts via a hierarchy of clocks to synchronize clocks through the body to the 
natural day/night cycle. The SCN is at the top of this hierarchy, and through paracrine and neuronal 
signaling, synchronizes circadian oscillation of central and peripheral clocks including that of the 
adrenal gland, which secretes glucocorticoids in circadian fashion. Glucocorticoids act to synchronize 
clocks throughout the periphery through a glucocorticoid receptor mediated mechanism. 
1.7.3.4 Stress and epigenetic alterations 
A lot of work in this area has focused on DNA methylation at the GR (encoded by the gene 
NR3C1), which was stimulated by the controversial findings of differential methylation in the 
promoter region resulting from different levels of maternal lick/grooming behaviour in rats 
332. In humans, maternal separation has been associated with increased methylation in the 
1-F promoter region of NR3C1 in preterm infants with at least 4 days’ maternal separation 
333. Maternal stress can also increase methylation of the NR3C1 gene in the offspring 334, with 
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the level of methylation correlated to the subjective level of stress. A neuronal specific 
promoter of the NR3C1 gene has previously been shown to be differentially methylated in 
post-mortem hippocampal tissue from suicide victims with a history of child abuse when 
compared to suicide victims without a history of child abuse 335. However, these results 
remain controversial, The GR is universally expressed and as such the promoter region is 
typically completely unmethylated. The changes described at the NR3C1 promoter are 
typically very small and perhaps not physiologically relevant. 
However, stress has been convincingly shown to affect DNA methylation at several other loci 
following early life stress. For instance, maternal anxiety levels have also been correlated 
with DNA methylation alterations at various sites throughout the genome in cord blood of 
the new born infant 336. In prepubertal girls, early life stress is associated with differential 
methylation at many loci in saliva derived DNA 337.  Early life stress has also been associated 
with alterations in DNA methylation in adulthood at the FKBP5 (FK506 binding protein) locus 
338,339, which is important in glucocorticoid signaling as I will discuss later.  
Maternal separation in neonatal mice has been shown to alter DNA methylation within the 
hypothalamic paraventricular nucleus at the arginine vasopressin  (AVP) 303 and NR3C1 340 
loci. There is evidence this could be caused by neuronal activity through upregulation of 
calmodulin-dependent protein kinase II and MeCP2 303. The polycomb repressor complex and 
the TET proteins also interact with the AVP locus prior to changes in DNA methylation 
associated with maternal separation 341. However, the exact mechanism behind stress 
mediated alterations in DNA methylation remain unknown. 
1.7.4 Glucocorticoid signaling 
1.7.4.1 Glucocorticoid receptor (GR) 
The GR is a member of the nuclear receptor family of transcription factors and is near 
ubiquitously expressed in the brain. The GR is present in the cytoplasm but upon ligand 
binding it homodimerizes (heterodimerisation is also possible and will be discussed later) and 
translocates to the nucleus to induce cell and context specific transcriptional alterations 
through binding to glucocorticoid response elements (GREs) 344 (illustrated in Figure 1.4). The 
primary endogenous ligand for the GR is cortisol in humans and corticosterone in rodents. 
The GR also has high affinity for synthetic glucocorticoids such as Betamethasone and 
Dexamethasone, to which preterm infants are commonly exposed.  
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In ligand free conditions, the GR is bound to several chaperone proteins in the cytoplasm 
including HSP70 and HSP90 345. The sensitivity of the GR to ligands is dependent on many co-
chaperone molecules, including FKBP51 and FKBP52 (encoded by the genes FKBP5 and FKBP4 
respectively) 346. FKBP51 inhibits and FKBP52 promotes nuclear translocation of the GR 
through interaction with dynein 347. The GR is also controlled through phosphorylation at 
various residues 348. 
1.7.4.2 Mineralocorticoid receptor (MR) 
Aldosterone is the primary physiological ligand for the MR and has crucial roles in the kidney 
and Renin-Angiotensin system. However, aldosterone does not cross the BBB in large 
amounts and is present only at low quantities in some parts of the brain 349. Therefore, 
cortisol or corticosterone in humans or rodents respectively, are the primary occupants of 
the MR in the brain.  
The MR has a high affinity for glucocorticoids and as such, the receptor remains fully bound 
even during the nadir in glucocorticoid diurnal expression. In comparison, during this same 
period only about 10% of the GR remains bound to corticosterone 350. The MR and GR share 
a large amount of homology in their DNA binding domains, however the MR is only expressed 
in subsets of neurons in the brain, such as the hippocampus and amygdala 351. 
There is high MR expression in the hippocampus and as the MR is constitutively occupied by 
GC under non-stress conditions its expression governs the baseline stress response in the 
hippocampus 352,353. During ligand free conditions the MR is predominantly located in the 
cytoplasm but maintains some nuclear localisation 354. In the cytoplasm it is bound to similar 
chaperone proteins as the GR, which aid in its nuclear translocation upon ligand binding 355. 
The MR binds DNA either as a homodimer or a heterodimer with the GR 356 and GR/MR 
heterodimers have an important role in stress mediated GR regulation of gene expression in 
the hippocampus following stress in adult rodents 357. Several SNPs within the MR locus are 




Figure 1.4 Outline of classic glucocorticoid (GC) signalling through GR. Under ligand free conditions, as seen in 1) 
the GR is bound by chaperone proteins such as FKBP5 and HSP90 (among others) which prevent its nuclear 
localisation. In 2) glucocorticoids enter the cell and displace the chaperone proteins and result in receptor 
dimerization (homodimerization is shown here but as mentioned heterodimerisation with the MR is also possible) 
which enables nuclear translocation. In 3) the induction of target gene expression is shown by the GR in response 
to ligand binding. 
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1.7.4.3 FKBP51 and FKBP52 
FKBP51 is a cytosolic protein which acts as chaperone molecule and scaffolding protein360. It 
acts to oppose the function of FKBP52, its most closely related relative, with respect to 
nuclear translocation of the GR via interactions with dynein 361. Both FKBP51 and FKBP52 
have enzymatic subunits but little is known about the function of these domains 346 and it is 
their scaffolding function which has garnered most research interest.  
Polymorphisms associated with the FKBP5 gene are associated with an increased recurrence 
of depressive episodes in depressed individuals suggesting an important role in 
neuropsychiatric disorders 367. Early life stress in humans is associated with differential DNA 
methylation at glucocorticoid response elements at the FKBP5 locus 368. Alterations in FKBP5 
expression have also been reported in individuals with ASD 369, schizophrenia 370, ADHD 371 
and anxiety disorders 372. In mice, chronic exposure to corticosterone reduces DNA 
methylation at the FKBP5 locus which correlates with increased expression 373.  
1.7.4.4 Synthetic glucocorticoid exposure 
Synthetic glucocorticoids have been routinely administered to pregnant females at risk of 
delivering prematurely for decades 377–379, as they readily diffuse across the placenta 380 and 
act to accelerate fetal organ maturation and improve outcome without adverse maternal 
side-effects 381. However, in cases of extreme preterm birth and severe bronchopulmonary 
dysplasia, glucocorticoids may be administered postnatally, which has been associated with 
improved neonatal outcome 382 but also an increased risk of cerebral palsy in some instances 
383. 
1.7.4.5 Glucocorticoid signaling through membrane receptors 
Studies in amphibians were the first to demonstrate that glucocorticoids could bind to 
membrane receptors 384. Corticosterone can, within seconds of administration, inhibit ATP 
mediated currents in cultured rat neurons. This is maintained when corticosterone is 
conjugated to bovine serum albumin, which cannot cross the cell membrane 385. These 
effects may be mediated by membrane bound GR or MR, but MR knockout mice do not show 
increased glutamate release in response to corticosterone in the hippocampus 386 and a 
similar effect has been described for GR in the amygdala 387. However, both the GR and MR 
lack transmembrane domains and it is unclear how they associate with the membrane.  
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Membrane mediated glucocorticoid signalling has also been described in the rat 
hypothalamus, which is not affected by GR or MR inhibition. In hypothalamic slices, both 
Dexamethasone and corticosterone produce a rapid inhibition of glutamatergic signalling, an 
effect which is blocked with CBR1 (cannabinoid receptor 1) inhibition. This implies the 
immediate effects of glucocorticoids on excitatory signalling is mediated by retrograde 
endocannabinoid release in the paraventricular nucleus (PVN) of the hypothalamus 388. 
Endocannabinoids are also released in response to electrical activity in the rat hypothalamus 
389 which may indicate CBR1 activation functions as an endogenous brake for neuronal 
activity in the hypothalamus. However, further research is needed to fully clarify these 
interactions. 
Glucocorticoids have also been shown to interact with various protein kinases to mediate 
rapid non-transcriptional effects 390,391. However, the primary mechanism of these effects is 
still unknown. 
1.7.4.6 Interaction between stress and inflammation 
As discussed previously, early life stress has been widely implicated in anxiety related 
outcomes later in life, but it is also closely associated with inflammation throughout the life 
course. In the Dunedin Multidisciplinary Health and Development Study, early life stress 
predicted plasma C-reactive protein (CRP; general inflammation marker) and fibrinogen level 
as well as white blood cell count at 32 years of age 392. Similar results were found in a British 
study which showed that being bullied between the ages of 7 and 11 was correlated with an 
increased CRP at 45 years of age 393. Moreover, the inflammatory mediator IFNγ (interferon) 
partially mediates the effects of early life stress on emotional processing in humans 394. In 
humans, older individuals show a lower NFkB response to stress then younger counterparts 
and the high NFkB response was associated with lower cortisol levels after stress in 
peripheral blood mononuclear cells 395. Stress during pregnancy but not before conception is 
also associated with increased maternal expression of classic pro-inflammatory genes in the 
third trimester, an effect which is driven by NFκB and AP1 (activator protein 1) 396. These 
studies show early life stress can independently predispose to an altered inflammatory 
profile in later life, however, to investigate the mechanisms which account for these 
correlations animal models are needed.  
There is also an interaction between stress and inflammation at the molecular level, as 
indicated in animal models. For instance, LPS given to rats at P14 results in altered fear 
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extinction behaviours in adulthood 397. IFNβ administration during pregnancy potentiates the 
effects of subsequent maternal separation (3 hours/day for 2 weeks from P1) 398. LPS induced 
NFκB mediated gene transcription in the hippocampus is also potentiated by stress in rodent 
models of chronic adolescent stress 399. GR and NFκB signalling can regulate each other 
through PKA mediated phosphorylation in vitro and in vivo 400. Therefore, it is clear that there 
is substantial interaction between stress and inflammation, but relatively little is known 
about this with respect to PTB. 
1.8 Circadian rhythms  
Circadian rhythms are signals which repeat over a 24 hour cycle. They are a highly 
evolutionarily conserved concept of timekeeping; even bacteria show evidence of circadian 
rhythms 401. In mammals, circadian rhythms pervade every aspect of biology as they exist on 
genetic (transcription-translation feedback loops) through to a behavioural levels (sleep-
wake cycles). 
Every cell in the body has its own transcriptional clock, and these clocks are arranged in a 
hierarchal structure where the clock within the superchiasmatic nucleus (SCN) of the 
hypothalamus synchronizes clocks throughout the body in response to light 402. Peripheral 
clocks are maintained in the absence of a functional SCN, but become dyssynchronous over 
time 403. Estimates suggest that up 42% of genes are subject to circadian oscillation in at least 
one tissue, with the same study suggesting over 50% of FDA (federal drug administration) 
approved drugs target these genes 404. As such understanding the mechanisms of circadian 
physiology is crucial to effectively understand and treat many common disorders. 
Many hormones, such as glucocorticoids are secreted in a circadian fashion. Glucocorticoid 
concentrations are characteristically high in the morning and low in the evening in humans. 
These rhythms are commonly disrupted in many neurodevelopmental disorders which will 
be discussed later, first I will introduce the mechanisms of circadian regulation of gene 
expression. 
1.8.1.1 Signaling in the SCN 
The SCN contains pacemaker neurons which set circuit level properties of the system and 
these are necessary for the circadian oscillation of gene expression. The spontaneous firing 
rate (SFR) is the main output of the SCN 405. There is typically little electrical activity in the 
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SCN during the night with steady pace action potentials starting near dawn and persisting 
through the day 406. This is the same in both nocturnal (e.g. rodents) and diurnal (e.g. humans) 
species as it encodes solar time rather than behaviour 405. The SCN has direct projections to 
other areas of the hypothalamus, the brain stem and subcortical areas 407. Alterations in the 
SFR of the SCN can affect core circadian transcription-translation feedback loops 408 and many 
genes involved in electrical activity and membrane potential are under the control of these 
loops, illustrating electrical-transcriptional bidirectional coupling 405. 
1.8.1.2 Circadian Rhythm Regulation 
The SCN synchronizes cellular clocks in response to light stimuli (as shown in Figure 1.3). 
Melanopsin expressing cells in the retina receive light stimuli and pass this information to 
the SCN via the retino-hypothalamic tract 416. In animal models SCN ablation causes 
systemic disruption of metabolism 417, immune responses 418 and altered sleep dynamics 419. 
There are sex differences in circadian rhythmicity: men and women display functional 
circadian differences following a forced desynchrony program, with women subject to 
greater levels of circadian modulation and decreased cognitive performance in the morning 
420. 
1.8.2 Core transcription-translation feedback loops 
Transcription-translation feedback loops are the fundamental unit of circadian rhythms 
(illustrated in Table 1.1). They consist of several interacting transcriptional loops, with 
members of each loop acting to increase transcription of another member which represses 
the initial activating member. Alterations in the transcription dynamics of the members of 
these loops may alter cell and tissue wide circadian rhythms. 
In humans, brain muscle ARNT-like protein 1 (BMAL1) transcription increases in the morning, 
BMAL1 then heterodimerizes with the circadian locomotor output cycles kaput (CLOCK) 
protein, whose expression remains relatively constant through the day 421. This heterodimer 
acts as transcription factor and binds to E-box motifs throughout the genome, driving 
transcription 422. The period (Per1-3) and cryptochrome (Cry 1-2) genes are upregulated in 
this fashion 423. Per and Cry proteins accumulate gradually through the day and become 
phosphorylated by the serine/threonine kinases casein kinase 1δ and 1ɛ (CK1δ and CK1ɛ), 
then Per/Cry heterodimerize before nuclear translocation. The Per/Cry heterodimer inhibits 
BMAL1 transcription, thereby decreasing their own transcription. Per and Cry are degraded 
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via ubiquitylation and subsequent proteasomal degradation at which point BMAL1 
expression increases and the transcriptional cycle restarts 423. 
A second transcription loop occurs as the CLOCK-BMAL1 heterodimer also interacts with the 
promoter region of NR1D1 (nuclear receptor 1D1) and NR1D2 (nuclear receptor 1D2) (REV-
ERBα and REV-ERBβ respective proteins) to promote their transcription. REV-ERBα and REV-
ERBβ compete with RAR-related orphan receptor α, β and γ (RORα, RORβ and RORγ) for 
binding sites at retinoic acid-related orphan receptor binding elements 424,425. REV-ERBα acts 
to repress BMAL1 out of phase with Per expression patterns and while not essential for 
circadian rhythms, is central to length of oscillation 425. 
A third transcriptional loop occurs as CLOCK-BMAL1 bind to and promote transcription of 
DBP (D-box binding protein), thyrotroph embryonic factor and hepatic leukaemia factor. 
These 3 proteins compete with the repressor NFIL3 (nuclear factor, interleukin 3 regulated) 
for binding at D-box motifs 402. The interaction between CLOCK -BMAL1 and the E-box motif 
at DBP is unstable and stochastic with evidence suggesting CLOCK-BMAL1 may be 
immediately degraded by the proteasome after binding to DBP 426. 
These three loops generate rhythms with different oscillation patterns with affinity for 





Table 1.1 Central circadian regulators along with their mechanism of circadian regulation and 
the phenotype of animals in which the respective genes are deleted. 
Protein Mechanism Phenotype of knockout mice Ref 
BMAL1 E-box motif binding 
Severe disruption in all aspects of circadian 
rhythms 427 
CLOCK E-box motif binding 
Rhythms maintained but altered 




Rhythms maintained with any deleted. 
Severe alterations in circadian rhythms 




Rhythms maintained with either deleted. 
Severe disruption in circadian rhythms with 
the deletion of both. 431 
REV-ERB α/β RORE motif binding 
Rhythms maintained with either deleted. 
Severe disruption of circadian rhythms 
with the deletion of both 432 
RORα/β/γ RORE motif binding 
Cerebellar defects, ataxia and metabolic 
defects with deletion of both. Limited 
disruption with either deleted alone.  433,434 
DBP D-box motif binding 
Mice maintain rhythms but altered 




1.8.3 Circadian secretion of glucocorticoids  
ACTH and CRH are secreted in a diurnal pattern 439 and glucocorticoids are secreted in an 
ultradian pulsatile fashion with overlying circadian rhythmicity 440. Classic studies in rats have 
shown that the SCN is necessary for corticosterone rhythms 441 but the peripheral adrenal 
clock is also necessary for glucocorticoid rhythms 442. The synthetic glucocorticoid, 
Dexamethasone, is able to reset peripheral clocks but not in the SCN, as the GR is not 
expressed here 443.   
The magnitude of the HPA axis response to a stressor is dependent on time of day as well as 
the type of stressor 444 and the circadian rhythmicity of glucocorticoid secretion is important 
for maintaining normal behaviour patterns. For instance an increased amplitude of 
glucocorticoid secretion without a difference in total secretion results in anxiety like 
behaviour in mice 445. Chronic restraint stress in adult mice causes phase shifts in circadian 
gene expression in peripheral organs as well as the cortex and hippocampus but not in the 
SCN 446. 
In terms of mechanisms, CRY1 and CRY2 interact with the GR when it is occupied, and act to 
reduce expression of glucocorticoid target genes. CRY1 or CRY2 null mice show higher 
circulating levels of corticosterone, and Dexamethasone exposure in these mice produces 
increased expression in twice as many genes than in wild type mice exposed to the same 
concentration 447. Per1 expression is altered following stress in adult mice with 
glucocorticoids having a spatial and stress specific effect 448. Increased Per1 expression is also 
seen in the paraventricular nucleus of the hypothalamus following inflammation and physical 
stressors (forced swim and immobilisation) 449. As such, stress and circadian rhythms are 
thoroughly interlinked. 
1.8.4 Circadian rhythms in neurodevelopmental disorders 
Disruption of circadian rhythms including sleeping pattern is common in many 
neurodevelopmental disorders and the presence of a typical sleep pattern at the age of 2 in 
babies who were born preterm is associated with a higher IQ at 3 years 450. Moreover, in term 
infants the quality and duration of sleep is associated with more mature facial processing as 
measured by eye tracking at 12 months 451. However, despite the high burden associated 
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with sleep disorders, relatively little is known about their mechanistic underpinnings in 
neurodevelopmental disorders. 
1.8.4.1 ASD 
Children with ASD show an elevated cortisol response to expected stressors but an 
unchanged baseline cortisol level 452, suggesting fundamental alterations in HPA axis 
functionality. Sleep disorders are very common in children with ASD 453, but even in those 
without diagnosed sleeping disorders there is evidence for altered sleeping patterns 454. 
Adults with ASD and a diagnosed sleep disorder have higher rates of unemployment than 
those without a diagnosed sleep disorder 455. This may be mediated in part by melatonin 
secretion: individuals with ASD have less melatonin than typically developing individuals at 
both diurnal and nocturnal stages of melatonin release 456,457.  
Many animal models of ASD show circadian rhythm disturbances. The valproic acid rat model 
of ASD produces abnormal expression of genes involved in circadian rhythm regulation 458 
and altered sleep dynamics 459. Animal models of Prader-Willi syndrome 460, 16p11.2 deletion 
syndrome 461, fragile X syndrome 462 and Rett syndrome 463 (all syndromic forms of ASD) also 
show evidence for circadian rhythm abnormalities. 
1.8.4.2 Other Neurodevelopmental Disorders 
Actigraphy measurements taken as part of UK Biobank indicate that altered circadian activity 
is predictive of many mood related disorders and various mental health outcomes 464. 
Individuals with schizophrenia show high levels of circadian disruption which is independent 
of medication and other factors 465 and commonly used mouse models of schizophrenia also 
exhibit circadian abnormalities 466. Bipolar disorder is also associated with an abnormal 
circadian signature 467 and individuals who respond well to treatment with lithium have 
normalised circadian activity in fibroblast cells compared to those who do not respond well 
468. Finally, altered expression of oscillating genes in various brain regions has been identified 
in post mortem brain tissue from individuals with major depressive disorder 469.  
1.8.5 The developing HPA axis and circadian rhythms 
The HPA axis is functional in humans by the second trimester 470 and the SCN appears as a 
visible structure at 27 weeks of gestation 471. Development of the adrenal cortex is dependent 
on age from point of conception rather than postnatal age 472. In contrast, cortisol rhythmicity 
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is associated with postnatal age, with term infants showing cortisol rhythms by 1 month of 
age 473 and preterm infants showing cortisol rhythms at one month of term corrected age 293. 
It should however be noted, there is large variation in perinatal rhythmicity, particularly in 
preterm infants, which makes firm conclusions difficult. Also, very preterm infants show 
circadian rhythms in oxygen consumption and temperature shortly after birth 474,475, variables 
which are under the control of the SCN. Infants born very preterm (less than 32 weeks of 
gestation) show improved weight gain, shorter NICU stay and increased daytime activity after 
exposure to an alternating light/dark cycle in the NICU, when compared to continuous light 
exposure 476,477. Other studies however have seen no effect of NICU lighting regime on 
circadian rhythm or sleep development 478. 
Animal models allow for the measurement of circadian gene expression in tissue and rats 
carrying the Per1: luc transgene allow for in vivo, real-time measurement of Per1 expression. 
In these rats, Per1 expression is seen in the uterus of pregnant dams by E10, with expression 
exponentially increasing until birth, diurnal rhythms in Per1 expression begin at E12 479. 
However the rat SCN does not form until E17 480, as such these are weak, peripherally 
mediated oscillations. Synchronised rhythmic expression within the rat SCN isn’t seen until 
birth 481. This indicates peripheral clocks in rodents may operate with autonomy until birth, 
when the SCN initiates rhythmic expression and the synchronisation of peripheral clocks.  
1.9 Conclusions 
As I have outlined here, PTB is associated with adverse neurodevelopmental outcome but 
the mechanistic underpinnings are largely unknown. PTB is also associated with many factors 
such as hypoxia, inflammation and stress which can affect brain development and epigenetic 
modifications in the brain. In this thesis, I will explore the effect of these factors and how 




1.10 Aims and hypotheses 
Chapter 3 
In this chapter I hypothesized that:  
• Dexamethasone, LPS and/or hypoxia induce transcriptomic differences in a 
forebrain slice culture model 
• These changes in transcription will associate with changes in genomic 5hmC in a 
forebrain slice culture model 
• Dexamethasone, LPS and or/hypoxia will produce functional alterations in primary 
glial cultures 
I aimed to test these hypotheses in the following ways: 
• To compare ex vivo cultured forebrain slices to littermate in vivo tissue at similar 
ages and identify optimum culture length 
• To investigate the dose at which Dexamethasone, LPS and hypoxia produce a 
physiological response under ex vivo culture conditions 
• To evaluate the effect of these factors independently and in combination on 
candidate gene expression 
• To evaluate 5hmC at candidate loci using DNA hydroxymethylation 
immunoprecipitation following Dexamethasone, LPS and/or hypoxia 
• To investigate the effect of these factors on the differentiation and cytokine 
secretion of primary cultured mouse OPCs and microglial respectively  
Chapter 4 
In this chapter I hypothesized that: 
• MMS will induce changes in the transcriptome and DNA methylome of the 
hypothalamus 
• MMS will result in altered behaviour in the adult period 
I aimed to test these hypotheses in the following ways: 
• To assess growth and blood glucose dynamics associated with MMS 




• To investigate the effects of MMS on the hypothalamic transcriptome in the neonatal 
period 
• To investigate the effects of MMS on the hypothalamic DNA methylome in the 
neonatal period 
• To examine the effect of MMS on behaviours during adulthood 
• To assess the effect of MMS on candidate gene expression in the HPA axis in 
adulthood 
• To assess the effect of MMS on DNA methylation at candidate loci in the 
hypothalamus in adulthood 
Chapter 5 
In this chapter I hypothesized that: 
• Administration of LPS potentiates the effects of subsequent MMS in the 
hippocampus and cortex 
I aimed to test these hypotheses in the following ways: 
• To assess the effect of LPS and/or MMS on weight gain  
• To investigate the expression of inflammation related genes in the brain 24 hours 
after LPS (which would be the onset of the MMS paradigm) 
• To examine aspects of synaptic pruning in the hippocampus following LPS and/or 
MMS 
• To investigate glial cell populations in the cortex following LPS and/or MMS 
• To examine the cortical transcriptome following LPS and/or MMS 
• To compare the cortical and hypothalamic transcriptomes after MMS to identify 




2 Materials and methods 
2.1 In vivo procedures 
2.1.1 Mice 
All mice were kept and procedures carried out in accordance with the University of 
Edinburgh’s Policy on the Use of Animals in Research and with Home Office regulations. Mice 
were kept in controlled temperature (22˚C) conditions with a 12-hour light/dark cycle (7.00-
19.00), and ad libitum access to food and water. Sexually mature C57BL/6JOlaHsd wild-type 
mice were obtained from Harlan (Harlan, UK), one male and two females were housed per 
cage and allowed to mate. Females were replaced after 6 litters and males replaced after 10 
months of age. Both male and female mouse pups were used for slice culture experiments, 
while only males were used for MMS experiments. Male pups were identified using 
anogenital distance 495. 
2.1.2 Randomisation 
Throughout this thesis, randomisation was done where appropriate. To do this, a random 
number list was generated in Microsoft Excel and a number assigned to each mouse. The 
random number list was then sorted using the “sort” function in Excel, from smallest to 
largest. The mice were then assigned to a pre-determined group based on experimental 
design. For instance, the first half of the mice (i.e. those with the smallest numbers) were 
assigned to the control group, while the second half of the mice (i.e. those with the larger 
numbers) were assigned to the MMS group. 
2.1.3 Subcutaneous and intraperitoneal (IP) injections 
Mice were taken at postnatal day (P)3 and injected subcutaneously on the footpad of the 
hindlimb with ink for identification purposes. This pattern was visible until P14 at which time 
the mouse’s ears were an appropriate size to be clipped for future identification. 
For in vivo LPS experiments, on P3 at 1pm pups were administered a single dose of 1μg/kg 
LPS or the same volume of vehicle (PBS; phosphate buffered saline) via IP injection into the 
lower left abdominal quadrant. The maximum volume injected was 100 μl/10 g.  
2.1.4 Modified maternal separation (MMS) paradigm 
MMS was carried out from P4 for 1.5 hours at 1pm for 3 consecutive days. The MMS 
paradigm consisted of removing designated pups from the home cage and placing them on 
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a heated pad covered with a paper towel. A cotton bud was then used to gently move each 
pup into a supine position whenever they settled into a prone position. After 1.5 hours, the 
pups were returned to the home cage. MMS was carried out adjacent to the home cage to 
allow for ultrasonic communication between pups and dam. 
Control pups were left in the home cage throughout whilst MMS was carried out on their 
littermates. All pups were handled at the start of the experiment for identification purposes. 
2.1.5 Physiological Measurements and Dissections 
The weight of all mice was taken prior to injection and prior to MMS each day. At the end of 
the experiments, mice were killed by decapitation. Using EDTA coated tubes, trunk blood was 
collected immediately following decapitation. Blood was kept on ice until centrifugation at 
12000 RPM for 10 minutes at 4˚ C. Plasma was then isolated before storage at -80˚ C. 
To remove the brain, the skin at the rear of the head was cut and the skull exposed, an 
incision was made at the base of the skull and a line cut from the base of the skull to the 
snout and the brain then fully exposed with forceps. The brain was then extracted after 
severing of the cranial nerves. Dissection was then immediately carried out on a glass 
platform covered with filter paper and surrounded by ice. Tissue was dissected before 
storage at -80˚ C. 
2.1.6 Tail venesection 
Adult mice at 3 months of age were restrained in a tube and their tail isolated. Using a scalpel, 
a small incision was made along the tail and blood was encouraged to exit the wound through 
palpation of the tail. Blood was collected using capillary action with EDTA coated tubes. Once 
sufficient blood was obtained, pressure was applied until blood stopped flowing and the 
mouse was then returned to its home cage. This was done at 7am and 7pm on the same day 
for each mouse for the evaluation of corticosterone. 
2.1.7 Glucose measurement 
Glucose was measured in the neonatal period immediately following decapitation using the 
Accu-Chek Performa glucometer. A glucose measuring strip was inserted into the machine 
and upon the prompt blood was applied to the strip. A reading of glucose concentration was 




For the elevated plus maze, open field and tail suspension tests, mice were brought to the 
behavioural testing area at least 1 hour before testing to acclimatise to the novel 
surroundings. Mice were then brought into the testing room one at a time for testing and 
then returned to their home cage afterwards. Mice which had been tested and those that 
were still to be tested were kept separate to avoid unnecessary agitation. Testing was done 
at the same time of day for all mice in a given behavioural task. Behavioural testing was done 
in a noise free environment and I was out of sight during the testing period. The elevated 
plus maze, open field and tail suspension tests were evaluated at 3 months of age and 
behaviour analysed with the PhenoMaster at 4 months of age.  
2.1.8.1 Elevated plus maze 
The apparatus was of the classic plus sign shape (width 5 cm and arm length 25 cm), with 2 
opposing closed arms (15 cm in height and 2.5 lux) and 2 opposing open arms (45 lux). The 
arms intersected at an open centre area. Mice were placed in the centre of the apparatus 
facing a closed arm and allowed to explore the maze for 5 minutes. The test was 
automatically started by the AnyMaze software (ANY-maze, Stoelting Co.,Wood Dale, IL, 
USA), when I left the video frame. AnyMaze recorded all activity during the testing period 
and analysed the movement of all mice accordingly. The maze was cleaned thoroughly with 
70% ethanol between mice. 
2.1.8.2 Open field 
Behaviour in the open field task was evaluated 24 hours after the elevated plus maze. The 
open field consisted of the classic square structure (50 cm x 50 cm, with 30 cm walls). The 
mice were placed in the centre of the maze and again the test was automatically started by 
the AnyMaze software once I left the frame and the mouse’s movement was subsequently 
tracked and analysed. The mouse was allowed to explore the maze for 5 minutes before it 
was returned to its cage and the apparatus cleaned with 70% ethanol before testing the next 
mouse. 
2.1.8.3 Tail suspension 
The tail suspension test was carried out on the same day as the open field test. The mouse 
was suspended by the tail with a 17 cm piece of tape attached to an elevated area 50 cm 
from the ground. A cone was place around the mouse’s tail to prevent climbing. The mouse 
was suspended for 6 minutes and recorded with a Canon IXUS 185 digital camera. The test 
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was then evaluated for mobility time, which was defined as active torso movement (i.e. not 
passive swinging from a previous movement), combined movement of front and rear legs or 
intense movement of a single set of limbs. Outside of these criteria the mouse was said to be 
immobile. For analysis the videos were duplicated and anonymized, through random number 
generation in Excel by an independent person. I was blind to the groups during analysis. After 
analysis duplicate values were averaged to obtain a score for a single mouse which was then 
used for subsequent statistical analysis. 
2.1.8.4 PhenoMaster 
To analyse indirect calorimetry, movement and food intake over the course of a 24-hour 
period, I used the TSE PhenoMaster system (TSE systems, Germany). Mice were single 
housed for 4 days before evaluation using the PhenoMaster system to allow acclimatisation 
to the novel water bottle used in the PhenoMaster system.  
The mice were then transferred to the PhenoMaster, which is a closed system allowing for 
the quantification of O2 intake and CO2 output, and the calculation of the respiratory 
exchange ratio. The system was also fitted with food and drink sensors to monitor food and 
water intake, infrared laser beams also enabled the quantification of movement. The mice 
were allowed to acclimatise to the system for 24 hours and measurements were then taken 
every 15 minutes for a further 3 days. Food and water intake were monitored closely and any 
mouse not drinking was given water in their cage using an upturned bijous cap. Data were 
exported to Excel where subsequent sorting and analysis was done before statistical analysis. 
2.2 In vitro procedures 
2.2.1 Organotypic forebrain slice culture 
C57BL/6JOlaHsd pups were taken at P1 and killed with an overdose of Pentobarbitone 
administered via intraperitoneal injection at 150mg/kg. Whole brains were dissected into ice-
cold L15 media. Next, 300µm coronal sections were cut using a McaIlwain Tissue Chopper 
(Campden Instruments LTD). Brains were then transferred to a petri-dish containing ice cold 
slice culture media (see Table 2.1 for details), where brain slices were separated using a Wild 
Heerbrugg 1x objective for the Wild M8 Stereo Zoom Microscope and 24G needles. After 
separation, slices were transferred using a spatula onto Millicell culture inserts in a 6-well 
plate with 1 ml/well of slice culture media. Forebrain slices were kept in an incubator at 37˚ 
C with 5 % CO2 unless otherwise stated. 
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Table 2.1 Recipe for slice culture media 
Reagent (Manufacturer) Catalogue number Volume to use (mls) 
EBSS (Thermo fisher Scientific) 24010043 62.8 
BME media (Thermo fisher Scientific) 21010046 167 
D-(+) Glucose solution (Sigma) G8769 2.7 
Heat inactivated horse serum (Thermo 
fisher Scientific) 26050088 12.5 
Pen/ strep (Sigma) P4333 2.5 
GlutaMAX-I Supplement(Thermo 
fisher Scientific) 35100000 2.5 
 
2.2.2 Dexamethasone, LPS and reconstitution 
Dexamethasone was reconstituted in 100% ethanol and LPS was dissolved in slice culture 
media to the concentrations indicated with each experiment. These vehicles were co-
administered to the control group during administration. 
2.2.3 Primary culture of mouse microglia and oligodendrocyte precursor cells 
2.2.3.1 Neural Tissue Dissociation 
Whole brain tissue was extracted from C57BL/6JOlaHsd mouse pups between P0-P2 and 
dissociated using the neural tissue dissociation kit from Miltenyi as per kit instructions. Whole 
brain tissue was weighed in 1 ml HBSS (without Ca2+ and Mg2+), an appropriate amount of 
enzyme P and buffer X (50 µl and 1900 µl respectively per 400 mg of tissue) was warmed to 
37˚ C in a Miltenyi C-tube. The enzyme/buffer mix was then added to the tissue and attached 
to a gentleMACS dissociator and program m_brain_01 was initiated. The mixture was then 
incubated under slow rotation at 37˚ C for 15 minutes. Next the C-tube was attached to the 
gentleMACS dissociator and program m_brain_02 was initiated. Then an appropriate amount 
of enzyme A and buffer Y (10 µl and 20 µl per 400 mg tissue respectively) was added to the 
C-tube followed by a further 10 minutes of slow continuous rotation at 37˚C. The C-tube was 
then attached to the gentleMACS dissociator and program m_brain_03 was ran before a final 
10-minute incubation at 37˚ C under slow continuous rotation. The cell dissociation was then 
passed through a 70 µm cell strainer and washed with 10 mls of HBSS (with Ca2+ and Mg2+) 
per 400 mg of tissue. The mixture was centrifuged at room temperature for 10 minutes at 
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2000 RPM. Supernatant was discarded, and the pellet was resuspended in 1 ml of 0.5 % 
filtered bovine serum albumin (BSA) in PBS. Cells were then counted in a 1:1 dilution of 
Tryphan Blue using the Countess II FL Automated Cell Counter and Countess cell counting 
chamber slides. 
2.2.3.2 PDGFRα isolation and culture conditions 
Once dissociated cell number was assessed, PDGFRα positive cells were isolated using 
PDGFRα (CD140α) Miltenyi microbeads as per manufacturer’s instructions. Briefly, 
dissociated cells were centrifuged at room temperature for 10 minutes at 2000 RPM. 
Supernatant was discarded, and pellet resuspended in 90 µl 0.5 % BSA in PBS per 107 live 
cells. The dissociated tissue was next incubated with 10 µl FcR blocking reagent per 107 live 
cells (included with PDGFRα cell isolation kit) for 15 minutes at 4˚ C. Then, 10 µl of PDGFRα 
microbeads per 107 live cells was added and the mixture was incubated for 15 minutes at 4˚ 
C. Cells were then washed in 2 mls of 0.5 % BSA in PBS per 107 cells and centrifuged for 10 
minutes at room temperature at 2000 RPM. Supernatant was discarded, and cells 
resuspended in 90 µl of 0.5 % BSA in PBS per 107 cells. The autoMACS Pro Separator was then 
primed for use with a wash program. Columns were changed every 2 weeks or every 108 cells. 
A positive selection programme was then run, with the positive fraction collected in position 
C and the negative fraction collected in position B of a rack pre-chilled to 4 ̊ C. Cells were then 
counted as outlined previously using the Countess automated cell counter. A 96 well flat-
bottomed plate was coated the previous day with 5µg/ml Poly D-Lysine and left overnight at 
37 ˚C. Before seeding the plate was washed three times with sterile PBS and allowed to air 
dry under sterile conditions. Cells were then seeded at a density of 10,000 cells per well in 
media (for recipe see Table 2.2) supplemented with PDGF-AA and NT-3 (see Table 2.4) and 
maintained at 37 ˚C with 5 % CO2 unless otherwise stated. 
2.2.3.3 CD11b isolation and culture conditions 
Dissociated cell number was determined and CD11b positive cells were isolated with the 
CD11b Miltenyi microbead kit. The isolation method was identical to the PDGFRα isolation 
protocol outlined previously with the following exceptions. As per manufacturer’s 
instructions the cells were not incubated with FcR blocking reagent and cells were 
resuspended in 90 µl of 0.5 % BSA in PBS per 108 cells following incubation with microbeads 
and subsequent centrifugation.  
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Once isolated CD11b+ cells were counted as previously outlined and seeded at a density of 
25,000 cells/well in media of a 96 well plate (see Table 2.2) supplemented with TGF-β2, ovine 
cholesterol and IL34 (see Table 2.4). The plates were not coated prior to use.  
Table 2.2 Formula for media in which isolated glial cells were cultured. Recipe for SATO media and details of glial 
specific additives are found in the following tables. Media was stored at 4 ˚C and used within 1 month. 
Reagent Amount/Volume Catalogue Number 
Neurobasal medium 
(without glutamine) 240 mls 21103049 
DMEM-high glucose 240 mls 10566016 
Glutamax  2.5 mls 35050061 
ITS-G (100X) 5 mls I3146-5ml 
B27 Supplement (50X) 10 mls 17504044 
Biotin (10μg/mL stock) 500 μl B4639-100MG 
NAC (50 mg/mL stock) 500 μl A9165-5g  
100 X SATO 5 mls   
Penicillin/ 
Streptomycin 5 mls 15140122 
 
Table 2.3 Recipe for 100x SATO which was added to the base media for glial culture, outlined in the previous table. 
Aliquots of 5mls were made and stored at -20 degrees until use. 
Reagent Amount/Volume Catalogue Number 
DMEM-high glucose 50 mls 10566016 
Apo-transferrin 500 mg T1147-100mg  
BSA 500 mg A7638 
Progesterone solution: 12.5 μL   
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        Progesterone 2.5 mg FP8783-1G 
        Ethanol 100% 100 μl   
Putrescine (80mg/ml) 1000 ul P5780-5G 
Sodium selenite solution: 500 μl   
        Sodium selenite 4 mg S5261-10G 
        0.1N NaOH 100 μl   
        DMEM-high glucose 10 mls 10566016 
 
Table 2.4 Growth factors and cytokines added to base media previously outlined. PDGF-AA and NT-3 were added 
to PDGFRα positive cells and TGF-β 2, ovine cholesterol and IL-34 were added to cultures containing CD11b positive 
cells. 
Reagent Concentration in Media Catalogue Number 
 PDGF-AA  10 ng/ml 100-13A-10ug 
 NT-3  5 ng/ml 450-03-10ug 
 TGF-β 2  2 ng/ml 100-35B-2UG 
Ovine Cholesterol 1.5 µg/ml 7000000P-100mg 
IL-34 CF 100 ng/ml 5195-ML-010/CF 
 
2.3 Extractions 
2.3.1 RNA Extraction  
RNA was extracted using Qiazol, a tissue homogenizer and the RNeasy mini kit. First 1 ml of 
Qiazol was added to 25 mg of tissue. Tissue was then disrupted using a Qiagen TissueLyser II 
at 2000 RPM for 2 minutes. Next 200 μl of chloroform was added and the tube briefly 
inverted and left for 5 minutes at room temperature. Samples were then centrifuged at 
10,000 RPM for 10 minutes at 4 ˚C. The upper aqueous was removed and an equal volume 
of 70 % ethanol added before mixing by inversion. The sample was transferred to a RNeasy 
mini spin column and centrifuged for 30 seconds at 10,000 RPM and flow through discarded. 
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Next 700 μl of RW1 buffer was added to the column before centrifugation for 30 seconds at 
10,000 RPM. In a similar fashion 2x500 μl of RPE buffer was added before centrifugation. RNA 
was then eluted with 40 μl of RNAse free water and centrifugation at 10,000 RPM for 1 
minute. RNA yield was then quantified, and integrity assessed via gel electrophoresis before 
storage at -80 ˚C. 
2.3.2 Quantification of RNA yield and assessment of integrity 
RNA yield was quantified using the Qubit RNA broad range assay. In Qubit tubes, 1 μl of 
sample RNA was added to 199 μl of a 1:200 dilution of Broad Range assay reagent in Broad 
Range buffer and RNA concentration assessed using the Qubit Fluorometer 2.0. 
Next 6x loading dye was appropriately diluted in 250 ng of RNA before gel electrophoresis at 
120 V for 45 minutes on a 1 % agarose gel containing gel red (final concentration of gel red 
0.005%) for nucleic acid visualisation. Appropriate RNA integrity was characterised as 2 
distinct bands indicating the 28s and 18s subunits of ribosomal RNA, with the 28s subunit 
appearing with approximately twice the intensity of the 18s subunit. 
2.3.3 DNA Extraction 
DNA was extracted using the Qiagen DNeasy Blood and Tissue kit. First, 50 mg of tissue was 
cut into small pieces before addition of 120 μl of buffer ATL and 20 μl Proteinase K solution, 
sample was incubated at 56 ˚C overnight in a Thermomixer at 1000 RPM. Sample was 
vortexed for 15 seconds before addition of 20 μl of RNase and incubated at room 
temperature for 2 minutes following mixing by inversion. Next, 200 μl of Buffer AL was added 
before further vortexing. Then, 200 μl of 100 % ethanol was added before vortexing. Sample 
was then added to a DNeasy spin column. The column was centrifuged at 8,000 RPM for 1 
minute and flow through discarded. Next, 500 μl of Buffer AW1 was added to the column 
before centrifugation at 14,000 RPM for 1 minute, again flow through was discarded. 
Similarly, 500 μl of Buffer AW2 was added to the column before centrifugation. DNA was 
then eluted using 100 μl of Buffer AE and centrifugation for 1 minute at 14,000 RPM. Once 




2.3.4 Quantification of DNA concentration 
DNA yield was quantified using the Qubit DNA broad range assay. In Qubit tubes, 1 μl of 
sample DNA was added to 199 μl of a 1:200 dilution of Broad Range assay reagent in Broad 
Range buffer and DNA concentration read using the Qubit fluorometer 2.0. 
2.3.5 Protein extraction from cultured brain slices 
Protein was extracted from either fresh or frozen cultured slices stored at -80 ˚C. Slices were 
incubated with 100 μl of RIPA buffer and 1 μl of cOmplete protease inhibitor under rotation 
at 4 ̊ C for 1 hour with vortexing before and after. Sample was then centrifuged at 12000 RPM 
for 15 minutes at 4 ˚C. Supernatant was removed and protein concentration assayed before 
storage at -20 ˚C. 
2.3.6 Quantification of protein concentration  
Protein was quantified using the Biorad DC protein assay as per manufacturer’s instructions. 
In summary, a 1.5 mg/ml concentration of BSA in RIPA buffer was serially diluted to create a 
standard curve. Next 5 μl of each standard and sample was added in duplicate to a 96-well 
microplate, a blank well was included to account for background. 20 μl of reagent S was 
added to 1 ml of reagent A to create working reagent A, 25 μl of working reagent A was added 
to each well. Next 200 μl of reagent B was added to each well and the 96 well plate was gently 
agitated for 15 minutes. Absorbance at 750 nm was then read, the blank was subtracted, and 
concentrations of samples extrapolated from a standard curve generated using standard 
functions in Microsoft Excel.  
2.3.7 Western blotting 
Western blotting was carried out using the Invitrogen XCell II apparatus for mini gels. 40 μg 
of protein was diluted in 1x loading dye, made to 30 μl with water and heated for 5 minutes 
at 95 ˚C, followed by cooling for 5 minutes on ice. The apparatus was appropriately 
assembled as indicated by the manufacturer, using a ThemoScientific 4-20% gel. The inner 
chamber was filled, and the outer chamber half filled with freshly made running buffer (see 
Table 2.5 for all buffers or solutions used in western blotting). 30 μl of sample was added per 
well, 4 μl of Chameleon pre-stained protein ladder was also used. Electrophoresis was then 
carried out at 120 V for 2 hours. After electrophoresis, the gel casing was opened, the 
cassette was discarded and the gel sandwich was appropriately assembled, as per 
manufacturer instructions, with filter paper and PVDF membrane in preparation for blotting. 
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The blotting apparatus was then assembled, and blotting carried out at 200 mA or 400 mA 
(for 1 or 2 gels respectively) for 2 hours at 4 ˚C. 
Following blotting, the membrane was removed and washed in distilled water. The 
membrane was incubated under rotation with Ponceau red stain for 5 minutes, followed by 
3 brief washes with distilled water, to assure successful transfer of protein. 
The membrane was stained for total protein using the Licor Revert Total Protein Stain as 
indicated by the manufacturer. In summary, the membrane was incubated with 5 mls of Total 
Protein stain for 5 minutes at room temperature under gentle agitation. The membrane was 
next washed twice with 5 mls of Wash Solution under gentle agitation, followed by imaging 
using the Licor Odyssey CLx system. 
The membrane was then blocked using 5 % non-fat milk powder in TBS-T (Tris buffered saline 
with 0.01% Triton) for 1 hour at room temperature. Washing was then carried out 3 times 
with TBS-T before incubation with an appropriate concentration of primary antibody (diluted 
in TBS-T) overnight under gentle agitation at 4 ˚C. Washing was then carried out 3 times with 
TBS-T before incubation with secondary antibody diluted at an appropriate concentration in 
TBS-T for 1.5 hours under gentle agitation at 4 ˚C. Before imaging the membrane was once 
more washed 3 times with TBS-T. 
The stained membrane was imaged using the Odyssey CLx system, and quantified relative to 
total protein using the lmageStudio lite software. 
Table 2.5 Table of solutions used for western blotting 
Solution Recipe 
PAGE Running Buffer (10x) 
1.9M Glycine 
250mM Tris  
pH to 8.3 (before SDS) 
1% Sodium Dodecyl Sulphate (SDS) 
1x made on day of use (1:10 dilution) 
Transfer Buffer (10x) 
1.9M Glycine 
250mM Tris  
pH to 8.3 
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1x made on day of use with 20% Methanol 
Tris-buffered Saline (TBS, 10x)  
500mM Tris 
1.5M NaCl 
pH to 7.6 
TBS with Tween (TBST, 1x) 




2.4.1 Cytokine ELISAs 
All ELISA’s were performed in 96 well plates and in triplicate. The capture antibody was 
diluted as indicated by the manufacturer in 1x coating buffer and 100 µl/ well was incubated 
overnight at 4 ˚C to coat the plate. Next the capture antibody was aspirated (for list of ELISAs 
used to evaluate cytokine levels in culture media see Table 2.6), and wells were washed 3 
times with 250 µl/ well of washing buffer, with 1-minute incubation time between each wash. 
The plate was then blotted on a paper towel to remove excess washing buffer and blocked 
for 1 hour with 100 µl per well of 1x ELIASPOT diluent (made from a 5x stock with deionized 
water). During this time the provided standards were appropriately reconstituted as 
indicated by the manufacturer and an 8 point standard curve made with 1x ELIASPOT diluent. 
After blocking, 100 µl of standards and samples were added to wells and incubated overnight 
at 4 ˚C for maximum sensitivity. Next the plate was washed 5 times with wash buffer, with 1-
minute incubation times between each wash. The detection antibody was then prepared 
according to manufacturer’s instructions and 100 µl was added per well. This was left to 
incubate for 1 hour at room temperature before 5 washes with washing buffer and 1-minute 
incubations between washes. The Avidin-HRP was then prepared in line with the 
manufacturer’s instructions and 100 µl/ well added to the plate for a total of 30 minutes. 
Next, in line with the previously outlined washes, 7 washes were carried out followed by the 
addition of 100 µl/ well of TMB solution for 15 minutes. Finally, 50 µl/ well of stop solution 
was added and the plate was read at 450 nm. A standard curve was generated, and data 
analysed using Microsoft Excel. 
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Table 2.6 List of ELISA's used and source 





2.4.2 Plasma corticosterone ELISA 
Plasma corticosterone was measured by ELISA using the Enzo kit following the 
manufacturer’s instructions. Briefly, 10 μl of sample was added to 10μl of appropriately 
diluted steroid displacement reagent and left at room temperature for 5 minutes. Next, 
samples were diluted with 480 μl of assay buffer in a glass tube. 1 ml of ethyl acetate was 
added, samples were inverted, and the aqueous phase was transferred to a fresh tube. This 
was repeated a further 2 times with 1 ml of ethyl acetate and the aqueous phase of the 
samples were dried under nitrogen until a powder formed. The powder was then dissolved 
in 750 μl of assay buffer.  
The ELISA was conducted as follows, 100 μl of samples and standards were added to wells 
with 50 μl of assay buffer, 50 μl of yellow antibody and 50 μl of blue conjugate. Appropriate 
controls were included as indicated by the manufacturer. The plate was incubated under 
gentle agitation at room temperature for 2 hours. The plate was then washed 3 times with 
300 μl of wash solution per well. 200 μl of pNpp substrate was added to each well and 
incubated for 1 hour under gentle agitation at room temperature. After, 50 μl of stop solution 
was added and the absorbance was read immediately at 405 nm. Subsequent analysis was 
done in Microsoft Excel. 
2.5 Microtome Sectioning 
Brain tissue was fixed overnight in 4 % paraformaldehyde, then transferred to 70 % ethanol 
for temporary storage before embedding in paraffin wax.  
Before sectioning, paraffin blocks were placed on ice to cool for at least 1 hour. Coronal 
sections were cut to 5 μm using a Leica 2M2125 RTS microtome, with ultrahard blades. 
Sections were then transferred to a water bath (Thermo Fisher Scientific, digital selection 
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flotation bath), set at 42 ˚C until flattened, after which they were transferred to a Superfrost 
slide. Three consecutive sections from a single sample were placed on each slide. Slides were 
then dried overnight at 37 ˚C and stored at room temperature until staining. 
2.6 Immunohistochemistry 
2.6.1 Immunohistochemistry on paraffin embedded sections 
Before staining, paraffin wax was removed from slides through a series of washes: 100 % 
xylene (5 minutes), 100 % xylene (5 minutes), 100 % ethanol (3 minutes), 100 % ethanol (3 
minutes), 90 % ethanol (3 minutes), 80 % ethanol (3 minutes), 70 % ethanol (3 minutes), 
water. 
Slides were immersed in sodium citrate buffer (pH adjusted to 6) and boiled for 20 minutes, 
and then left to cool for a further 20 minutes. Slides were then washed twice in PBS for 5 
minutes. Sections were encircled with a lipid pen and incubated with 200 μl of PBS with 10 % 
horse serum in a humid chamber for 1 hour and 30 minutes at room temperature to block 
against non-specific binding. Meanwhile, the primary antibody (see Table 2.7) was diluted in 
PBS with 10 % horse serum at the desired concentration. Blocking solution was then removed 
and 200 μl of primary antibody mixture applied. Slides were kept in a humid chamber 
overnight. Next the slides were washed 3x 10 minutes with PBS. The secondary antibody was 
diluted in PBS with 10 % horse serum and then applied to sections for 1 hour and 30 minutes. 
Slides were then washed 3x 10 minutes in PBS. Mounting media and coverslips were then 
applied to slides, which were then left to dry overnight in the dark at room temperature. 
Slides were imaged using the Zeiss AxioScan Z1 system using a 10x objective. Files were then 
exported with original metadata to a Tiff format before downstream analysis. 
Table 2.7 Antibodies used for immunohistochemistry 
Antibody Catalogue number Dilution 
IBA1 13481357 1 in 750 
GFAP ab7260  1 in 2000 
Olig2 NBP1-28667 1 in 1000 
MBP ab40390 1 in 1000 
DAPI D9542  1 in 1000 




2.6.2 Image analysis 
Cell counts were carried out on IBA1 and Olig2 stained sections. Fluorescent images were 
exported with automatic exposure chosen in the Zen2 lite software. Cells were counted 
manually using the Cell Counter tool within the ImageJ software. Three consecutive sections 
per mouse were quantified and results averaged to produce a single biological replicate. 
GFAP staining was analysed with respect to percent area. Fluorescent images were exported 
to a Tiff file with a universally applied brightness setting. Regions of interested were drawn 
in Image J and the Yen threshold was applied 496. The image was then made binary and 
percent area quantified using the area function in ImageJ. Three consecutive sections per 
mouse were quantified and results averaged to produce a single biological replicate.  
2.7 Golgi-Cox staining  
Golgi staining was performed on cultured slices using the sliceGolgi kit from Bioenno. Staining 
was performed as detailed in the manufacturer’s protocol. Briefly, fresh slices were fixed 
using fixative solution, after 30 minutes the solution was refreshed and left for a further 3 
hours. Fixed slices were then washed 3 times with PBS-T for 15 minutes. Next the slices were 
covered with impregnation solution and left in a humid chamber for 6 days. Sections were 
then washed 3 times in PBS for 5 minutes/wash. Slices were then incubated with Solution C 
for 5 minutes followed by a 1 wash in PBS-T. Sections were then immersed in Solution D and 
finally washed 3x 5 minutes in PBS-T. Sections were then transferred to slides and mounted 
as previously outlined in the previous section and visualized under brightfield using a Zeiss 
Z1 Imager microscope. 
2.8 Immunocytochemistry of OPC cultures 
Media was removed from the 96 well plate and cells were washed twice with 100 µl of PBS 
and then fixed in 50 µl of 4 % PFA for 25 minutes. PFA was then removed and cells were 
washed three times for 5 minutes with 100 µl PBS. 100 µl of 10 % horse serum in PBS was 
then applied for 1 hour at room temperature. The primary antibody was diluted in 10 % horse 
serum in PBS and applied overnight at 4 ˚C. Primary antibody solution was then removed and 
cells were washed 3 times for 5 minutes in PBS. Secondary antibody was diluted in blocking 
buffer a volume of 50 µl was applied per well and left for 2 hours at room temperature. 
Secondary antibody was removed and cells washed 3 times for 5 minutes with PBS. The cells 
were left in PBS at 4 ˚C to avoid dehydration. 
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Fluorescently labelled cells were imaged using the Incucyte S3 system. Quantification of 
percent area was done using the Incucyte S3 software. 
2.9 Confocal microscopy of cultured brain slices 
To asses cell death in cultured brain slices, propidium iodide was diluted in culture media for 
1 hour. Slices were then washed 4 times for 5 minutes in 1xPBS before fixation with 4% 
paraformaldehyde for 15 minutes. Slices were then washed 3x 5 minutes with 1x PBS and 
stained with DAPI for 15 minutes. Slices were again washed 3x 5minutes with 1x PBS and 
mounted and coversliped in line with method used for microtome cut sections.  
Slides were imaged using the Leica TCS SP5 confocal microscope, using the 20x objective.  
2.10 Reverse transcription (RT) and qPCR 
RNA (1 μg) was DNAse treated as per manufacturer’s instructions. Briefly, 1 μl DNAse, 1 μl 
RNAse inhibitor and 1 μl DNAse buffer were added to RNA and made to 10 μl with nuclease 
free water in PCR tubes. Samples were incubated at 37˚ C for 30 minutes, stop solution (1 μl) 
was then added and incubated at 6 5˚C for 10 minutes.  
Reverse transcription was performed using the Applied Biosystems RT kit as per 
manufacturer’s instructions. To DNAse treated RNA 2 μl of 10x random primers, 2 μl of 10x 
RT buffer, 0.8 μl of dNTPs, 1 μl of RT enzyme and nuclease free water to a final volume of 20 
μl (no RT enzyme was added to the no RT control). Reverse transcription was then carried 
out using a G-storm thermocycler using the conditions outlined below in Table 2.8.  
Table 2.8 Conditions used for reverse transcription of RNA to cDNA using a G-storm thermocycler 






The cDNA was then diluted 1:15 with nuclease free water and 2.4 μl added to 1 well of a 384 
well plate, with 5μ l of Qanta fastmix II, 0.2 μl of 100 μm forward primer, 0.2 μl of 100 μm 
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reverse primer (primers were designed using the UPL assay design software), 0.1 μl of 
designated UPL probe and 2.6μl of nuclease free water. All samples were assessed in 
triplicate. No RT and water controls were included for each assay. The plate was then sealed, 
and qPCR carried out using the Roche Lightcycler 480 using the cycling conditions outlined in 
Table 2.9, which were optimised for 6-Carboxyfluorescein (FAM) hydrolysis. 
Table 2.9 Cycling conditions used for FAM hydrolysis probe-based analysis of reverse transcribed RNA using the 
Roche 480 LightCycler 
Stage Temperature (˚C) Duration (mm:ss) Ramp 
Number of 
Cycles 
Preincubation 95 5:00 4.8 1 
Program 
95 0:10 4.8 
50 
60 0:30 2.5 
Cool 40 0:30 2 1 
 
Samples of cDNA were pooled from all experimental groups and a serial dilution carried out 
to create a standard curve with concentrations 1:2, 1:4, 1:8, 1:16, 1:32, 1:64, 1:128. A set of 
arbitrary concentrations correlating to their dilution was attached to the standard curve 
points. The concentration of each of the samples was then extrapolated from the standard 
curve and normalised to the extrapolated concentration of the house keeping gene, TBP (see 
Table 2.10 for a full list of primers used in qPCR). 
 
Table 2.10 List of primers and associated UPL probe used in this thesis for the assessment of gene expression 
Gene Forward primer sequence (5'→3') Reverse primer sequence (5'→3') Probe 
TBP gggagaatcatggaccagaa gatgggaattccaggagtca 97 
TNF alpha ctgtagcccacgtcgtagc ttgagatccatgccgttg 25 
IL-6 gctaccaaactggatataatcagga ccaggtagctatggtactccagaa 6 
IL-1 alpha tccataacccatgatctggaa ttggttgagggaatcattcat 29 
MBP  cctcagaggacagtgatgtgttt agccgaggtcccattgtt 16 
PGK1 L  ccaaggctttggagagtcc gatcagctggatcttgtctgc 72 
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VEGFA L  gtacctccaccatgccaagt tcatgggacttctgctctcc 64 
SLC1A2  atactggctgcaccaatgc cccaaatgaatggggtcat 58 
SLC7A5  cctttacgctgtagcagttcac gaagctgccaagctcgtg 34 
TREM2  gtggtgttgagggcttgg gctgctggcaaaggaaag 2 
FKBP5 tctgacaggccgtattccat tcgtgaaagagaagggaactg 20 
DNMT1 gctaccagtgcacctttggt atgatggccctccttcgt 1 
DNMT3a ggtgcactgaaatggaaagg gaagaggtggcggatgac 13 
ARCVF atggcctggaggatgataca tcatctgctgtgtcttcaaagg 1 
DLG4 cgctaccaagatgaagacacg caatcacagggggagaattg 10 
Aif1 (iba1)  tgggatcatcgaggaattg ggatttgcagggaggaaaa 3 
Car9  attcctgcttcactgctggt ctttggtcccacttctgtgc 16 
C4b  tctcacaaacccctcgacat agcatcctggaacacctgaa 10 
C1q  gaagatgtctgccgagcac tcctttaaaacctcggatacca 1 
Cx3cr1  ggcctagagctcaaagaaatcc cacagaccttcgatcccagt 16 
Cx3cL1  cgcgttcttccatttgtgt cacatgatttcgcatttcgt 74 
HLA-A2  accagaaaatgacaaaagacttca caggaggacaggaacgtcat 41 
MEGF10  caccccactacaggccatt tcagcgcacacactgtcac 16 
Mertk  ctgaggactgcttggatgaac cacagagaaggtgggtcgat 67 
Lgals3 (Galectin 3)  gtgaaacccaacgcaaaca ctcattgaagcgggggtta 97 
TGF beta 1  ctgggcaccatccatgac cagttcttctctgtggagctga 15 
vGLUT1 (slc17a7)  gcaggaggagtttcggaag agtgtgcgtggtcactgg 47 
Synapsin  ggacggaagggatcacatta tgagctgcttgtcttcatcc 25 
Per1  accactgagagcagcaagagt ctcaggaggctgtaggcaat 3 
Nr3c1  cagtgttttctaatggatattcaagc ggagcacaccaggcagag 10 
NR3C2  gccggcatgaacttagga ccctcttctgggctctgg 5 
Fos  gggacagcctttcctactacc agatctgcgcaaaagtcctg 67 
CRH  gaggcatcctgagagaagtcc tgttaggggcgctctcttc 34 
POMC  gcttgcaaactcgacctctc ttttcagtcaggggctgttc 72 
CRHR1  cttctccttctggggctga aggtgccaatgaggtccac 10 
HSD11b1  tctacaaatgaagagttcagaccag gccccagtgacaatcacttt 1 
Cyp11b1  agctcagacttggtgcttcag gcccatggaatacagattcac 3 
stAr  aaggctggaagaaggaaagc ccacatctggcaccatctta 2 




2.11 3’ mRNA Sequencing 
Sequencing was done on 12 samples per chip for both the hypothalamus (6 control and 6 
stress) and cortical (3 control, 3 LPS, 3 stress and 3 LPS+stress) sequencing datasets. 
Sequencing was carried out by staff at the Wellcome Trust Clinical Research Facility at the 
Western General hospital, University of Edinburgh. RNA quality was assessed using the 
Agilent Bioanalyser, with an average RNA integrity number of 9.3 across all sequenced mRNA 
samples, with all samples above 9.0. Library preparation was done using the QuantSeq 3’ 
mRNA-Seq Library Prep Kit following manufacturer’s instructions. Briefly, oligodT priming 
was initiated and reverse transcription of the first strand done before RNA was removed and 
second strand synthesized using random priming to create a double stranded cDNA library, 
followed by magnetic bead-based purification. The cDNA library was then amplified for 11 
cycles before another magnetic bead-based purification step. 
Template was prepared using the Ion PI Hi-Q OT2 200 kit as indicated by the manufacturer. 
Sequencing was done using the Ion PI Chip Kit v3, and the Ion Hi-Q Sequencing 200 Kit and 
the Ion Proton platform was used. 
2.11.1 3’ mRNA sequencing analysis 
Raw pH DAT files were produced directly from the Ion Proton platform, which were then 
converted to flow signals. In total an average of 7.7 million reads and 8.4 million reads per 
sample were achieved for the hypothalamic and cortical dataset, respectively. Polyclonal 
(21.8% for the hypothalamic dataset, 21.9% for the cortical dataset) and low quality reads 
(6.9% for the hypothalamic dataset, 5.4% for the cortical dataset) were filtered out before 
data alignment to the mm10 reference genome using STAR 2.5.3a in an automated workflow. 
Of the filtered reads 99.3% were successfully aligned to the genome in both datasets. Further 
downstream analysis was done using Degust and differential gene expression done using the 
Voom/limma and the Voom with sample weights methods for the hypothalamic and cortical 
datasets, respectively. Voom with sample weights was used to correct for within group 
variation in the smaller cortical dataset. 
2.12 Hydroxymethylated and methylated DNA immunoprecipitations 
DNA was extracted as previously described using the Qiagen Blood and Tissue kit, and 
subsequently measured using the Qubit broad range double strand DNA assay. 
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2.12.1 DNA sonication 
DNA was sonicated using the Covaris E220 Focused Ultrasonicator. 5 μg of DNA was diluted 
in 130 μl of TE in a Covaris crimp cap microTUBE. Sonication was for 18 cycles of 30 seconds 
on/ 30 seconds off at the conditions specified in Table 2.11. Sonication quality was assessed 
by gel electrophoresis using a 1% agarose gel at 90 v for 90 minutes. A 100 BP DNA ladder 
was used to check size of sonicated DNA. A range of lengths between 100 and 600 base pairs 
with a mean of 200-300 base-pairs was deemed adequate (see Figure 2.1 for an example). 






Table 2.11 Conditions for DNA sonication using 130 μl Covaris microtubes with the Covaris E220 Focused 
Ultrasonicator 
Peak Incident Power (W) 175 
Duty Factor 10% 
Cycles per Burst 200 
Treatment time (s) 305 
Temperature (⁰C) 7 
 
 
Figure 2.1 UV picture of DNA sonicated as outlined using the Covaris E220 Focused Ultrasonicator for DNA 
immunoprecipitations. DNA is fragmented to a 100-600BP range with a peak around 200BPs 
2.12.2 Immunoprecipitation 
2.5 μg of sonicated DNA was diluted in 450 μl of TE and heated for 10 minutes at 95 ˚C. 50 μl 
of 10x IP buffer was added per sample (see Table 2.12 for a list of solutions used in DNA 
immunoprecipitations). From each sample, 10 % input was taken and stored at 4 ˚C. 1 μl of 
anti-5hmC antibody was added to each sample followed by incubation under rotation at 4 ˚C 
for 3 hours. 
40 μl of magnetic protein G Dynabeads  were washed with 800 μl of PBS-BSA 0.1 % for 5 
minutes at room temperature. The beads were then collected with a magnetic rack and 
supernatant aspirated. This was repeated a total of 3 times, after the final wash the beads 
were resuspended in their original volume with 1x IP buffer. Washed beads were then added 
to the DNA-antibody mix and incubated under rotation for 1 hour at 4 ˚C.  
Magnetic beads were then collected and supernatant aspirated. Beads were washed 3x with 
1 ml of 1x IP buffer. Beads were then incubated with 250 μl of digestion buffer and 20 μl of 
20m g/ml proteinase K and incubated overnight on a Thermoshaker at 1000 RPM and 55 ˚C. 
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The beads were removed with a magnetic rack and supernatant containing DNA 
immunoprecipitated fragments used for the following steps. 
Table 2.12 Solutions used for DNA immunoprecipitations 
Solution Reagent Quantity 
IP buffer 
(10x)                                                                                        
100 mM Na-Phosphate pH 7.0  (mono and dibasic) 1 mls        
1.4 M NaCl                                                                     2.8 mls     
0.5 % Triton X-100                                                       0.5 mls     
H2O                                                                               5.7 mls    
0.22uM sterile filter   
Proteinase K 
digestion 
buffer                                                              
50 mM Tris pH 8.0                                                                  500 ul      
10 mM EDTA                                                                            200 ul     
0.5 % SDS                                                                                  250 ul      
H2O  9.05 mls 
0.22uM sterile filter                                                                                           
PBS-BSA 
0.1%  
PBS 9 mls 
BSA 10 mg/ml stock 1 ml 
 
2.12.3 DNA Clean up 
Immunoprecipitated DNA and input DNA were then processed with the Qiagen PCR 
purification kit, used as per manufacturer’s protocol. Briefly, 20 μl of 3 M sodium acetate, pH 
5, was added to each sample. 1 ml of buffer PB was then added and samples were applied to 
a column before centrifugation at 12000 RPM for 1 minute. Flow through was discarded and 
750 μl of Buffer PE added to the column before further centrifugation at 12000 RPM for 1 
minute. Flow through was discarded and column was dried via centrifugation at 12000 RPM 
for 30 seconds. DNA was eluted with 20 μl of nuclease free water. DNA was stored at -20 ˚C 
for future use. 
2.12.4 qPCR of immunoprecipitated DNA 
Sonicated DNA from samples was pooled and a standard curve made with a serial dilution 
(1:2, 1:4, 1:8, 1:16, 1:32, 1:64). To assess non-specific antibody binding an IgG control was 
included during immunoprecipitation and a water control included during PCR amplification. 
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Samples, inputs and controls were diluted with 100 μl of nuclease free water. 3 μl of sample 
was loaded per well with 5 μl of qPCR master mix with SYBR green ,0.02 μl of both forward 
and reverse primer (100 μM), and 1.96 μl of nuclease free water. Plates were centrifuged at 
2000 RPM for 2 minutes prior to thermal cycling with the LightCycler 480 Instrument (cycling 
conditions outlined in Table 2.13). 
Positive and negative control candidate regions taken from Thomson et al, 2015497 to ensure 
efficient immunoprecipitation and that minimal bias was introduced from whole genome 
amplification. See Table 2.14 for a list of primers used. 
Similar to the analysis of cDNA qPCR data, sample values were extrapolated using a standard 
curve but normalised to input rather than a house keeping gene. If evaluating PCR bias from 
whole genome amplification, raw Ct values of the samples were compared, as normalisation 
would hide bias. 
Table 2.13 Cycling conditions for qPCR analysis of DNA products using SYBR green fluorescence based LightCycler 
Stage Temperature (˚C) Duration (mm:ss) Ramp Number of Cycles 
Activation 95 10:00 4.8 1 
Denaturation 
95 0:15 4.8 
70 
60 1:00 2.5 
Melting Curve 
95 0:05 4.8 
1 65 1:00 2.5 
75   0.11 
Cooling 40 0:10 2.5 1 
 
Table 2.14 List of primers used for candidate assessment of immunoprecipitated DNA throughout this thesis 
Gene  Forward primer (5'→3') Reverse primer (5'→3') 
Car9 AAGCTGAGCTGGTGATCCTGA GGTTCTGTCTGGCCCTATGC 
VEGFA AGAGTTCCCAAAGGTGCGGG TCTCACCCTGTCACCCACG 
PGK1 TGGTGGGAAGAGGAAAACGG TGCCTTGTGGACTGATTGCT 
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BNIP3 CCTAAACAGCCCCTTGGGTT CCAGCCTGCATGAGACACTT 
GR  CACACTGCTGGGGCTTGATA CAGGGGTGCAAAGCTCAATG 
AVP  TTTAACCGTGTGGGGCAAGA GCCCAGGACTTTAACCGTGT 
Auts2 TGTATCTGGCCCACCACAAC TGGCTTGAGTTGAGTGCTGT 
Astn2  GCAAGGCTTAACGGCATCAC CAGTGGTCAGAGTCAGAGAGAC 
Tex19.2 
(Positive 
control)   GGGAGATATGTAAATGAGCTGG CATCCTTACCTCCCTGACTGAG 
GAPDH 
(Negative 
control)  CCACTCCCCTTCCCAGTTTC CCTATAAATACGGACTGCAGC 
 
2.12.5 Whole genome amplification (WGA) 
The SeqPlex Enhanced DNA Amplification Kit was used for WGA as per manufacturer’s 
instructions. 10 μl of immunoprecipitated DNA was used, with 15 PCR cycles used in the 
amplification step. Prior to adapter removal, concentration was assessed using the 
Nanodrop. For the sample with the lowest concentration the volume containing 2.1 μg of 
DNA was calculated and this volume was used for adapter removal in all samples. Final 
elution was done in 30 μl of nuclease free water for sequencing. 
2.12.6 Ion torrent proton sequencing 
Three samples were sequenced per chip, with a total of 9 samples sequenced. Three samples 
from both the control and stress group were included, along with a single pooled input from 
each group and an IgG control sample to account for non-specific binding.  
Sequencing was carried out by the staff at the Wellcome Trust Clinical Research Facility at 
the Western General Hospital in Edinburgh. Sample concentration was determined using the 
Qubit DNA high sensitivity assay and 100 ng of DNA was used for library preparation using 
the Ion Xpress Plus Fragment Library Kit. Amplification was carried out for 8 cycles and 
purified using the Agnecourt AMPure XP PCR clean up kit. Libraries were then checked for 
quality and concentration using the Agilent Bioanalyser DNA high sensitivity kit before 
pooling in equal concentration and templates prepared using the Ion PI Hi-Q OT2 200 kit and 
sequencing carried out using an Ion PI Chip kit. 
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2.12.7 meDIP sequencing analysis 
Before sequencing sample quality was assessed using the Agilent Bioanalyser DNA High 
sensitivity kit to ensure appropriate sample quality. As part of an initial, onboard quality 
control step reads below 50bps were excluded, as sequencing accuracy dramatically 
decreases below this threshold 497. This and conversion to binary alignment map (BAM) files 
were done using the Ion Torrent Suite software version 4.0.2. 
Further analysis was done using Galaxy. Using the “bamCompare” tool BAM files were 
divided into 150BPs and normalisation of data to the input and IgG controls was done. The 
resulting output of this analyses were BIGWIG files which were converted to WIG files using 
the in-built “bigwigtowig” tool. WIG files were then aligned to the mm10 reference genome 
using the “convert genome coordinates” tool, which were then sorted by genome locus and 
sliding window analysis carried out using the “sliding window over length normalised regions 
of interest” tool, with the length of each gene normalised to 100%. Analysis of differentially 
methylated regions was done using DeSeq2 (version 1.12.3). Matthew Sinton helped with 
meDIP sequencing analysis. 
2.13 Statistical analysis 
Further statistical analysis was carried out for all comparisons (excluding sequencing 
datasets, which were analysed as described above) using the SPSS v24 software (IBM). Tests 
for homogeneity of variance and normality were done for each analysed variable, with no 
non-normal distributions identifeid. An independent t-test was used to analyse 2 
independent groups. A one-way ANOVA was used to assess differences between 3 
independent groups. A two-way ANOVA was used to evaluate differences between 2 
independent variables across multiple groups. 
Data collation and organisation was done in Microsoft Excel and GraphPad Prism v5 was used 
to make graphs. A p value of less than 0.05 was taken to be statistically significant. 
 
Table 2.15 List of products used, manufacturer and catalogue number 
Product Manufacturer Catalogue number 
LPS  Sigma-Aldrich L4391 
EDTA coated tubes  Sarstedt 16.444 
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L15 media  Thermo Fisher Scientific 31415086 
Millicell culture inserts  Millipore PICM0RG50 
Dexamethasone  Sigma-Aldrich D4902 
Neural tissue dissociation kit  Miltenyi  130-092-628 
Miltenyi C-tube  Miltenyi  130-093-237 
GentleMACS dissociator  Miltenyi  130-093-235 
70µm cell strainer  Millipore 10788201 
Tryphan Blue  Thermo Fisher Scientific 15250061 
Countess II FL Automated Cell 
Counter  Thermo Fisher Scientific AMQAF1000 
Countess cell counting 
chamber slides  Thermo Fisher Scientific C10228 
PDGFRα (CD140α) Miltenyi 
microbeads Miltenyi  130-01-502 
AutoMACS Pro Separator  Miltenyi  130-092-545 
Poly D-Lysine  Sigma-Aldrich P6407 
CD11b Miltenyi microbead kit  Miltenyi  130-049-601 
Qiazol  Qiagen 79306 
RNeasy mini kit  Qiagen 74106 
Qubit RNA broad range assay  Thermo Fisher Scientific Q10211 
Qubit tubes Thermo Fisher Scientific Q32856 
6x loading dye  Thermo Fisher Scientific Q32856 
Gel red nucleic acid stain Biotium 41003 
DNeasy Blood and Tissue kit  Qiagen 69506 
Qubit DNA broad range assay  Thermo Fisher Scientific Q32853 
RIPA buffer  Thermo Fisher Scientific 89900 
Complete protease inhibitor  Roche 4693116001 
Biorad DC protein assay  Biorad 5000111 
Bovine serum albumin  Sigma-Aldrich A9418 
Western blot loading dye Licor 928-40004 
4-12% gels for western blotting Thermo Fisher Scientific XP04205  
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Chameleon pre-stained protein 
ladder  Licor 928-60000 
Filter paper and PVDF 
membrane  Bio-rad 162-0260 
Ponceau red stain  Sigma-Aldrich P7170 
Licor Revert Total Protein Stain  Licor 926-11010 
Corticosterone ELISA Enzo Life Sciences AD1-900-097 
Ultrahard blades  Thermo Fisher Scientific 3053835 
Superfrost slide  Thermo Fisher Scientific J1800AMNZ 
Lipid pen  Vectorlabs H-4000 
Mounting media  Sigma-Aldrich F4680 
Coverslips  VWR 631-0137 
SliceGolgi kit  BioEnno 0.00376 
Paraformaldehyde  Sigma 252549 
DNAse  Promega M6101 
PCR tubes  Starlab Group I1402-3700 
Applied Biosystems RT kit  Applied Biosystems 4374996 
Nuclease free water  Qiagen 129114 
384 well plate  Sarstedt 72.1985.202 
Qanta fastmix II  Quantabio 95118-012 
UPL probe library Roche 4683633001 
Plate seals VWR 391-1295 
QuantSeq 3’ RNA-Seq Library 
Prep Kit  Lexogen 012.24A 
Ion PI Hi-Q OT2 200 kit  Thermo Fisher Scientific A26434 
Ion PI Chip Kit v3  Thermo Fisher Scientific A26433 
Ion Hi-Q Sequencing 200 Kit Thermo Fisher Scientific A26433 
Ion Proton Platform Thermo Fisher Scientific 2456290-0449 
100BP DNA ladder  Thermo Fisher Scientific 15628019 
Magnetic rack  Thermo Fisher Scientific CS15000 
Proteinase K  Roche 115879001 
PCR purification kit  Qiagen 28104 
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SYBR green qPCR master mix New England Biolabs M30004E 
SeqPlex Enhanced DNA 
Amplification Kit  Sigma-Aldrich SEQXE 
 
3 The effects of LPS, hypoxia and Dexamethasone in 
Organotypic forebrain slice culture and primary OPC and 
microglia cultures 
3.1 Introduction 
PTB is often associated with antenatal exposure to synthetic glucocorticoids, hypoxia and 
inflammation. In preterm neonates these factors are rarely present in isolation and the 
nature of their interaction, and the physiological consequences of this for brain development 
are largely unknown.  
The difficulty in assessing cellular and biochemical parameters of the brain in neonatal infants 
necessitates the use of animal models. Most studies investigating the effect of early life 
insults on brain development use mice due to genetic tractability, quick reproduction and the 
presence of many conserved mechanisms and processes. I took advantage of the trajectory 
of postnatal brain development in mice to model factors associated with PTB, at times with 
neurodevelopmental relevance to PTB in humans. I used an ex vivo mouse forebrain slice 
culture model as well as primary cultures of mouse microglia and oligodendrocyte precursor 
cells (OPCs) to model the effects of Dexamethasone, LPS and/or hypoxia on various 
physiological and biochemical parameters. 
Epigenetic marks such as DNA methylation and hydroxymethylation are potential 
mechanisms through which PTB associated factors may mediate an effect. They are 
dynamically present in the brain during development 110,204 and are altered in 
neurodevelopmental disorders 187 and following preterm birth 184. I therefore used this 
forebrain slice culture model to assess the effect of Dexamethasone, hypoxia and/or LPS on 
the expression of candidate modifiers of DNA methylation state. 
Human studies have identified genetic variants associated with the genes FADS2 (Fatty acid 
desaturase 2), ARVCF (Armadillo repeat gene deleted in Velo-Cardio-Facial syndrome) and 
DLG4 (Discs Large Homology 4) as conferring susceptibility to WMI in preterm infants 251,498. 
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I therefore also investigated the effect of Dexamethasone, hypoxia and/or LPS on expression 
of these candidate genes to understand the mechanisms and interactions involved in their 
relationship with PTB and WMI. 
Sparrow et al 184, identified differential methylation associated with several genes involved 
in neurodevelopment (e.g. SLC7A5, SLC1A2 and TREM2) in buccal cells of preterm infants at 
term equivalent age. However, the relevance of this to the brain and the underlying causative 
mechanisms are unclear. Therefore, I investigated the expression of these candidate genes 
in the forebrain slice culture model outlined above during Dexamethasone, LPS and/or 
hypoxia exposure. 
As discussed previously understanding the neonatal response to hypoxia and how this 
contributes to atypical neurodevelopment is crucial for the development of novel 
therapeutics. 5hmC is dynamically present through neurodevelopment 204, enriched in 
neurons 147 as well as genes associated with neurodevelopment and ASD 499. Previous studies 
have demonstrated 5hmC is enriched at hypoxia response genes following hypoxia in cancer 
cells 234. I tested the relevance of this to early brain development in the organotypic forebrain 
culture model using a candidate approach. As discussed previously, 5hmC at certain genomic 
elements is associated with active transcription, so understanding its involvement in the 
hypoxia response would provide valuable mechanistic insight. 
WMI is a common result of preterm birth and may be caused by several factors. WMI is of 
particular importance as it is an indicator of future neurodevelopmental outcome 59. OPCs 
are neural stem cells committed to the oligodendrocyte lineage and, as discussed earlier, 
they are particularly susceptible to PTB related factors. OPC proliferation and differentiation 
dynamics are crucial to correct myelination, therefore I investigated the effect of 
Dexamethasone, LPS and/or hypoxia on the ability of primary cultured mouse OPCs to 
produce mature myelinating oligodendrocytes. 
A high incidence of inflammation is associated with PTB and microglia are one of the primary 
cellular mediators of inflammation within the brain. As such understanding the microglial 
response to PTB related factors is important. Microglia are also crucial to several homeostatic 
developmental processes such as myelination and synaptic pruning 500,501. Microglia are also 
important in the pathogenesis of neurodevelopmental disorders with the cortical 
transcriptome of individuals with ASD showing a specific signature indicating microglial 
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dysfunction 33. Therefore, I also investigated the effect of Dexamethasone, hypoxia and/or 
LPS on the secretion of cytokines from primary microglia isolated from neonatal mice. 
3.2 Aims and hypotheses 
3.2.1 Hypotheses 
1. Dexamethasone, LPS and/or hypoxia induce transcriptomic differences in a forebrain 
slice culture model 
2. Changes in transcription will associate with changes in genomic 5hmC in a forebrain 
slice culture model 
3. Dexamethasone, LPS and or/hypoxia will produce functional alterations in primary 
glial cultures 
3.2.2 Aims 
1. To compare ex vivo cultured forebrain slices to littermate in vivo tissue at similar ages 
2. To investigate the dose at which Dexamethasone, LPS and hypoxia produce a 
physiological response under ex vivo culture conditions 
3. To evaluate the effect of these factors independently and in combination on 
candidate gene expression 
4. To evaluate 5hmC at candidate loci using DNA hydroxymethylation 
immunoprecipitations following Dexamethasone, LPS and/or hypoxia 
5. To investigate the effect of these factors on the differentiation and cytokine 
secretion of primary cultured mouse OPCs and microglial respectively  
3.3 Methods 
3.3.1 Animals 
Adult mice were housed 3 per cage (2 females and 1 male) for breeding, and offspring were 
killed on P0/P1 or P8 as indicated below with an overdose of anaesthetic. Brains were 
extracted from both sexes for all experiments.  
3.3.2 Forebrain slice cultures 
In order to identify the optimal forebrain slice culture period, I undertook initial 
characterisation experiments in which 300µm forebrain sections were cultured for 7 or 10 
days. At the end of the culture period slices were exposed to propidium iodide for 1 hour to 
label dead cells, then slices were washed 3 times in PBS and fixed in 4% PFA before washing 
and staining with DAPI to label all cells. Slices were then visualised using confocal microscopy. 
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For all forebrain slice culture experiments, an n of 1 was defined as a single forebrain slice 
from a single animal. Forebrain slices were maintained at 37˚C and 5% CO2 unless otherwise 
stated. 
 
To compare the ex vivo slice culture period to in vivo development, after birth half of the 
litter was randomly assigned to either a culture or non-culture group. The culture group were 
killed, and forebrain slices cultured as per the protocol described previously. The non-culture 
group remained with their mother until the end of the culture period (P8) after which they 
were killed before their brains removed and forebrain isolated. Tissue was either fixed for 
immunohistochemistry and Golgi-cox staining or snap frozen on dry ice for subsequent RNA 
extraction. 
To evaluate optimum doses of Dexamethasone and LPS and which concentration of oxygen 
to use, dose-response curves were generated with increasing concentrations of each 
condition. RNA was extracted and cDNA generated before qPCR analysis of a well 
characterised response gene for each condition. 
For gene expression profiling, slices were cultured for 7 days before incubation with 100nM 
Dexamethasone for 5 hours, before media removal and washing with PBS. On the subsequent 
day, slices were exposed to 100ng/ml of LPS for 5 hours before washing with PBS and fresh 
media replacement, followed by immediate incubation under 1% oxygen for 24 hours. Slices 
were then snap frozen on dry ice for subsequent RNA extraction and gene expression 
profiling via qPCR. 
3.3.3 DNA hydroxymethylation immunoprecipitation (hmeDIP) 
To assess 5hmC at candidate regions, I used hmeDIP. DNA was extracted from cultured 
forebrain slices using the Qiagen blood and tissue DNA extraction kit as per manufacturer’s 
instructions. Next, 2.5 µg of DNA was sonicated to a mean length of 250 base pairs using a 
Covaris Ultrasonicator. Sonicated DNA was incubated with anti-5hmC antibody, which was 
then pulled down using magnetic protein A coated beads. The beads were washed 
thoroughly in buffer as described previously and enriched 5hmC released by an overnight 
digestion with proteinase K at 55 ˚C. DNA enriched for 5hmC was then purified using the 
Qiagen PCR purification kit. Candidate regions were interrogated using qPCR, with primers 
designed using the UCSC genome browser and primer BLAST. Regions were normalised to 
10% input. An IgG and a water control were included with each experiment. 
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OPC cell differentiation and microglial cytokine production 
The effect of Dexamethasone, LPS and/or hypoxia on OPC cell differentiation and microglial 
cytokine production was examined using primary mouse cell cultures. Mice at P0-P1 were 
killed by overdose of anaesthetic and brains extracted. Whole brain tissue from 4 pups was 
dissociated using the Miltenyi Neural Dissociation kit (for an n of 1). PDGF-Rα or CD11b 
coated beads were used for MACS isolation of OPCs or microglia respectively. Cells were 
seeded into 96 well plates at 12,500 or 25,000 cells per well for OPC and microglia culture 
respectively and maintained at 37˚C and 5% CO2 unless otherwise stated. Experiments were 
done in triplicate and averaged to produce an n of 1. 
 
Cells were cultured for 24 hours before exposure to Dexamethasone, LPS and/or hypoxia. 
Similar to the forebrain slice culture paradigm, primary cells were exposed to 100nM 
Dexamethasone for 5 hours and subsequent washing with PBS, followed by exposure to 
100ng/ml LPS for 5 hours and subsequent incubation under 1% oxygen for 24 hours. Media 
from cultured microglia was collected at the end of the culture period for cytokine ELISAs, 




3.4.1 Comparison of candidate gene expression in cultured slices and non-cultured 
littermate tissue 
In Figure 3.1, candidate gene expression was measured in cultured slices and non-cultured 
tissue. As seen in Figure 3.1A, a range of candidate genes showed no difference in expression 
following the culture period when compared to non-culture littermates. However, a 
difference was seen in the expression of DNMT1 and a trend was seen for HIF1α, as seen in 





Figure 3.1 Relative expression of candidate genes in forebrain slices cultured for 7 days and forebrain tissue from 
P8 littermates.  (A) no significant difference in expression of TET1, TET2, DNMT3a or MBP (degrees of freedom 
(df)=6 for all 4, p=0.665, 0.196, 0.362 and 0.332 respectively) between non-cultured tissue (white columns) and 
cultured (grey columns) slices was seen. In (B) downregulation of DNMT1 expression during the culture period 
(df=5, p=0.001) was identified. In (C) a trend towards an upregulation of HIF1α in cultured slices compared to non-
cultured tissue (df=6, p=0.015) was seen. N=6 and 7 for cultured and non-cultured groups respectively. Data were 
analysed using an independent t-test, error bars indicate standard error of the mean. A p-value<0.008 was 
statistically significant after Bonferroni correction for multiple comparisons. ** indicates p<0.01. Expression was 




























3.4.2 Dexamethasone, LPS and hypoxia induce physiological responses in an ex vivo 
forebrain slice culture model 
I tested the ability of Dexamethasone, LPS and hypoxia to produce physiological responses in 
the forebrain slice culture model. Slices were incubated with varying concentrations of 
Dexamethasone, LPS or Oxygen. RNA was then extracted, and expression of well 
characterised response genes was measured. As seen in Figure 3.2A, the expression of FKBP5 
increased following all doses of Dexamethasone. In  Figure 3.2B, the expression of IL-1α, IL-6 
and TNF-α increased in a dose-dependent fashion with LPS. Similarly, in Figure 3.2C, the 
expression of PGK1 (phosphoglycerate kinase 1) and VEGFA (vascular endothelial growth 
factor A) increased in a dose-dependent fashion in response to decreasing oxygen 
concentrations. Also, in 1% oxygen there was an accumulation of the HIF1α protein (Figure 
3.2D). Subsequent experiments were carried out using 100nM Dexamethasone, 100ng/ml 
LPS and 1% Oxygen. 
 
 
Figure 3.2 Dexamethasone, LPS and hypoxia produce physiological effects in the forebrain slice culture paradigm. 
(A) relative expression of FKBP5 increases with exposure to 5 hours of Dexamethasone. (B) following 5 hours of 
LPS exposure the expression of IL1α, IL6 and TNFα (represented in open, grey and black bars respectively) increased 
in a dose-dependent fashion with LPS concentration. (C) there was a dose-dependent increase in the relative 










































































oxygen) is represented by the open bars and hypoxic conditions of 3% and 1% groups are represented by grey and 
black bars respectively. (D) HIF1α protein was assessed by western blot, with representative bands shown, and 
normalised to total protein showing an increase in presence at 1% oxygen (df=3, p=0.009) as indicated by an 
independent t-test. ** indicates p<0.01. For all experiments shown n=4-8 and error bars indicate standard error 
of the mean. Gene expression was normalised to TFRC and TBP. 
 
3.4.3 PTB related factors alter the expression candidate genes following 
combinations of Dexamethasone, LPS and hypoxia 
I tested the immediate transcriptional response of candidate genes to all combinations of 
Dexamethasone, LPS and hypoxia. These candidate genes were taken from a number of 
sources, including previously described modifiers of DNA methylation (TET1, TET2 and 
DNMT3a), candidates identified by Sparrow et al (TREM2, SLC7A5 and SLC1A2) and 
candidates are involved in perinatal WMI (FADS2, DLG4 and ARVCF). In FIGURES I show the 
genes which show consistent trends or which achieve statistical significance, but all statistical 
comparisons are shown in Table 3.1.  
As seen in FIGURE, I investigated the independent effect of Dexamethasone, LPS or hypoxia 
on candidate gene expression using qPCR. As can be seen in FIGURE A, there were no 
significant effects of Dexamethasone on expression of these genes. As can be seen in FIGURE 
B, there were also no significant effects of hypoxia on candidate gene expression but there 
was a non-significant trend towards an increase in TET1, TET2 and SLC7A5 expression. 
Similarly, as seen in FIGURE C, there were also no significant effects of LPS alone on the 




Figure 3.3 Relative expression, normalised to TBP of Dexamethasone (A), hypoxia (B) and LPS (C) in the forebrain 
slice culture model, of candidate genes. In A, there was no difference in expression of TET1 (p=0.841, df=9), TET2 
(p=0.963, df=9), DNMT3A (p=0.485, df=9), SLC7A5 (p=0.108, df=9) or ARVCF (p=0.68, df=12) following 


























































































(p=0.013, df=12), TET2 (p=0.013, df=21), DNMT3A (p=0.835, df=11), SLC7A5 (p=0.007, df=21) or ARVCF (p=0.283, 
df=9) following hypoxia. In C, there was no difference in expression of TET1 (p=0.07, df=15), TET2 (p=0.894, df=15), 
DNMT3A (p=0.835, df=11), SLC7A5 (p=0.117, df=15) or ARVCF (p=0.326, df=5) following LPS. All comparisons were 
made using an independent t-test following Bonferroni correction for multiple comparisons. Data are expressed 
as mean and standard error bars. 
Next, I investigated the effect of combinations of these insults on the expression of the same 
genes by qPCR. As seen in FIGURES A and B there were no significant effects on gene 
expression for the “Dexamethasone and hypoxia” or “Dexamethasone and LPS”. However, 
there was a non-significant trend towards an increase in expression of TET1 and TET2 
following Dexamethasone and hypoxia, as seen in FIGURE A. I next looked at the effects of 
“LPS and hypoxia” and “Dexamethasone, LPS and hypoxia” in FIGURE C and D, respectively. 
In FIGURE C, ARVCF was significantly increased in both groups. As seen in FIGURE D, TET2 was 
significantly increased with “Dexamethasone, LPS and hypoxia”, but a similar trend was 
observed for “LPS and hypoxia” as seen in FIGURE C. Trends towards an increase in expression 
were also seen for TET1 and SLC7A5 in both groups. 
 
Figure 3.4 Outline of candidate gene expression following Dexamethasone (Dex) and hypoxia (A), Dex and LPS (B), 
LPS and hypoxia (C) and Dex, LPS and hypoxia (D). In A there were no differences in candidate gene expression 
following Dexamethasone and hypoxia of TET1 (p=0.014, df=22), TET2 (p=0.102, df= 22), DNMT3a (p=0.861, 
df=28), SLC7A5 (p=0.704, df=14) or ARVCF (p=0.012, df=17) after correction for multiple comparisons. In B, there 
were no differences in expression of TET1 (p=0.029, df=13), TET2 (p=0.572, df=11), DNMT3A (p=0.258, df=15), 
SLC7A5(p=0.207, df=21) or ARVCF (p=0.391, df=10) following Dexamethasone and LPS, after correction for 
multiple comparisons. In C, ARVCF (p=0.001, df=19) was significantly increased but no difference was seen in 
expression of TET1 (p=0.018, df=16), TET2 (p=0.007, df=20), DNMT3A (p=0.11, df=21) or SLC7A5 (p=0.018, df=21) 
following LPS and hypoxia. In D, TET2 (p=0.001, df=21) and ARVCF (p=0.0003, df=19) were significantly increased 

























































































































(p=0.01, df=19) after Dexamethasone, LPS and hypoxia. ** indicates p<0.006 (adjusted threshold for statistical 
significance, *** indicates p<0.001. All comparisons were made using an independent t-test and followed by a 
Bonferroni correction for multiple comparisons. Data are expressed as mean and standard error bars. 
Table 3.1 Table showing the p-value (with degrees of freedom) in all candidate genes and conditions analysed. 
Each condition was compared with their own control group using an independent t-test with a Bonferroni 
correction post-hoc. The adjusted p-value threshold for statistical significance was p<0.006. All comparisons 
which met this criteria are highlighted in bold. 
 
3.4.4 There is no change in 5hmC at the SLC7A5 locus following LPS and/or hypoxia 
SLC7A5 was subject to the highest level of differential methylation in Sparrow et al and I 
found it to be increased in expression following various combinations of hypoxia. I also saw 
a similar pattern with the TET enzymes (see Error! Reference source not found.), and as 
discussed in the introduction, 5hmC is thought to mark sites of active transcription when 
located within the gene body. Therefore, I next assessed 5hmC levels within well conserved 
regions of the SLC7A5 gene body following LPS and/or hypoxia. I used hmeDIP and assessed 
enrichment through qPCR at candidate regions. The regions assessed within the SLC7A5 
mouse gene can be seen in Figure 3.3A, alongside an indication of human conservation. There 
were no differences in 5hmC following LPS and/or hypoxia at any of the regions assessed, see 
Figure 3.3B. Fitting with the previous literature, 5hmC levels across these 3 loci were 
correlated with each other, see Figure 3.3C. 
Gene Dex LPS Hypoxia Dex and LPS Dex and Hypoxia LPS and Hypoxia Dex, LPS and Hypoxia
TET1 0.841 (9) 0.07 (15) 0.013 (12) 0.029 (13) 0.014 (22) 0.018 (16) 0.028 (16)
TET2 0.963 (9) 0.894 (15) 0.013 (21) 0.572 (11) 0.102 (22) 0.007 (20) 0.001 (21)
DNMT3A 0.485 (9) 0.835 (11) 0.368 (14) 0.258 (15) 0.861 (28) 0.11 (21) 0.441 (18)
ARVCF 0.638 (12) 0.326 (5) 0.283 (9) 0.391 (10) 0.012 (17) 0.001 (19) 0.0003 (19)
DLG4 0.84 (12) 0.068 (6) 0.173 (13) 0.248 (12) 0.173 (14) 0.071 (20) 0.101 (20)
FADS2 0.325 (12) 0.366 (5) 0.894 (15) 0.004 (15) 0.004 (21) 0.286 (20) 0.309 (19)
SLC7A5 0.108 (9) 0.117 (15) 0.007 (21) 0.207 (15) 0.704 (14) 0.018 (21) 0.01 (19)
SLC1A2 0.108 (13) 0.929 (12) 0.341 (12) 0.057 (15) 0.486 (13) 0.046 (24) 0.971 (24)
TREM2 0.045 (14) 0.503 (4) 0.798 (12) 0.373 (15) 0.248 (14) 0.809 (14) 0.1 (12)




Figure 3.3 5hmC was assessed at the SLC7A5 locus following LPS and/or hypoxia. In A) the mouse SLC7A5 gene as 
seen through the UCSC genome browser is seen in the top blue track, with exons represented as thicker segments. 
Underneath, the black track represents the degree of conservation with the human SLC7A5 locus, thick segments 
represent regions of high conservation. The red vertical lines indicate the regions assessed for 5hmC and are 
numbered as they are referenced in the subsequent graphs (B-G). In B-D, the level of 5hmC (normalised to 10% 
input) at different intragenic regions of the 5hmC locus is shown (B- p=0.085 LPS, 0.907 hypoxia and 0.068 
interaction; f-statistic= 3.298, 0.014 and 4.695 respectively; df=32) (C- p=0.258, 0.679 and 0.538; f-statistic=1.357, 
0.177 and 0.393, respectively; df=32) (D- p=0.098, 0.531, 0.83; f-statistic=4.01, 4.07 and 0.47, respectively; df=32), 
no differences were found across any of the regions and conditions assessed but there was a trend towards an 
interaction between LPS and hypoxia in region 1 (B, p=0.068). In E-F the correlation between 5hmC at the 3 
different regions was examined with Region 1 showing a positive correlation with Region 2 (panel E; p=0.001 and 
r=0.551) and Region 3 (panel F; p<0.001 and r=0.841), and also 5hmC in Region 2 was positively correlated with 
5hmC in Region 3 (panel G, p=0.01 and r=0.428). A two-way ANOVA was used to analyse data represented in B-D, 
with error bars representing standard error of the mean. A Pearson’s correlation was carried out in E-G. 
3.4.5 Accumulation of 5hmC at hypoxia response genes following LPS and/or hypoxia 
I saw an increase in expression of the TET enzymes following hypoxia, and 5hmC has been 
implicated in the hypoxia response in cancer 234. Therefore, I looked at the presence of 5hmC 


























































































































































































































between LPS and hypoxia at the Car9 locus. There were no effects of LPS and/or hypoxia at 
the PGK1, VEGFA or BNIP3 loci, as seen in Figure 3.4 B-D. 
 
Figure 3.4 5hmC at candidate regions associated with classic hypoxia response genes following LPS and/or 
hypoxia. In A) 5hmC associated with the Car9 locus was affected by hypoxia (p=0.026, f-statistic=5.768, df=20) 
and an interaction between LPS and hypoxia (p=0.013, f-statistic=7.423, df=20) was seen with no effect of LPS 
(p=0.704, f-statistic=0.149, df=20). Similar graphs are shown in B, C and D for the PGK1 (p=0.805, 0.491 and 0.937; 
f-statistic=0.062, 0.491 and 0.006 for hypoxia, LPS and an interaction, respectively, df=20), VEGFA (p=0.948, 0.498 
and 0.547; f-statistic=0.004, 0.478 and 0.376 for hypoxia, LPS and an interaction respectively) and BNIP3 (p=0.419, 
0.542 and 0.478; f-statistic=0.666, 0.377 and 0.511 for hypoxia, LPS and an interaction, respectively, df=20) loci 
respectively, none of which showed alterations in 5hmC at the candidate regions tested. A two-way ANOVA was 





























































































































































































3.4.6 Morphological assessment of primary mouse OPCs and microglia after LPS 
In Figure 3.5, primary mouse OPCs and microglia isolated from the neonatal mouse forebrain 
were imaged using brightfield before and after LPS administration. Under normal conditions 
(Figure 3.5A) OPCs display a typical bipolar morphology. Following exposure to LPS (Figure 
3.5C), some cells retain this morphology, but some cells appear with a more rounded cell 
body, indicative of a mature oligodendrocyte. Under normal LPS-free conditions (Figure 3.5B) 
microglia have a characteristic elongated morphology. Following exposure to LPS (Figure 
3.5D), they assume a more ramified morphology with a rounder cell body which is typical of 
a transition to an inflammatory phenotype. 
 
Figure 3.5 Assessment of primary mouse OPC and microglia cultures before (A and B) and after (C and D) LPS. In 
A) a bipolar morphology can be seen, which is characteristic of OPCs, after LPS treatment (C) these cells display a 
more ramified morphology which is consistent with a mature oligodendrocyte. In B) under homeostatic conditions, 
microglia have an elongated cell body and long processes which is typical of quiescent state microglia. In D) after 
A B
C D
















exposure to LPS microglial cell bodies become rounded and have a more ramified structure, a phenotype typically 
associated with inflammatory conditions. 
 
 
3.4.7 LPS and hypoxia increase microglial cytokine release 
Microglia are one of the primary mediators of neuroinflammation, and the elevated presence 
of cytokines in the blood is associated with adverse neurodevelopmental outcomes 502. As 
such, the local microglial production of cytokines in response to PTB related factors may also 
have and important role. To overcome the problem of cellular heterogeneity, I isolated and 
cultured microglia from the forebrain of neonatal mice and exposed them to 
Dexamethasone, LPS and/or hypoxia and measured cytokine secretion into the media, a 
schematic of the paradigm is shown in Figure 3.6A. In Figure 3.6B, TNFα was increased 
following LPS with undetectable levels in control conditions. There was no independent or 
interaction effect associated with Dexamethasone or hypoxia. In Figure 3.6C, IL1β was 
increased following hypoxia. There was no independent or interaction effect associated with 
Dexamethasone or LPS. In Figure 3.6D, IL6 was increased following LPS. There was no 





Figure 3.6 The effect of LPS, hypoxia and Dexamethasone on TNFα (B), IL1β (C) and IL6 (D) production in primary 
cultured microglia. In A) a schematic of the experimental design shows CD11b cells were isolated from neonatal 
mouse forebrains and cultured in the presence of Dexamethasone, LPS and/or hypoxia before quantification of 
cytokines from the supernatant using an ELISA. In B) TNFα was increased in the media following LPS (p=0.003, f-


















































































statistic=0.061, df=15) or interaction (p=0.291, f-statistic=1.22, df=15) between the factors. In C) IL1β was 
increased following hypoxia (p<0.001, f-statistic=27.084, df=15) with no effect of LPS (p=0.279, f-statistic=1.25, 
df=15), Dexamethasone (p=0.88, f-statistic=0.024, df=15) or interaction (p=0.279, f-statistic=1.25, df=15) between 
the factors. In D), IL6 was increased following LPS exposure (p<0.001, f-statistic=29.981, df=15) with no effect of 
hypoxia (p=0.294, f-statistic=1.203, df=15), Dexamethasone (p=0.145, f-statistic=2.425, df=15) or interaction 
(p=0.294, f-statistic=1.203, df=15) between the factors. ** indicates p<0.01 and *** indicates p<0.001. Data were 
analysed using a three-way analysis of variance (ANOVA). A p-value<0.016 was said to be statistically significant 
following Bonferroni correction for multiple comparisons. Error bars show standard error of the mean. N= 4-6 for 
all groups. 
3.4.8 Hypoxia is associated with a decreased production of mature myelinating 
oligodendrocytes in primary cultured mouse OPCs 
Reduced numbers of mature myelinating oligodendrocytes may cause hypomyelination and 
facilitate WMI. As such, it is important to understand the factors associated with PTB which 
may affect the production of mature oligodendrocytes from OPCs. To examine this, PDGF-
Rα+ cells were isolated from neonatal mouse forebrain tissue and exposed to 
Dexamethasone, LPS and/or hypoxia. The ability of these cells to produce mature myelinating 
oligodendrocytes was then measured (described in Figure 3.7A). 
In Figure 3.7B, hypoxia decreased the percentage of MBP positive oligodendrocytes at the 
end of the differentiation period. There was a trend towards the same effect for LPS and 




Figure 3.7 The effect of LPS, hypoxia and Dexamethasone on OPC differentiation. In A) a schematic of the 
experimental design shows PDGF-Rα cells were isolated from neonatal mouse forebrains and cultured in the 
presence of Dexamethasone, LPS and/or hypoxia before addition of 100units/ml of Leukemia inhibitory factor (LIF), 
to stimulate differentiation, for 3 days. Cells were then fixed, stained and imaged. In B) there was a decrease in 
the proportion of MBP positive cells following hypoxia (p=0.016, f-statistic=7.067, df=15) and a trend towards a 
decrease associated with LPS (p=0.051, f-statistic=4.365, df=15), with no effect of Dexamethasone (p=0.319, f-
statistic=1.052, df=15) or an interaction between the factors (p=0.141, f-statistic=2.371, df=15). * indicates 





























In this chapter I show that: 
1. There is comparable candidate gene expression between cultured slices and non-
cultured littermates but there were significant differences in DNMT1 and HIF1α 
expression 
2. Dexamethasone, LPS and hypoxia produce physiological responses under ex vivo 
culture conditions 
3. There was limited interactions between Dexamethasone, LPS and hypoxia in terms 
of candidate gene expression 
4. When assessing 5hmC, there was a significant interaction between LPS and hypoxia 
at Car9, a classic hypoxia response gene 
5. There were no significant interactions found between LPS and hypoxia in terms of 
microglial cytokine secretion and OPC differentiation in primary glial culture systems 
3.5.1 Forebrain slice culture model 
Multiple forebrain slices can be obtained from a single animal and a single animal can 
therefore be represented in multiple groups of the ex vivo forebrain slice culture model. As 
such each group is composed of very similar tissue composition, thereby reducing variation 
between groups and reducing the number of animals used. It also provides more defined 
conditions than an in vivo environment, facilitating the analysis of specific pathways and 
mechanisms.   
The experimental design for the initial experiments (Figure 3.1-3.5) described in this chapter 
were suboptimal. A separate control group was used for the comparison with each individual 
group which hinders comparisons across groups. Future studies should design experiments 
so that an individual control group is compared across all experimental conditions. This would 
facilitate statistical analysis with an ANOVA and accordingly increase statistical power. 
3.5.2 Dexamethasone 
I used 100nM of Dexamethasone in these experiments. This is a relatively low dose and was 
used to model the in utero exposure to Dexamethasone many preterm infants receive. This 
concentration has been used previously in various brain culture paradigms 503,504 but to my 
knowledge, this is the first instance of this concentration being used to examine factors 
associated with early life brain development. 
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I used expression of FKBP5 as a marker of Dexamethasone exposure. Transcription of FKBP5, 
as discussed in the introduction, is directly induced by the GR when a ligand is bound and 
FKBP51 (protein of the FKBP5 gene) acts to negatively regulate GR mediated effects. In Figure 
3.2, the expression of FKBP5 saturates at the very low dose of 50nM of Dexamethasone. This 
implies a low threshold at which transcription of FKBP5 is maximally induced by 
Dexamethasone. A previous study saw a similar result using cortisol exposure in cultured 
human adipose tissue 505. Considering there is not a consensus Dexamethasone 
concentration to use in culture which models prenatal Dexamethasone exposure, I 
proceeded with 100nM as it has previously been used in the literature and my dose-response 
experiment demonstrated a clear induction of FKBP5 expression at that concentration 
implying a physiological response.  
As outlined previously, ex vivo slices, or primary cultured cells were exposed to 
Dexamethasone for 5 hours on the day prior to LPS exposure. The in vivo half-life of 
Dexamethasone is 36-72 hours 506, as such the 5 hour exposure used here was low. LPS 
exposure was not initiated until 19 hours after Dexamethasone was removed from the slices, 
and from this timepoint it was a further 29 hours before the slices were processed and 
analysed (5 hours of LPS and 24 hours of hypoxia). It is therefore likely that any effects of 
Dexamethasone administration had subsided by the time of analysis. However, my primary 
interest in this study was to investigate the relationship between LPS and hypoxia in the 
context of prior Dexamethasone exposure and to investigate whether this had any 
‘programming’ effect on this interaction. 
3.5.3 Relevance of hypoxia 
The forebrain slice culture paradigm is done using a semi-permeable membrane with the 
slices maintained at the liquid-air interface. The slices were maintained under control 
conditions at room oxygen levels of 21% (a partial pressure of 160mmHg). Research in the 
awake adult mouse brain shows that physiological oxygen concentrations in the forebrain 
vary between 80mmHg in larger arterioles and 20mmHg or below in the capillary bed 507. 
These values are likely to be similar, if not lower, in the neonatal brain where hypoxia is a 
critical mediator of normal brain development 508. Therefore, one major limitation of this 
study is the supraphysiological oxygen concentrations used for the control group.  
As seen in Figure 3.1, HIF1α gene expression was increased in cultured forebrain tissue in 
comparison to in vivo conditions. Upregulation of HIF1α expression has previously been seen 
85 
 
in response to hyperoxia in tumours 509. Therefore, the exposure to supraphysiological 
oxygen concentrations is a possible cause of the increased HIF1α expression seen in the 
forebrain slice culture. Despite this, a dose-dependent increase in the expression of classic 
HIF1α response genes (PGK1 and VEGFA) was seen following hypoxia. There was also an 
increase in HIF1α protein (Figure 3.2) after 1% oxygen exposure which indicates a 
physiologically relevant response to hypoxia in this model. 
3.5.4  
Effects on candidate gene expression  
As seen in Error! Reference source not found., both TET1 and TET2 were increased in 
expression following hypoxia both independently and with various combinations of 
Dexamethasone and LPS. Previous studies have shown increased expression of the TET 
enzymes following hypoxia occurs in some, but not all, cell lines 153. To my knowledge, 
upregulation of TET1 and TET2 during hypoxia has not previously been reported during early 
postnatal brain development. As discussed in the introduction, the TET enzymes are 
members of the α-ketoglutarate dependent dioxygenase family and are therefore dependent 
on oxygen as an essential substrate. Therefore, it is somewhat paradoxical that a lack of 
oxygen should upregulate the expression of these enzymes. However, Laukka et al 
demonstrated that the Km of TET1 and TET2 for oxygen is 30µM and therefore, they can 
maintain normal activity even under hypoxic conditions 510. 
HIF1α has been shown to recruit TET1 to HIF1α target sites across the genome to mediate 
5mC conversion to 5hmC and facilitate subsequent hypoxia induced gene expression changes 
in cancer cell lines 234. TET1 has also been reported to interact with HIF1α and HIF2α in a 
fashion independent of its catalytic subunit. Wang et al show TET1 binds to HIF1α and acts 
to stabilise its C-terminus, while TET1 competes with PHD2 for hydroxylation sites on the 
HIF2α protein, and in doing this reduces HIF2α hydroxylation and therefore its degradation 
511. However, this work was carried out in cancer cell lines and its relevance to other, non-
cancerous cells and in vivo conditions is unclear. 
Future work in this area should consider whether TET mediated hydroxymethylation is 
integral to the hypoxia response in vivo and if this involvement is a transient mechanism to 
facilitate hypoxic gene expression or part of a pathogenic series of events which themselves 
can alter brain development and neurodevelopmental outcome. The manipulation of 5hmC 
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is a key tool for understanding its importance in these processes. Typically, cytosine 
analogues such as 5-azacytidine are used to cause experimental non-specific DNA 
demethylation through their integration during DNA repair or replication instead of resident 
cytosine nucleotides. However, to understand the accumulation of 5hmC during hypoxia at 
hypoxia response genes, site specific manipulation of 5hmC is needed. A recent tool 
described by Xu et al, uses the fusion of a Cas9 (with disabled endonuclease activity) to the 
TET3 catalytic domain, which can be recruited in a site-specific manner to DNA by guide RNAs 
to facilitate 5hmC induction 512. This technology may prove to be a useful tool in the 
elucidation of 5hmC importance during hypoxia and normal development. 
As seen in Error! Reference source not found., in my ex vivo forebrain slice culture paradigm, 
SLC7A5 expression is specifically increased in all instances of hypoxia (except for 
Dexamethasone + hypoxia). SLC7A5 expression has previously been shown to be upregulated 
during hypoxia in various cancer cell lines 513–516 but to my knowledge this has not been shown 
in non-cancerous brain tissue or indeed using an ex vivo mouse forebrain culture system. 
Tarlungeanu et al showed that deletion of SLC7A5 from endothelial cells produces abnormal 
neurodevelopmentally-regulated behaviours in mice and these are rescued with leucine and 
isoleucine intra cerebroventricular administration. They also demonstrated that mutations 
within SLC7A5 are associated with ASD in humans 186. Previously, Sparrow et al showed that 
SLC7A5 is differentially methylated in buccal swabs taken at term equivalent age from infants 
born preterm, when compared to term born controls 184. Dysregulation in SLC7A5 (whether 
this be upregulation or downregulation) may therefore play a role in adverse perinatal events 
and affect neurodevelopmental outcome. 
LPS has been shown to sensitise to subsequent hypoxia exposure in previous studies 517. Here 
I provide limited support for this hypothesis. The expression of ARVCF (Error! Reference 
source not found.) was not changed by LPS or hypoxia independently but was increased 
when LPS preceded hypoxia and this was not affected by Dexamethasone. The inability of 
Dexamethasone to ameliorate this alteration in expression may be because it was transiently 
present in the media and the anti-inflammatory effects of Dexamethasone (which as 
discussed previously are primarily mediated through increased NFKBIA transcription) have 
subsided by the time of LPS exposure. Another possibility is that, as NFKBIA acts to limit the 
activation of the NFkB pathway, the interaction between LPS and hypoxia occurs 
independently of NFkB. For example a signal could be propagated through IRF5 or MAPK/AP-
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1, which can mediate a response to LPS independently of NFkB signalling 518 and which are 
also involved in hypoxia signalling 519. 
3.5.4.1 5hmC at hypoxia response loci 
I found an interaction between hypoxia and LPS at an analogous region of the Car9 gene 
which was enriched in Mariani et al 234. I also found an effect of hypoxia alone but the 
presence of a interaction with LPS makes inferring biological significance from this difficult, 
as can be seen with a visual inspection of the data (Figure 3.4). There were no changes in 
5hmC among other hypoxia response genes and this may be for a number of reasons. Firstly, 
the previous study looked primarily in human immortalised cancer cell lines which typically 
have dramatically reduced 5hmC levels 520. If this was true for the cell lines used in the 
Mariani et al study, then small effect sizes would result in significant enrichment, but the 
physiological relevance of the changes may be questionable. Secondly, I used mouse cultured 
tissue, whereas Mariani et al used human cells. There may be species specific differences in 
the mechanistic response to hypoxia. Finally, Mariani et al used a genome wide approach to 
assess 5hmC whereas here I used a candidate approach. As such, I may have missed regions 
of 5hmC enrichment through the candidate nature of my approach. 
The interaction between LPS and hypoxia with respect to 5hmC at the Car9 locus is 
interesting. As previously discussed, there is evidence that LPS can potentiate a subsequent 
hypoxia exposure. A potential mechanism for this may be epigenetic remodelling of DNA 
and/or chromatin by LPS, which may affect the ability of transcription factors and DNA 
binding proteins, associated with hypoxia, to bind DNA 521. However, this needs a more 
comprehensive study using in vivo models of hypoxia and inflammation with sequencing-
based approaches to fully understand. 
A more comprehensive study using in vivo hypoxia exposure to pups should be done using 
sequencing methods to assess the effect of hypoxia on 5hmC. This could also be validated in 
infarct regions of human neonatal brain tissue, using the contralateral uninjured hemisphere 
as a control. A candidate ChIP for TET1-3 at hypoxia response genes could also be done to 
identify specific mediators of these effects. Finally, the effect of hyperoxia and its interaction 
with hypoxia should be assessed. As discussed previously, preterm infants are often exposed 
to intermittent episodes of hypoxia and hyperoxia. As such, the evaluation of this more 
clinically relevant combination should be assessed. For instance, an experiment could include 
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4 groups: control, hypoxia, hyperoxia and intermittent hypoxia/hyperoxia. Dissection of 
various brain regions could be done and genome wide hydroxymethylation assessed. 
Effect of PTB associated factors on primary cultured mouse glial cells 
My finding that there is a reduction in myelin producing mature oligodendrocytes following 
hypoxia (see Figure 3.7) is one that has been previously reported in the literature 522,523. I also 
saw a trend toward a decrease in the number of myelin producing mature oligodendrocytes 
following LPS exposure. However, this trend falls just outside statistical significance. 
Inflammation induced hypomyelination is a common feature in perinatal brain injury models 
251.  This experiment was underpowered to detect a difference in mature myelinating 
oligodendrocytes at the effect size seen here. For future studies, to achieve a power of 0.8 
the sample size of each group would need an additional 5 samples. 
I showed that hypoxia upregulated IL1β secretion from primary cultured microglia, but no 
effect or interaction was seen with LPS. Considering IL1β is implicated in classic LPS signalling, 
this was somewhat surprising. Studies have shown that IL1β is involved in the immediate 
response to LPS but is also maintained with LPS exposure in peripheral macrophages 524,525. 
However, the dose of LPS used in my study was relatively low and microglia have distinct 
characteristics to other macrophage populations. It is possible that IL1β is transiently 
produced by primary cultured mouse microglia in response to low dose LPS but to my 
knowledge, this has not previously been reported. IL1β has previously been identified as a 
HIF1α target 526,527, but to my knowledge this is the first description of such an effect in 
cultured primary murine microglia.  
I show that OPC exposure to hypoxia results in a reduction in MBP positive cells after the 
induction of differentiation, and I show a similar but not significant trend for LPS (Figure 
3.7B). I was therefore surprised that the effect size was not larger in the LPS + hypoxia group 
compared to either factor independently, this may be due to several reasons. Firstly, an effect 
for LPS fell just outside the threshold for statistical significance of p<0.05. However as 
described previously, this study was underpowered to detect a change at the effect size 
observed and a reduction in myelinating oligodendrocytes following inflammation has 
previously been reported in the literature 250. Therefore, a larger sample size is required to 
test this hypothesis. Secondly, impaired OPC differentiation, increased OPC cell death, 
increased mature oligodendrocyte cell death or decreased OPC proliferation are examples of 
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mechanisms which may result in a decreased percentage of MBP positive cells in this assay. 
It is therefore possible LPS and hypoxia act either through a similar mechanism which 
saturates, or through different mechanisms which interact in an unknown fashion to limit 
adverse outcome. 
In conclusion, in this chapter I have characterised a forebrain slice culture paradigm and have 
shown it is comparable, in terms of glial populations, neuronal morphology and candidate 
gene expression patterns, to littermates which are left with their mother through the culture 
period. I established factors associated with PTB, such as Dexamethasone, the inflammatory 
mimic LPS and hypoxia produce physiological responses in this forebrain slice culture 
paradigm. I have also shown these factors produce differential expression of several 
candidate genes associated with cytosine modifications and WMI in PTB. I demonstrated 
using primary mouse OPC cultures that hypoxia results in a decreased production of mature 
myelinating oligodendrocytes. Finally, I also show in primary mouse microglia cultures a 




4 Characterisation of MMS in the neonatal and adult periods 
4.1 Introduction 
As discussed in the introduction, PTB is associated with an increased risk of lower IQ 528 and 
with various neurodevelopmental disorders 529, but the mechanisms behind these 
associations are largely unknown. Early life stress interacts with, and regulates gene networks 
which are enriched for variants associated with schizophrenia and major depressive disorder 
530. Moreover, early life stress in the form of temporary childhood neglect is associated with 
an increased incidence of ADHD and a lower IQ in later life 531. However, the relevance of this 
to stress associated with PTB is unknown. Therefore, understanding the mechanisms of stress 
PTB may give important insight into the atypical neurodevelopment associated with PTB. 
PTB is often accompanied by extended stays in the NICU, which is associated with stressors 
such as invasive procedures, sleep deprivation, excessive light and noise. However, the 
investigation of stress associated with PTB in humans is difficult, as stressful experiences such 
as painful procedures are invariably confounded by the severity of any associated pathology. 
This means independently assigning effects to stress is challenging in the preterm 
environment. Despite these difficulties, exposure to painful procedures has been 
independently associated with reduced MRI metrics in grey and white matter at term 
equivalent age, when various confounders are corrected for 532.  
Canonical glucocorticoid signalling occurs through the binding of glucocorticoids to cytosolic 
GR and MR which then heterodimerise and elicit gene expression changes through direct 
DNA binding. Therefore, understanding transcriptomic changes following stress may provide 
insights into mechanisms and processes affected. This can be done by exploring the 
expression of candidate genes with qPCR, e.g. genes with well characterised responsiveness 
to GR signalling, such as Per1 533. Alternatively, unbiased transcriptome-wide approaches 
(e.g. 3’ mRNA sequencing) can be used to investigate the differential expression of mRNA 534. 
Previous studies using a combination of maternal separation and limited nesting models have 
used RNA sequencing to profile gene expression in regions of the brain associated with 
reward, and have demonstrated that transcription factors may play a key role in the 
consequences of early life stress 535,536. Therefore, investigating the enrichment of 
transcription factor binding sites in sequencing datasets may indicate transcription factors 
which drive any transcriptome alterations seen. 
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PTB and neurodevelopmental disorders are associated with alterations in various epigenetic 
marks, including DNA methylation; for example early life stress has also been associated with 
altered DNA methylation in humans 537 and animal models (maternal separation) 303. It has 
been proposed that stress may alter DNA methylation through glucocorticoid and FKBP51 
(encoded by FKBP5) signalling 366. This may play an important role in stress associated 
learning, as exposure to early life stress can modify the subsequent response to stress 538. As 
such, understanding the effect of early life stress on DNA methylation may provide insights 
into processes and mechanisms involved. A commonly used technique to assess both 
genome wide (with sequencing) or candidate (with qPCR) alterations in DNA methylation is 
DNA methylation immunoprecipitation (meDIP) 497. This is similar to the technique used in 
the previous chapter to assess the presence of DNA hydroxymethylation. 
To understand the effects of early life stress on adult outcome in animal models, behavioural 
tests are commonly employed. As early life stress in humans is associated with an increased 
risk of anxiety and depression in adulthood, tests of anxiety and depression are commonly 
used in models of early life stress. The elevated plus maze (EPM) and open field (OF) are used 
as tests of anxiety in rodents 539, where increased activity in exposed areas (i.e. the open arms 
in the EPM and the centre zone in the OF) is proposed to associate with reduced anxiety. The 
tail suspension test  is a commonly used measure of depression like behaviour in mice 540, 
and has previously been used in the analysis of behaviour following early life stress 541. 
As discussed in the introduction many neurodevelopmental disorders are associated with 
circadian rhythm abnormalities 542. Some of these have been replicated in animal models, for 
example classic studies in non-human primates have shown circadian rhythm alterations in 
temperature regulation follow maternal separation 543. The limited nesting material model in 
rodents also disrupts patterns of activity and sleep 544. The monitoring of in cage habitual 
behaviour over the course of a normal day following early life stress would therefore provide 
valuable insights into the consequences of early life stress. 
The most commonly used model of early life stress is maternal separation, in this model pups 
are removed from the home cage for 3+ hours per day for 10+ consecutive days. However, 
the mother is the sole source of nutrition during this developmental period and extended 
periods of maternal separation can produce hypoglycaemia in pups 309. The neonatal brain is 
particular susceptible to fluctuations in glucose concentrations 545 and therefore 
distinguishing between the effects of nutrition and stress is difficult in this model. Maternal 
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separation may also be associated with variable stress exposure, as during the paradigm 
some pups may fall asleep while others may engage more with the stress, possibly leading to 
the conflicting results seen in this model. Moreover, traditional maternal separation models 
do not accurately recapitulate stress associated with the NICU, where frequent manual 
manipulations and sleep deprivation are common. Other models of early life stress such as 
the limited nesting model are models of fragmented maternal care and may be less relevant 
to stress associated with PTB. To better understand the consequences of stress associated 
with the preterm environment on brain development, better animal models are needed. 
Therefore, in this chapter I developed a novel model of early life stress, modified maternal 
separation (MMS), which is relevant to PTB. I characterise the effect of MMS in both the 
neonatal and adult periods. 
4.2 Hypotheses 
1. MMS will induce changes in the transcriptome and DNA methylome of the 
hypothalamus 
2. MMS will result in altered behaviour in the adult period 
4.3 Aims 
1. To assess growth and blood glucose dynamics associated with MMS 
2. To use immunohistochemistry to evaluate glial proportions in the hypothalamus 
following MMS 
3. To investigate the effects of MMS on the hypothalamic transcriptome in the neonatal 
period 
4. To investigate the effects of MMS on the hypothalamic DNA methylome in the 
neonatal period 
5. To examine the effect of MMS on behaviours during adulthood 
6. To assess the effect of MMS on candidate gene expression in the HPA axis in 
adulthood 
7. To assess the effect of MMS on DNA methylation at candidate loci in the 




4.4.1 Animals and MMS 
Only C57BL/6JOlaHsd male animals were used in the following experiments. For breeding, 2 
females and 1 male were kept in a single cage. On P3, male pups were randomised to control 
or MMS groups and received a subcutaneous ink injection to the footpad for identification 
purposes. On P4, pups assigned to the MMS group were removed from their home cage and 
placed on a heating pad. They were repeatedly inverted to the supine position for 1.5 
hours/day for 3 consecutive days (P4-P6). MMS was carried out adjacent to the home cage 
to allow for communication through ultrasonic vocalisation. Control pups were left in the 
home cage whilst MMS was carried out. Both groups were handled at the start of the 
paradigm in a similar manner.  
Following MMS, one cohort of animals was killed, and brains extracted. The brain was divided 
in half along the midline, with one half snap-frozen on dry ice for subsequent RNA/DNA 
extraction and the other half fixed overnight in 4% paraformaldehyde for paraffin 
embedding, sectioning and immunohistochemistry. An n of 10/group was used for this set of 
experiments, with the specific n for each experiment identified in their associated figure 
legends in the results section. 
Following MMS, a second cohort were returned to the home cage and allowed to mature 
without further intervention. They were weaned at P21, with control and MMS littermates 
housed together. At P90-P130 behavioural testing was carried out. Animals were then killed 
by cervical dislocation, tissue extracted and snap frozen for subsequent analysis. An n of 
11/group was used for these experiments, with the specific n for each experiment mentioned 
in the associated figure legend in the results section. 
4.4.2 Immunohistochemistry 
Following embedding in paraffin, 5μm coronal forebrain sections were cut using a 
microtome. Sections were arranged, 3/slide and deparaffinisation and 
immunohistochemistry was carried out as previously described. Images were taken using an 
AxioScan slidescanner and quantification was done using image J. 3 consecutive sections per 
animal were quantified and averaged to obtain an n of 1. Iba1+ and Olig2+ cells were 
normalised to area, while GFAP+ cells were quantified as percent coverage. 
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4.4.3 RNA profiling (qPCR and 3’ mRNA sequencing) 
RNA was isolated from frozen tissue as previously described. For candidate gene analysis with 
qPCR, 1 μg of RNA was reverse transcribed into cDNA following DNAse treatment. Expression 
of candidate genes was measured using FAM hydrolysis on a Roche 480 LightCycler and 
normalised to expression of TBP. 
3’ mRNA sequencing was carried out by staff at the Wellcome Trust Clinical Research Facility, 
at the Western General Hospital, Edinburgh. Library preparation was done with 500ng of 
RNA, and sequencing carried out with 12 samples per chip. Data were mapped to the mm10 
genome and differential gene expression analysis done using Degust with the Voom/limma 
method. 
4.4.4 meDIP sequencing 
DNA was isolated from the hypothalamus as previous described. Immunoprecipitation was 
carried out on 2.5μg of sonicated DNA after aliquoting 10% input for normalisation. An IgG 
control was included with each immunoprecipitation. Whole genome amplification was done 
before sequencing and efficiency of immunoprecipitation and homogeneity of whole 
genome amplification were assessed using qPCR for previously identified positive and 
negative regions 497.  
Ion torrent sequencing was done by the staff at the Wellcome Trust Clinical Research Facility, 
at the Western General Hospital, Edinburgh. 3 samples were sequenced per chip and data 
mapped to the mm10 genome annotation. Downstream analysis was done using Galaxy. 
4.4.5 Elevated plus maze (EPM) 
Animals were tested with the EPM at P90-P100. Animals were habituated to the novel 
holding area outside the testing room for at least 1 hour prior to testing. Then animals were 
taken in one at a time for testing. They were placed in the centre of the maze facing the 
closed arm and allowed to explore the maze for 5 minutes. Their movement was tracked and 
quantified by the AnyMaze software. The maze was cleaned with 70% ethanol and residual 
ethanol allowed to evaporate for 5 minutes prior to testing the next animal. 
4.4.6 Open field (OF) maze 
Animals were tested in the OF 24 hours after the EPM. The animals were also habituated to 
the holding area for 1 hour prior to testing and animals tested one at a time. For testing, 
animals were taken into the testing room and placed in the centre of the OF and allowed to 
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explore the maze for 5 minutes. Similar to the EPM the animal’s movement was tracked and 
quantified with the AnyMaze software and the apparatus was cleaned with 70% ethanol 
between tests with 5 minutes evaporation time allowed for residual ethanol. 
4.4.7 Tail suspension test 
The tail suspension test was carried out 1 hour after the OF. An 18 cm piece of tape was 
attached to the mouse’s tail, which was then attached to an edge 50 cm above the floor. The 
mouse was left for 6 minutes and its activity recorded. The total time immobile for each 
animal was quantified blindly. 
4.4.8 In cage monitoring 
Circadian metabolic and activity parameters were measured use the TSE-Systems 
PhenoMaster. Animals were single housed for habituation to the novel spout of the water 
bottle used with the system for 4 days prior to measurement. Animals were introduced to 
the system and left for 4 days; data from the first 24 hours were discarded as mice 
acclimatised to the novel environment. During this time mice had ad libitum access to food 
and water as usual. For normalisation of calorie expenditure data, TD-NMR was performed 






4.5.1 Assessment of growth, blood glucose dynamics, corticosterone and candidate 
gene expression following MMS 
Considering the potential nutritional deficiencies associated with other models of early life 
stress, I first assessed growth dynamics during MMS and blood glucose levels immediately 
following MMS. As seen in Figure 4.1A, there were no differences in weight gain between the 
control and MMS groups. There was no difference in weight at the start of the paradigm on 
P4 (see Figure 4.1B), the brain/body weight ratio on P6 (see Figure 4.1C) or blood glucose 
levels at P6 (see Figure 4.1D). I next tested plasma corticosterone levels on P6 in both control 
and MMS groups, as it is the principal hormonal stress mediator in rodents. As seen in Figure 






Figure 4.1 Weight was measured immediately before MMS in both control and MMS groups from P4-P6. In A, 
weight was normalised to the starting weight at P4, with no effect of MMS on weight gain (control-black line, 
MMS-grey line)(p=0.94, f-statistic=0.015, df=60), n=11/group. B shows there was no difference between control 
and MMS groups in starting weight (p=0.95, df=18), n-=11/group. C demonstrates MMS was not associated with 
an altered brain/body weight ratio at P6 (p=0.45, df=3), n=4/group. In D, blood glucose measured immediately 
following the paradigm on P6 shows no difference between groups (p=0.91, df=5), n=6/group. In B-D, the control 
group are represented by the clear circles with the MMS group represented by the black filled circles. A was 
compared using a repeated measures ANOVA and B-D were compared using an independent t-test. Error bars 













































































































































Figure 4.2 Corticosterone was measured by ELISA in plasma isolated immediately following MMS on P6. There was 
no difference between the control group (clear circles) and the MMS group (black filled circles) (p=0.29, df=6) as 
indicated by an independent t-test, n=7-9. Error bars indicate standard error of the mean. 
I next investigated candidate gene expression in the hypothalamus of control and MMS 
groups using qPCR. As seen in Figure 4.3, Per1 and DNMT1 were increased in expression 






































































Figure 4.3 Candidate gene expression in hypothalamic tissue immediately following the paradigm on P6 was 
measured by qPCR and normalised to the expression of TBP. There were no differences in the expression of the GR 
(p=0.053, df=9), MR (p=0.49, df=10) or DNMT3a (p=0.09, df=9) but Per1 (p=0.009, df=9) and DNMT1 (p=0.03, df=9) 
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were increased in expression as indicated by independent t-tests, n=9-11. The control group are represented by 
clear circles and the MMS group by black filled circles. * indicates p<0.05, *** indicates p<0.001. Error bars indicate 
standard error of the mean. 
4.5.2 Iba1+, Olig2+ and GFAP+ cell proportions in the hypothalamus following MMS 
Glial cells are crucial to typical brain development and are very plastic to insults. The GR is 
ubiquitously expressed in the brain and therefore glucocorticoid signaling may affect these 
cells. Therefore, I investigated the proportion of GFAP+ astrocytes, Iba1+ myeloid cells and 
Olig2+ cells of the oligodendrocyte lineage using immunohistochemistry. As seen in Figure 
4.4, there were no differences in the proportion of GFAP, Iba1 or Olig2 labelled cells in the 




Figure 4.4 Paraffin sections were stained for GFAP, Iba1 and Olig2. In A and B, representative images of GFAP+ 
staining from the hypothalamus are shown. In C, GFAP+ cells are quantified as percent coverage in control (clear 
circles) and MMS (black filled circles) pups with no differences found (p=0.867, df=5). In D and E, representative 
images from Iba1 (green) and DAPI (blue) stained hypothalamic sections are shown, which are quantified in F as 
cells/mm2  for control (clear circles) and MMS (black filled circles) pups, no differences were found (p=0.311, df=4). 
In G and H, representative images of Olig2 (green) and DAPI (blue) stained hypothalamic sections are shown, which 
are quantified in I as Olig2+ cells/mm2 for control (clear circles) and MMS (black filled circles) pups (p=0.791, df=5). 
Scale bar indicates 100µm. All statistical comparisons were made using independent t-tests, n=6-9. Error bars 








































































































4.5.3 Assessment of the hypothalamic transcriptome using 3’ mRNA sequencing 
As there were changes in candidate gene expression (see Figure 4.3) following MMS in the 
hypothalamus, I next evaluated transcriptome wide disruptions in the hypothalamic mRNA 
using 3’ mRNA sequencing. As seen in Figure 4.5A, there was only a single gene with an FDR 
corrected <0.05 (D630033O11Rik; FDR of 0.002131, unadjusted p-value of 4.92E-08, logFC of 
2.662301), and using an MDS plot to cluster the samples in an unbiased fashion there was no 
discernable pattern (see Figure 4.5B). This indicates that MMS resulted in minimal and only 




Figure 4.5 3’ mRNA sequencing was done on RNA extracted from the hypothalamus of control and MMS groups 
(n=6/group). In A, a volcano plot shows all genes which were analysed for differential expression using the 
Voom/limma method. Blue and red dots indicate genes which had a logFC less or more than 1.5, respectively. Only 
1 gene had an FDR corrected of<0.05, D630033O11Rik, which is indicated with its name. In B an MDS plot is used 
to cluster all samples in an unbiased fashion. The x-axis represents Dimension 1, which accounted for 50% of the 
variation in the data. The y-axis represents Dimension 2, which accounted for 15% of the variation in the dataset. 







I then used the genes with a logFC greater than 1.5 (as indicated by the blue and red dots in 
Figure 4.5A) for gene ontology analysis to indicate broad processes which are involved in 
subtle transcriptional changes. As seen in Figure 4.6A, there was enrichment in the cellular 
component and biological process categories for terms related to motile cilia. Also, under 
molecular function, terms enriched included “DNA-binding RNA pol specific” and “ligand-
gated cation channel activity”. Two genes which were included under these terms were 
NR4A3 and FOS respectively. These genes were validated by qPCR and showed significant 




Figure 4.6 In A, the results of a gene ontology analysis are shown. Analysis was done for genes with a logFC change 
of greater than 1.5. Enriched terms were classified under cellular component (pink), biological process (yellow) 
and molecular function (green). Examples of enriched terms are those relating to the cilium and neuronal activity. 
Genes identified in the “DNA-binding RNA pol specific” and “Ligand-gated cation channel activity” included NR4A3 
and Fos, respectively. In B, they were validated by qPCR and were significantly increased (p=<0.001 and 0.002 for 
FOS and NR4A3, respectively, df=16) in their expression as indicated by an independent t-test, n=9-10. ** indicates 




















































Using the same threshold of a logFC greater than 1.5, I carried out a transcription factor 
enrichment analysis with the Opossum software, to identify motifs associated with the 
binding of particular transcription factors which were enriched among the genes. The results, 
which are presented in Figure 4.7, show enrichment for transcription factors of the NFkB 
family and other transcription factors such as Klf4 and SP1, which are important in a variety 
of pathways including neuronal differentiation and activation. 
 
 
Figure 4.7 Transcription factor binding enrichment analysis of genes with a logFC of greater than 1.5 indicates 
enrichment for motifs associated with the NFkB pathway and pathways involved in differentiation and neuronal 
activity (i.e. KLF4 and SP1). For each transcription factor 2 metrics of enrichment, Fischer score (clear bars) and z-






















4.5.4 Investigation of DNA methylation in the hypothalamus following MMS 
As I saw increased expression of the DNA methylase, DNMT1, in the hypothalamus following 
MMS (see Figure 4.3), I chose to investigate broad patterns of DNA methylation in the 
hypothalamus using meDIP (see Figure 4.8A for a schematic describing this approach). 
Differentially methylated regions were identified using the DESeq2 method, which showed 
substantial overlap with an alternative method, edgeR (see Figure 4.8B). Differentially 
methylated regions were annotated and catalogued as to their genomic association (as seen 
in Figure 4.8C). Regions which could not be annotated such as long repetitive regions were 
omitted at this stage. Of these regions, those annotated to protein coding regions were 
further subdivided into their respective genomic locations (see Figure 4.8D). The 4501 (see 
Figure 4.8C “protein”) identified differentially methylated regions associated with protein 





Figure 4.8 A) shows a schematic of the meDIP protocol. DESeq2 was used to assess differential methylation. B) 
shows there was substantial overlap between DESeq2 (green circle) and edgeR (red circle) methods (numbers 
indicate quantity of differentially methylated regions found using each method). In C, annotated regions which 
were differentially methylated between control and MMS groups are catalogued by their associated genomic 
elements. In D, the differentially methylated regions from the “protein” category in C are further subdivided into 





















Unbiased clustering of all differentially methylated regions, using a principal component 
analysis (see Figure 4.9A), demonstrated MMS had a specific and distinct effect on DNA 
methylation within the hypothalamus. In Figure 4.9B, a volcano plot of all regions assessed 
for differential methylation is shown, with significantly differentially methylated regions 
shown in pink. All significantly differentially methylated regions were then grouped into a 
heat map and clustered by Euclidean distance (see Figure 4.9C). Samples were then 




Figure 4.9 In A, a principal component analysis of samples from control (dark blue) and MMS (pink) groups shows 
a distinct and specific effect of MMS on DNA methylation. In B, a volcano plot of all regions assessed for differential 
methylation is shown. Samples with an FDR corrected <0.05 are indicated in pink, while those with an FDR 
corrected >0.05 are shown in dark blue. In C, a heatmap shows all differentially methylated regions clustered by 
Euclidian distance, with dark green indicating an increase in methylation with white indicating a decrease in 
methylation. A correlation heatmap is shown in D, with dark green indicating a higher degree of correlation and 








Gene name Neurodevelopmental relevance Reference 
Cdon Involved in neuronal migration Powell, 2015 546 
Gprin1 SNPs implicated in schizophrenia Qin, 2005 547 
Dnajc14 
Decreased expression in the PFC of individuals with 
Schizophrenia Arion, 2007 548 
Fzd1 Involved in differentiation and presynaptic function Varela-Nallar, 2009 549 
Mast1 
Mutations associated with cerebellar hypoplasia, 
corpus callosum and cortical abnormalities Tripathy, 2018 550 
Zbtb16 Corticosteroid responsive transcription factor Fahnenstich ,2003 551 
Adarb1 
Decreased  expression in postmortem tissue of 




Reader of 5mC and 5hmC, shown to interact with 
DNMT1 
Zhang,2011 553  and 
Zhou, 2014 554 
Cdh10 
SNPs implicated in ASD and associated with 
excitatory/inhibitory balance 
Wang, 2009 555  and 
Smith,2017 556 
Atf7 
Involved in NFkB signaling and subsequent telomere 
shortening in neonatal infants Lazarides, 2019 557 
Wbscr17 
Deleted (1 of 26 genes) in Williams-Beuren syndrome 
and SNPs in mothers increase risk of ASD in offspring Connolly, 2017 558 
Robo3 
Mutations cause horizontal gaze palsy and progressive 
scoliosis due to abnormal axon guidance Fricke, 2001 559 
Usp44 
Loss of function mutation associated with intellectual 
disability Harripaul, 2018 560 
Mlxipl Involved in Williams-Beuren syndrome Cairo, 2001 561 
Diaph3 
Involved in cell migration and guidance, may function 
down stream of SHANK3. Implicated in ASD Vorstman, 2011 562 




Implicated in neurodevelopmental disorders including 




Methylation level at this locus, in blood, is associated 
with adult and childhood cognitive abilities Lorgen-Ritchie, 2019 565 
Lypd1 Plays a role in anxiety related behaviour Tekinay, 2009 566 
Pla2g4a SNPs implicated in Schizophrenia Peet, 1998 567 
Bmp3 
SNPs near locus associated with cognitive decline in 
patients with schizophrenia Hashimoto, 2013 568 
 
Figure 4.10 Genes with a previously identified role in neurodevelopment or neurodevelopmental disorders which 
were found among the top 100 differentially methylated regions identified by meDIP sequencing, along with their 
relationship with neurodevelopment. 
Many of the genes found to be differentially methylated have also been associated with 
neurodevelopmental disorders, see  
Figure 4.10 for more information. Therefore, I performed a gene ontology analysis of all 
significantly differentially methylated regions which were annotated to protein coding genes 
(see Figure 4.11). Under the category of cellular component, all enriched terms were 
associated with the synapse. Under molecular function, enriched terms were associated with 
cell adhesion and transcription factor binding. Under the category of biological processes, 
synaptic and cell adhesion terms once more appeared. 
 
Figure 4.11 Gene ontology analysis of differentially methylated regions associated with protein coding regions was 
done for terms associated with cellular component (pink), molecular function (yellow) and biological processes 
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(green). Enriched terms included terms related to synaptic elements in the cellular component and biological 
processes categories 
As the term “DNA-binding transcription factor activity” was enriched, I decided to look for 
enrichment of transcription factor binding motifs around differentially methylated genes. As 
seen in Figure 4.12 this was done for all synapse associated genes as indicated by the Gene 
Ontology analysis. All transcription factors with a Fisher score higher than 7 are shown in 
Figure 4.12A, with a subset listed underneath in Figure 4.12B with their function indicated. 
In Figure 4.12C, the same analysis is done but for genes with differential methylation in the 
promoter region. Only two transcription factors had a Fisher score of higher than 7, both of 
which have important roles in cell proliferation. 
 
Figure 4.12 Transcription factor binding enrichment analysis was done for differentially methylated regions 
associated with synaptic genes (A and B) and genes which had differential methylation in their promoter regions 















Transciption Factor Information Z-score Fisher score
Pou5f1 Master regulator of stem cell self renewal (Oct4 is coding protein) 15.098 10.84
NFIL3 Key regulator of  circadian rhythms 13.047 10.078
SRY Master regulator of male sexual development 11.654 10.492
Synapse related genes
Transcription factor Information Z-score Fisher score
Klf4 Stem cell self renewal, dysregulation in mice leads to hydrocephalus 11.921 10.61
Zfx Overexpressed in gliomas 10.615 7.842
Differentially  methylated promoter regions
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(C). In A, transcription factors with a Fischer score of higher than 7 are shown, with Fischer score (clear bars) and 
z-score (black bars) indicated. In B, candidate transcription factors from A are listed. In C, all transcription factors 
with a Fischer score of greater than 7 for differentially methylated regions in characterized promoters are listed. 
 
Next I evaluated the relationship between DNA methylation and expression. I identified all 
common genes with a logFC change in expression greater than 0.5 and those which were also 
differentially methylated. The expression of these genes was not correlated with their 
methylation, see Figure 4.13. 
 
Figure 4.13 Genes with a change in expression of logFC of 0.5 or more as indicated by 3’ mRNA sequencing and 
which were associated with a differentially methylated region (greater than or equal to 2-fold change) were 
correlated using a Pearson correlation. There was found to be no correlation with transcript expression and 
differential methylation (correlation coefficient=0.07 and p=0.36). 
4.5.5 The effect of MMS on behaviours during adulthood 
Next, I investigated the effect of MMS on behaviour during the adult period using the EPM 
at 3 months of age. Representative track plots from control and MMS groups can be seen in 
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A. Animals from the MMS group travelled further during the testing period but did not have 
an altered preference for the open arms, closed arms or centre zone, as seen in Figure 4.14C 
and D respectively. The MMS group also had a higher average speed and a higher mobile 
time, as seen in Figure 4.15A and B. The MMS group travelled further in the closed arm but 
had the same average duration of visit, as seen in Figure 4.15C and D. However, there were 
no differences between the control and MMS group in distance travelled in the open arm or 




Figure 4.14 At 3 months of age mice were tested with the EPM. In A and B representative track plots can be seen, 
with the open and closed arms indicated in A. The MMS group travelled further during the testing period (p=0.02, 
df=20) with no difference in time spent in the open arms, closed arms or centre zone (p=0.46, 0.27 and 0.32 
respectively, df=20 for all zones). All statistical comparisons were made using independent t-tests, n=11 for all 
groups in all graphs. * indicates p<0.05. Error bars indicate standard error of the mean. 







































































Figure 4.15 Further results from the EPM. The MMS group travelled at a faster overall speed (p=0.02, df=20) and 
spent a greater amount of time mobile (p=0.02, df=20), as seen in A and B respectively. In the closed arm only, the 
MMS group travelled further (p=0.048, df=20) but spent the same amount of time there during each visit (p=0.27, 
df=20), as seen in C and D respectively. In the open arms only, there were no differences between control and MMS 




































































































































statistical comparisons were made using independent t-tests, n=11 for both groups in all graphs. * indicates 
p<0.05. Error bars indicate standard error of the mean. 
Mice were then tested in the OF, representative track plots for control and MMS groups can 
be seen in Figure 4.16A and B with the inner and outer zones of the OF indicated in A. Similar 
to the EPM, the MMS group travelled further with no altered preference for time spent in 
the inner or outer zones during the course of the test, as can be seen in Figure 4.16C and D. 
The MMS group also moved faster with a higher total mobile time, see Figure 4.16and F. The 
MMS group travelled further in the outer zone, but had a shorter average length of visit, as 
seen in Figure 4.16G and H. Mice from the MMS group also travelled further within only the 
inner zone, with no difference in the average length of their visit to this zone, as seen in 




Figure 4.16 Mice were tested in the OF 24 hours after the EPM. Representative track plots of control and MMS 
animals can be seen in A and B respectively, with the inner and outer zone indicated in A. Mice from the MMS 
group travelled further than the control group (p=0.02, df=20), without an altered proportion of time spent in the 
inner or outer zones (p=0.07 and 0.07 respectively, df=20 for both), as seen in C and D. All statistical comparisons 
were made using independent t-tests, n=11 for both groups in all graphs. * indicates p<0.05. Error bars indicate 
standard error of the mean. 
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Figure 4.17 Mice from the MMS group also moved quicker (p=0.02, df=20) and spent more time mobile (p=0.02, 
df=20), as seen in A and B. In the outer zone only mice from the MMS group travelled further (p=0.04) with a 
shorter duration of visit to this zone (p=0.048, df=20), as seen in C and D. In the inner zone only, mice from the 
MMS group travelled further (p=0.01, df=20) but there was no difference in the duration of visit to this zone 
(p=0.48, df=20), as seen in E and F. All statistical comparisons were made using independent t-tests, n=11 for both 





































































































































On the same day as the OF, mice were tested with the tail suspension test for 360 seconds. 






















Figure 4.18 Tail suspension test was carried out following the OF. Total test time was 360 s and there was no 
difference between control and MMS groups (clear and black circles respectively) (p=0.32, df=20) as indicated by 
an independent t-test, n=11 for both groups. Error bars indicate standard error of the mean. 
 
 
Considering the EPM and OF constitutes a novel stressful environment, I next investigated if 
the increased activity observed in those mazes was representative of habitual hyperactivity 
in mice following MMS. To do this I used the TSE-Systems PhenoMaster to analyse various 
behaviours with respect to time. In Figure 4.19A the activity of control and MMS groups over 
24 hours is shown. This is quantified in B, which shows there was no difference in movement 




Figure 4.19 In cage behavioural monitoring using the TSE-Systems PhenoMaster was done at 4 months of age. In 
A the cumulative distance moved by the control (black line) and MMS (grey line) are shown with respect to time. 
The lighter aspect of the graph indicates when the lights were on, with the darker aspect indicating when the lights 
were off (n=7 for both groups). This is quantified in B, which shows no difference in movement between control 
and MMS animals during lights on or off (as indicated by the backgrounded shading and the nomenclature AM 
and PM) (p=0.36; f-statistic=1.004; df=24 for a group effect, p=0.35; f-statistic=0.348; df=24 for an interaction 





































































































































graph). Statistical analysis was done using a two-way ANOVA with repeated measures. Error bars indicate 
standard error of the mean. 
 
I next wanted to assess the effect of MMS on self-care behaviour following MMS. I used the 
PhenoMaster system to quantify grooming behaviour in control and MMS groups. As seen in 
Figure 4.20A and B, there were no differences in grooming behaviour in the x or y-axis over 
the course of 24 hours, as assessed by repetitive beam breaks in the designated plane of 
interest. 
 
Figure 4.20 There were no differences in self-grooming behaviours of the control (clear circles) and MMS (black 
circles) groups along the x-axis (p=0.96, df=12) or y-axis (p=0.73, df=12) as measured by the PhenoMaster system 
and quantified as number of repetitive beam breaks. Independent t-tests were used for all comparison, n=7/group 


















































Using the PhenoMaster system I also evaluated the respiratory exchange ratio of each 
animal. This is a ratio of O2 inspired and CO2 expired, providing an approximation of fuel 
source used during habitual activity. This was measured every 15 minutes throughout the 
course of a 24 hour period. The respiratory exchange ratio for control and MMS groups can 




Figure 4.21 The respiratory exchange ratio was calculated using the PhenoMaster system for control (black lines) 
and MMS (grey lines) with respect to time of day. The light aspect of the graph indicates when the lights were on, 
with the dark aspect indicating when the lights were off. There was no subjective difference between groups so no 
further statistical analysis was performed. Error bars indicate standard error of the mean. 
I also monitored cumulative food intake over the course of 24 hours using the PhenoMaster. 
As seen in Figure 4.22A and quantified in B, there was a trend towards a decreased food 
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consumption during the day and an increased food consumption at night in the MMS group 





Figure 4.22 Food intake was measured over the course of 24 hours for control (black line) and MMS (grey line), as 
seen in A. The light aspect of the graph indicates when the lights were on with the dark aspect indicating when 
the lights were off. This is quantified in B, where there is an effect of time (p>0.001, f-statistic=106.558, df=24), 








































statistic=2.768, df=24), as indicated by a two-way ANOVA with repeated measures, n=7 for each group. Error bars 
indicate standard error of the mean. 
 
To further characterise the metabolic phenotype of these animals, their daily caloric 
expenditure was measured indirectly using heat given off during a 24 hour period in the 
closed PhenoMaster system. Daily calorie expenditure was normalised to lean mass and was 
not different between groups, nor was gross weight or fat mass (Figure 4.23A-D). 
 
Figure 4.23 Calories spent per day/kg were quantified as heat given off in the PhenoMaster system at 4 months of 
age and data were normalised to lean body mass. As seen in A, there were no differences between control (clear 
circles) and MMS (black circles) groups (p=0.99, df=12). There were also no differences in gross weight (p=0.14, 
df=12), lean mass (p=0.55, df=12) or fat (p=0.36, df=12) as seen in B, C and D respectively, which were quantified 
using TD-NMR. All statistical comparisons were made using independent t-tests, n=7 for both groups in all graphs. 
































































































I next measured plasma corticosterone at 7:00 and 19:00, timed to assess the peak and 
trough in circadian corticosterone secretion. As seen in Figure 4.24, there was no effect of 
















































Figure 4.24 Plasma corticosterone was sampled at 7am and 7pm at 3 months of age. The 7am timepoint is 
indicated by the light aspect of the graph and the AM nomenclature, the 7pm timepoint is indicated by the dark 
aspect of the graph and the PM nomenclature.  There was no difference between groups (p=0.506, f-
statistic=0.453, df=32) or an interaction with time (p=0.26, f-statistic= 1.317, df=32). There was an effect of time 
(p=0.025, f-statistic=5.512, df=32). Statistical comparison was done using a two-way ANOVA, n=8-9 for all groups. 
Error bars indicate standard error of the mean. 
4.5.6 The effect of MMS on candidate gene expression during adulthood 
Next I assessed candidate gene expression in genes associated with stress signaling in the 
tissues of the HPA axis at 4 months of age using qPCR. In the hypothalamus there were no 
changes in the expression of the GR, MR, Per1 or FKBP5 as seen in Figure 4.25A. In the adrenal 
gland there were no alterations in the expression of Cyp11b1, MC2R or stAr, as seen in Figure 
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4.25B. In the pituitary gland there were no changes in the expression of the GR, MR, Per1, 
FKBP5 or POMC, as seen in Figure 4.25C. 
 
Figure 4.25 Candidate gene expression was assessed in the hypothalamus (A), adrenal gland (B) and pituitary 
gland (C) at 4 months of age in control (clear circles) and MMS (black filled circles) groups, and normalised to TBP. 
In A, there were no differences in the expression of the GR (p=0.35, df=15), MR (p=0.76, df=18), Per1 (p=0.80, df=) 
or FKBP5 (p=0.72, df=15) in the hypothalamus. In B, there were no differences in the expression of Cyp11b1 
(p=0.35, df=17), MC2R (p=0.72, df=19) or stAr (p=0.80, df=18) in the adrenal gland. In C, there were no differences 
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POMC (p=0.78, df=18) in the pituitary gland. All statistical comparisons were done using independent t-tests, n=7-
11 for all tests. Error bars indicate standard error of the mean. 
Considering the crucial role of the hippocampus as an input to the HPA axis, I also examined 
candidate gene expression changes here in control and MMS groups. As seen in Figure 4.26, 
there were increases in expression of the GR, FKBP5 and Per1 associated with MMS. No 
differences were observed for expression of the MR or HSD11B1. 
 







































































Figure 4.26 Candidate gene expression was measured in the hippocampus and normalised to TBP. There were 
increases in the expression of the GR (p=0.003, df=18), FKBP5 (p=0.003, df=20) and Per1 (p=0.004, df=20), but no 
changes in the expression of the MR (p=0.37, df=19) or HSD11b1 (p=0.08, df=20). Statistical comparisons were 












4.5.7 The effect of MMS on DNA methylation at candidate loci during adulthood 
I next investigated DNA methylation at candidate loci in the hypothalamus at 4 months of 
age at 4 loci. Two of the candidate regions chosen were those associated with the Auts2 and 
Astn2 loci which I found to be differentially methylated immediately following MMS on P6 
(from the meDIP sequencing dataset). These genes also have characterised roles in the 
genetics of ASD 564,569. The other 2 loci were analogous regions to those within the GR 570 and 
AVP 303 loci, which have previously been described in the literature to be susceptible to early 
life stress mediated alterations in DNA methylation. As seen in Figure 4.27 there were no 
changes seen across any of the loci assessed. 
 

























































Figure 4.27 DNA methylation was assessed at candidate loci at 4 months of age in control (clear circles) and MMS 
(black circles) groups. Immunoprecipitated DNA was normalised to 10% input and an IgG control was included 
with each assay (grouped as triangles). There were no differences in DNA methylation at loci associated with Auts2 
(p=0.31, df=19), Astn2 (p=0.68, df=19), GR (p=0.63, df=18) or AVP (p=0.45, df=19) genes. Statistical comparisons 
were made using independent t-tests, n=10-11 for all groups and comparisons. Error bars indicate standard error 




In this chapter I have outlined a novel model of early life stress which has relevance to PTB. I 
have shown that: 
1. MMS was not associated with differences in weight gain or blood glucose levels 
2. There were no changes in Iba1+, Olig2+ or GFAP+ cellular composition in the 
hypothalamus following MMS 
3. MMS was associated with only subtle changes in the hypothalamic transcriptome 
immediately following the paradigm 
4. MMS was associated with widespread alterations in the DNA methylation landscape 
of the hypothalamus immediately following the paradigm 
5. There was a stress specific hyperactivity seen in adult mice who were exposed to 
MMS 
6. There were significant alterations in stress related gene expression in the 
hippocampus of adult mice exposed to MMS in the neonatal period 
7. There were no effects seen in DNA methylation at candidate genes in the 
hypothalamus of adult animals exposed to MMS in the neonatal period 
4.6.1 Corticosterone in the neonatal period 
I found no difference in plasma corticosterone immediately following MMS on P6. 
Corticosterone is the primary hormonal mediator of stress and is therefore typically elicited 
by stress. However during the neonatal period in mice (P1-P12), there is a stress 
hyporesponsive period, which is characterised by reduced corticosterone secretion in 
response to various stimuli 572. This is primarily caused by reduced adrenal activation by ACTH 
upon HPA stimulation 573. I also found only subtle transcriptomic changes seen using 3’ mRNA 
sequencing in the hypothalamus. Moreover, upon transcription factor binding enrichment 
analysis there was no signature of GR transcriptional targeting. However, I did see an 
enrichment for transcription factors associated with NFkB signalling. NFkB signalling can be 
stimulated during stress through canonical GR activation and the FKBP51 protein 574. I also 
found a significant increase in Per1 expression following MMS on P6. I will now discuss the 
possible interpretations of these results.  
Per1 is highly responsive to stress signalling 448 and this could be an indication of canonical 
GR mediated effects, but the lack of a transcriptome wide signature (and only a minor NFkB 
signature which was not validated) indicates this may only be subtle with an effect size too 
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small to survive the statistical corrections necessary for transcriptome wide comparisons. As 
I found no differences in plasma corticosterone, this scenario necessitates a mechanism for 
local glucocorticoid activation or accumulation. However, corticosterone plasma levels were 
analysed using an ELISA which does not discriminate between free corticosterone and bound 
corticosterone. Only free corticosterone is biologically active, as such it is possible there was 
a shift in the ratio of bound and unbound corticosterone following MMS which was sufficient 
to induce Per1 expression but insufficient to leave a strong transcriptome wide signature. 
There may also be an increased local conversion of dihydrocortisone into corticosterone by 
the enzyme HSD11b1.  
An alternative possibility is the increase in Per1 expression is not caused by glucocorticoids. 
Per1 is a core regulator of circadian rhythms and its expression is controlled by other 
circadian regulators. Sleep deprivation is a central component of MMS and MMS was 
performed under excessive lighting. As described in the introduction, both light and sleep are 
potent regulators of the transcription-translation feedback loops which underpin circadian 
rhythmicity. Therefore, MMS may induce effects on Per1 through altered circadian feedback 
rather than glucocorticoids. This theory is furthered by the lack of an enrichment in 
glucocorticoid binding motifs among genes with a logFC greater than 1.5, as well as the 
overall minimal transcriptional phenotype associated with MMS in the hypothalamus. 
Future work could look to further investigate this in a number of ways. Firstly, MMS could be 
performed in HSD11b1-/- mice. As such, the local conversion of dihydrocortisone to its active 
form of corticosterone could not occur. Therefore, if Per1 was still increased in expression, 
this mechanism could be ruled out. Secondly, mass spectrometry could be used to fully 
characterise the presence of glucocorticoids within the hypothalamus following MMS. 
Commercially available ELISAs are only validated for use on plasma, as such tissue 
corticosterone was not evaluated here. The local tissue level of glucocorticoids can vary 
independently of plasma levels 575 and therefore local accumulation should be investigated 
in the future. Finally, the expression of Per1 could be measured following MMS at multiple 
timepoints to fully characterise the circadian oscillation of Per1 following MMS. This would 




4.6.2 Corticosterone at 3 months 
At 3 months of age that there were no differences between control and MMS animals in 
baseline AM or PM plasma corticosterone levels. I also show at 4 months of age there were 
no differences in candidate gene expression related to stress signalling in any of the HPA axis 
depots. Together these data suggest MMS is not associated with alterations in baseline 
glucocorticoid signalling at 3-4 months of age. Previous studies using the traditional maternal 
separation paradigm have shown increases in baseline corticosterone at 6 weeks and 3 
months but not at 1 year of age 303. This discrepancy may be due to the different type of 
stress associated with MMS and other models. At 3 days, MMS also occurs for a much shorter 
period than other models (typically 10+ days), this increased length and developmental 
timing of stress may also play a role. 
However, I do demonstrate stress specific hyperactivity associated with MMS. Future studies 
should investigate glucocorticoid signalling characteristics under stress conditions in the 
MMS model. Important experiments would include analysis of plasma corticosterone 
following stress (i.e. a 15-minute restraint stress or a social stress such as introduction of an 
aggressive male) and subsequent expression characteristics of stress related genes through 
the HPA axis and hippocampus. 
4.6.3 Immunohistochemistry 
As described previously, specific cell lineages are associated with distinct transcriptional and 
DNA methylation profiles. Therefore, changes seen using 3’ mRNA sequencing or meDIP 
sequencing could be attributed to shifts in cellular proportions. To investigate this in a 
candidate approach, I used Iba1, Olig2 and GFAP to evaluate cell populations in the 
hypothalamus following MMS. Iba1 was used as it labels cells of the myeloid lineage and 
would label any infiltrating macrophages as well as resident microglia. Olig2 is a pan marker 
of the oligodendrocyte lineage and was chosen as a general indicator of oligodendrocyte 
proportions but alterations in subpopulations of oligodendrocytes cannot be ruled out. GFAP 
labels a subpopulation of astrocytes and was chosen as it is upregulated during astrocytosis. 
Even though GFAP is not a comprehensive marker of astrocytes, a previous studying using 
single cell sequencing in the mouse hypothalamus identified only a small number of 
astrocytes in the hypothalamus (~4% of all cells 576). Although the method I used for 




4.6.4 3’ mRNA sequencing  
3’ mRNA sequencing differs from traditional RNA sequencing as only the 3’ fragment is 
sequenced following library preparation. This allows accurate sequencing with comparable 
differential expression power to traditional methods but with much less depth required 534. 
However, 3’ mRNA sequencing cannot measure non-coding RNA or alternative splicing in 
mRNA (as only a single 3’ read per transcript is obtained).  
Following sequencing, Gene Ontology of genes with a logFC of greater than 1.5 showed 
enrichment for terms related to motile cilia. The only site which motile cilia are present in 
the hypothalamus is along the third ventricle, where they facilitate CSF flow. Considering 
these cells account for only a small proportion of total cells within the hypothalamus, 
enrichment of terms related to cilia movement may indicate profound alterations in their 
function even among the admittedly small changes seen in this dataset. CSF movement is 
impaired following sleep deprivation with a decrease in associated molecular clearance 
mechanisms, in adult animals 577. The relevance of these mechanisms for the neonatal brain 
are unknown but it is likely that the clearance of molecules from CSF during sleep also plays 
a crucial role. These concepts will be explored in greater detail in the next chapter. 
Following MMS on P6, the brains from control and MMS mice were divided along the midline. 
As such, an alternative possibility for enrichment of cilia related terms is asymmetric division 
of the hemispheres resulting in a larger ventricular surface area, and thereby more motile 
cilia included in one group over the other. There is no evidence of this from 
immunohistochemistry but considering the small number of cells lining the ventricle it is 
difficult to rule this possibility out. 
Gene Ontology analysis also implicated increased neuronal activation within the 
hypothalamus. Previous work using the limited nesting material model of early life stress has 
described increased glutamatergic transmission in the hypothalamus 571. Stress in adult 
animals also results in CRH neuronal activation which occurs independently of 
corticosterone, and this is an important mechanism in stress adaption 578 but this has not yet 
been demonstrated in neonatal animals. Glucocorticoid signalling may also act 
independently of its traditional cytosolic receptors to induce neuronal activation in a 
mechanism dependent on endocannabinoid signalling 388.  
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Upon transcription factor binding enrichment analysis, I saw enrichment of several 
transcription factors associated with NFkB signalling. NFkB signalling is classically associated 
with inflammation and this link will be expanded upon further in the next chapter.  
4.6.5 meDIP 
The first paper indicating that DNA methylation may be involved in the response to early life 
stress was a candidate approach by Murgatroyd et al, 2009 303 which described changes in 
DNA methylation at the AVP locus at 6 weeks, 3 months and 1 year of age within the 
paraventricular nucleus following the traditional version of maternal separation. In contrast, 
I found no AVP associated loci to be differentially methylated at P6 or in my candidate 
approach at 4 months of age (see Figure 4.27). The discrepancy between these findings may 
be because Murgatroyd et al, 2009 looked only at the paraventricular nucleus where I looked 
at the entire hypothalamus. Of course, MMS is also a different model to traditional maternal 
separation and as such may have different effects. 
Similar to the transcriptomic dataset, these effects may be glucocorticoid dependent or 
independent. Considering the dramatic nature of these changes and the only minor evidence 
for glucocorticoid mediated transcriptional effects, the effect on DNA methylation is more 
likely to be independent of glucocorticoids. Future experiments could clarify this by repeating 
these experiments but including a group with pharmacological inhibition of the GR, for 
example with the molecule RU-43044 581.  
A possible mechanism for glucocorticoid mediated effects is through FKBP51, which can 
modulate the activity of DNMT1 through CDK5 366. FKBP51 is a crucial binding partner and 
regulator of GR signalling. Its primary role within the cell is to bind proteins, and as such it is 
involved with the integration of stress signalling with several cellular pathways. Therefore, it 
is a primary candidate to mediate the effects of stress signalling on alternative pathways. A 
way to investigate the role of FKBP51 in this capacity is to immunoprecipitate FKBP51 from 
hypothalamic tissue following MMS, which could then be analysed with a proteomics 
approach to assess FKBP51 binding partners under control and MMS conditions. This is an 
experiment I attempted but unfortunately the poor quality of FKBP51 antibodies available 
made this impossible. Future work should expand on this mechanism and perhaps repeat this 
experiment using mice with a tagged FKBP51, which would facilitate efficient pulldown. 
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Alternatively, as with the transcriptomic dataset, neuronal activity is a prime candidate for 
glucocorticoid independent effects. Neuronal activity in the dentate gyrus of adult mice is a 
potent inducer of alterations in DNA methylation, with accumulation at plasticity related 
genes 582. However, to my knowledge a similar mechanism has not been described in the 
hypothalamus or in the neonatal brain. Also in the adult hippocampus DNA methylation has 
been described to be crucial in synaptic function, with both DNMT1 and DNMT3a required 
583. Again I am unaware of any studies which demonstrate a similar effect in the neonatal 
brain or hypothalamus but Gene Ontology analysis of differentially methylated regions which 
were associated with protein coding regions in my dataset (see Figure 4.11), revealed strong 
enrichment for synapse related terms. Therefore, this is a good candidate mechanism for the 
effects seen here. To investigate this mechanism in the future, a comprehensive analysis of 
neuronal activity in the hypothalamus following MMS should be done. This analysis should 
include immunohistochemistry for markers of neuronal activation such as c-FOS. Areas of c-
FOS accumulation should then be assessed with electrophysiological techniques in vivo or 
using acute ex vivo slices. Then the coupling of DNA methylation to neuronal activity could 
be investigated in naïve animals using optogenetic mediated stimulation of neuronal activity 
following by microdissection and assessment of DNA methylation. Differentially methylated 
regions could then be compared with those from MMS, significant overlap in differential 
methylation would strongly suggest neuronal activation was the mechanism responsible for 
changes in DNA methylation following MMS. 
I saw no correlation between differentially methylated regions and gene expression. This may 
seem surprising, as DNA methylation is classically associated with gene expression. Indeed, 
the promoter regions of genes with high levels of expression are typically entirely 
unmethylated, and the promoter regions of genes with little or no expression are typically 
highly methylated 584. In my dataset there were fewer than 20 promoter regions differentially 
methylated. The biological significance of changes in DNA methylation at these loci is not 
clear as small changes in DNA methylation, at loci with already low levels of DNA methylation 
may lead to a large fold change but have little or no physiological consequences. Outside of 
promoter regions the relationship between DNA methylation and gene expression is far less 
clear 584 and it is, therefore, not surprising to see that differential methylation does not 
associate with differential gene expression in these regions. 
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The physiological impact of the alterations in DNA methylation seen in this chapter are not 
clear. DNA methylation is highly dynamic during human brain development 110 and thereby, 
altered DNA methylation caused by stress may alter developmental trajectories and thereby 
affect long-term neurodevelopment. I demonstrate differential methylation at synapse 
associated genes, and this may have an important role in neuronal circuit development. An 
important future experiment will be to evaluate the presence of synapses both following 
MMS at P6 and in the adult period. This could simply be done using protein extraction and 
western blotting for synaptic markers such as PSD95 or vGlut. Alternatively, serial sectioning 
of embedded brain tissue and subsequent immunohistochemistry for pre and post synaptic 
markers could be done, followed by imaging and co-localisation analysis to investigate the 
spatial distribution of synapses following MMS, as per Zhu et al, 2018 585. 
4.6.6 Behaviours 
4.6.6.1 EPM, OF and PhenoMaster 
Here I demonstrate stress specific hyperactivity in adult male mice following MMS. Studies 
have previously reported hyperactivity in the EPM and OF following early life stress but to 
my knowledge none have also performed in cage behavioural monitoring, to demonstrate 
this is truly a stress specific phenotype. 
The EPM and OF are often used in combination to assess anxiety in mice and the results of 
both tests have been shown to positively correlate in both C57BL/6JOlaHsd and BALB/c mice 
539. Previous literature describing hyperactivity in the EPM and OF have used the traditional 
maternal separation paradigms with at least 30 hours of total separation time. The power of 
MMS is underscored by similar results occurring with only 4.5 hours of total separation. A 
primary motivator to create MMS was the variance in behavioural outcome following 
traditional maternal separation. For instance, using 3 hours/day of maternal separation from 
P2-P14 female mice had altered behaviour in the EPM, with males being resilient 588. Another 
study using the same paradigm but for 4 hours/day, saw no effect on female behaviour 589, 
whilst a different study showed maternal separation (6 hours/day from P15-P21) had no 
effect on behaviour in the EPM or OF in mice 590. Maternal separation (6 hours/day P5-P21 
or 3 hours/day P3-P14) in rats seems to more consistently show changes in the EPM and OF 
tests 591,592.  
With respect to the limited nesting model of fragmented maternal care, studies have 
reported no differences in behaviour in the EPM or OF 593. 
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4.6.6.2 Tail suspension 
Early life abuse is associated with an increased incidence of depression in adult life 594. 
Therefore, I tested for depressive symptoms in adult mice exposed to MMS. The tail 
suspension test is a commonly used measure of depression related behaviour in mice 540. The 
primary outcome is immobile time, which was not different between groups. The forced 
swim test (which I did not use) is another commonly used test for depressive symptoms, in 
which the time immobile is also the primary outcome. The forced swim and tail suspension 
tests do not always correlate 595, perhaps indicating that they measure distinct behaviours. 
Therefore, it may be useful in the future to use the forced swim test. The tail suspension test 
was chosen here as it provides a widely used test of depressive symptoms but is associated 
with less stress than the forced swim test. However, even though these are the most 
common preclinical tests for depressive symptoms, there are pressing questions about their 
relevance to human depression. To reduce a condition as heterogeneous as depression to a 
single metric is inherently reductionist and non-scientific, there have also been variable 
results using these models 596. The ability of selective serotonin reuptake inhibitors (SSRIs) to 
decrease immobile time in these tests has led to a form of validity. However, these effects 
occur with hours/days of administration whereas anti-depressive effects of SSRIs in humans 
can take months to be seen 597.  
Future studies should focus on aspects of depression related traits rather than single metric 
tests. For instance testing taste preference between water and a 1% sucrose solution has 
previously been used to model the reduced enjoyment of food associated with human 
depression 536. Alternatively studies should analyse habitual behaviour and activity using, as 
done here with the PhenoMaster or variations in which novel objects can be introduced 598. 
There are gender differences in depression associated with early life stress in humans and 
mice, with females preferentially affected 593,599. Here, I only used male mice, which is the 
principal limitation of this work. A comprehensive study of MMS in female mice is needed. 
4.6.6.3 Assessment of in cage behaviour 
Here I assessed in cage behaviour using the TSE Systems PhenoMaster. To my knowledge this 
is the first study to use this or a related system to follow up the effects of a model of early 
life stress. This system provides a variety of data with both high temporal and spatial 
resolution but is associated with some caveats. As this system cannot track multiple objects 
independently, animals must be single housed during this experiment. This single housing 
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extends to 4 days before introduction to the system as the PhenoMaster uses a novel 
waterspout which necessitates isolated training. Mice are social animals and single housing 
in this manner is not recommended and constitutes a chronic stressor. Moreover, the system 
uses lasers to track mouse behaviour which can be interrupted by the build-up of nesting 
material. As such only limited nesting material can be used within the cage and there is also 
a completely lack of any environmental enrichment. Therefore, this entire experiment took 
place during 8 days of continuous chronic stress. The first 24 hours of data from the 
PhenoMaster were not used as the mice acclimatised to the environment, this first 24 hours 
could be viewed as an acute stress similar to the introduction into the EPM or OF. It is 
nonetheless interesting that the MMS group were not different among any of the measured 
variables during this period of chronic stress. Therefore, the most plausible interpretation of 
these behavioural results is that MMS results in acute stress specific hyperactivity. 
To my knowledge there are no human studies which characterise the behavioural response 
to acute stress in individuals exposed to early life stress, but this may be an interesting 
validation of my results. It is obviously unethical to expose people to acute stress with the 
hypothesis they will have an exaggerated reaction, therefore a behavioural response to an 
acute stress which is an unavoidable part of habitual activity would be required. A study such 
as this would require extensive cross discipline collaboration with respect to feasibility and 
design. 
4.6.7 Candidate gene expression changes in the hippocampus 
I did not find any changes in candidate gene expression throughout the HPA axis, but I did 
find changes within the hippocampus. The hippocampus has a crucial role in regulating the 
HPA axis 287. As such these data indicate that the stress-induced hyperactivity seen in the 
EPM and OF may not be due to fundamental alterations in the HPA axis, but changes in its 
regulation from the hippocampus. I found a signature of neuronal activation in the 3’ mRNA 
sequencing dataset and previous work has shown DNA methylation can be altered by 
neuronal activity 582. Therefore, all the effects I describe may be driven by hippocampal input 
into the HPA axis. 
Future studies should focus on the hippocampus and fully characterise its role in MMS, in 
both the neonatal and adult stages. An experiment to investigate hippocampal input to the 
hypothalamus both immediately following MMS and in adulthood could be done by using 
single cell patch clamp techniques in acute brain slices, followed by reverse labelling of 
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neurons with biotin. The hippocampus innervates numerous nuclei within the hypothalamus 
which then relay information to the paraventricular nucleus so there are many possible 
locations and mechanisms involved. However, immunohistochemistry could then be done on 
biotin labelled cells to identify specific cellular subtypes and their hippocampal location. 
4.6.8 Therapeutic targets 
The endocannabinoid system can interact with stress through a number of mechanisms, 
mostly to limit the extent of stress signalling 605. The CBR1 can control glutamate release, and 
CBR1-/- mice show enhanced glutamatergic signalling in the PFC following chronic stress in 
adult animals 606.  CBR1 agonists have anxiolytic properties in adult mice in the EPM and OF 
607 but their use in the neonatal period to attenuate the effects of early life stress is unknown. 
Therefore, CBR1 agonists would be an interesting candidate to administer with MMS. 
Previously, pharmacological inhibition of FKBP51 has been difficult due to its homology with 
FKBP52. However recently, specific inhibitors have been generated named SAFit1 and 2 374. 
Their use has been associated with anxiolytic effects in adult animals 375. These would also be 
interesting candidates to investigate if their co-administration with MMS could abrogate the 
effects described here. 
Increased maternal care may also be beneficial. Brief removal and handling of pups for 15 
minutes is associated with an increased level of maternal grooming when the pups are 
returned to the cage 608. Therefore, increased maternal contact and care may be an easier 
method of mitigating the effects of stress in the perinatal period. 
4.7 Conclusion 
The effects of stress associated with PTB on brain development are largely unknown and 
studying this in humans is difficult due to the confounders associated with preterm birth. This 
necessitates the use of animal models to understand the consequences and mechanisms 
involved. However, many models of early life stress fail to accurately recapitulate the stress 
associated with PTB. Therefore, I created a novel model of early life stress, called MMS. Using 
MMS, I demonstrate that DNA methylation is particularly vulnerable to alterations following 
early life stress and that the amount of stress needed to produce behavioural effects in later 








5 The effect of LPS administration prior to MMS in the cortex 
and hippocampus 
5.1 Introduction 
In the previous results chapter, I showed an enrichment for NFkB binding motifs among 
differentially expressed genes in the hypothalamus immediately following MMS. NFkB 
signalling is classically associated with immune activation and inflammation and in this 
chapter, I tested the hypothesis that exposure to LPS and associated activation of NFkB 
signalling prior to MMS would potentiate the transcriptional response and other outcomes. 
In this chapter I use a single dose of 1mg/kg LPS to model neonatal sepsis. LPS is a component 
of the bacterial cell wall and an agonist of the TLR4 receptor. It is commonly used to model 
bacterial infections and has previously been used at 1mg/kg to model sepsis 609. In preterm 
infants, perinatal sepsis is associated with an adverse neurodevelopmental outcome 
independent of other factors 610 and in animal models it is associated with hypomyelination 
in the brain, altered growth, altered behaviour in adulthood and has been shown to sensitise 
to other early life insults 250,611,612. 
LPS in animal models potentiates subsequent hypoxia/ischemia 517,613 and in human neonatal 
imaging studies, different patterns of brain injury are seen in term born infants with neonatal 
encephalopathy with or without additional exposure to chorioamnionitis 236.  LPS in animal 
models or inflammation in human neonates may also interact with stress to impact on the 
later phenotype. For instance the interaction between early life inflammation and neonatal 
stress may explain some of the developmental heterogeneity in individuals with 
schizophrenia or bipolar disorder 614. It is also known that pregnant women with depression 
have increased circulating cytokine levels which correlate with the infant stress response at 
one year 615. However this is a complicated relationship, and early life stress may also 
influence circulating cytokine levels, as has been observed in adult rhesus monkeys 616. Early 
life stress and inflammation seem to be mechanistically linked, as administration of non-
steroidal anti-inflammatory drugs can ameliorate hyperactivity in adult animals exposed to 
stress in utero 617. In adult rats, evidence also suggests stress can prolong an inflammatory 
event 618. However, the consequences of this for the neonatal brain are unclear. 
Sleep deprivation is a central component of the MMS model, and sleep deprivation has been 
shown to reduce the glymphatic clearance of inflammatory molecules from the brains of 
adult animals 577. Glymphatic vessels have been found in humans and resemble those in mice, 
143 
 
and a similar clearance process through glymphatic vessels is thought to operate in humans 
619. These processes have not been described in neonatal animals to date most likely due to 
the associated technical difficulties, but it is known that both CSF flow through the brain 620 
and sleep 621 are of critical importance for brain development. 
Individuals with ASD have an increased number of synapses 84 and individuals with 
schizophrenia have fewer synapses 82,96 across several brain regions when compared to 
typically developing individuals, and altered synaptic pruning is a potential mechanism 
involved. As discussed in the introduction, many immune related genes also have functions 
related to synaptic pruning e.g. MEGF10 622, C4 100 , CSMD1 101, TGFβ 623 and CX3CR1 624. In 
this chapter I will investigate the effect of LPS and/or MMS on aspects of synaptic pruning. 
Much of the evidence for microglia mediated synaptic pruning comes from the mouse 
hippocampus 501,624,625, which is where I focus my area of investigation during this chapter. 
The importance of glial cells to brain development is widely appreciated and the local 
redistribution or reduction/expansion of these cells can have a large effect on brain function 
and development 626. As outlined previously here and in the introduction, microglia are 
involved in key processes such as synaptic pruning and the central inflammatory response. 
In post mortem tissue from individuals with ASD there are specific alterations in microglia 33. 
Studies in mice indicate that individual microglia are extremely long lived 268 and therefore 
early life factors such as stress or inflammation may program future dysfunction in the same 
cell. Astrocytes are important for brain development 626 and also have a role in microglia 
mediated synaptic pruning 627,628. In my first results chapter I showed that LPS exposure in 
primary cultured mouse OPCs resulted in a trend towards a reduced production of mature 
myelinating oligodendrocytes, which has also previously been described in the literature. 
Neonatal inflammation models produce hypomyelination 629, and WMI is a predictor of 
neurodevelopmental outcome 59. In this chapter I investigate markers of microglia, astrocytes 
and oligodendrocytes in the hippocampus and cortex following LPS and/or MMS. 
Finally, in the central dogma of molecular biology RNA is transcribed from DNA before its 
translation into protein. The transcriptome plays an integral role in defining cellular identity 
and is highly dynamic and plastic through development as well as reflecting responses to 
environmental perturbation. As described in the introduction, cortical dysfunction has been 
linked to many neurodevelopmental disorders and early life insults. In this chapter I 
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interrogate the cortical transcriptome in an unbiased manner using 3’ mRNA sequencing 





5.2 Hypothesis and aims 
5.2.1 Hypotheses 
Administration of LPS will potentiate the effects of subsequent MMS in the hippocampus and 
cortex 
5.2.2 Aims 
1. To assess the effect of LPS and/or MMS on weight gain  
2. To investigate the expression of inflammation related genes in the brain 24 hours 
after LPS (which would be the onset of the MMS paradigm) 
3. To examine aspects of synaptic pruning in the hippocampus following LPS and/or 
MMS 
4. To investigate glial cell populations in the cortex following LPS and/or MMS 
5. To examine the cortical transcriptome following LPS and/or MMS 
6. To compare the cortical and hypothalamic transcriptomes after MMS to identify 
common regulators  
5.3 Methods 
5.3.1 Animals 
C57BL/6JOLAHSD male mice were used for the following experiments. A single male was 
housed with 2 females under a 12-hour light/dark schedule with constant temperature and 
humidity. Litters were randomly reduced to 4 males on P2. On P3, these 4 males were then 
randomised to the following 4 groups:  
1. Control group- PBS via IP injection and no MMS 
2. LPS group- 1mg/kg LPS via IP injection and no MMS 
3. MMS group- PBS via IP injection and MMS 
4. LPS+MMS group- 1mg/kg LPS via IP injection and MMS 
Pups then received subcutaneous ink injections to their footpad for identification purposes. 
Offspring were killed by decapitation at P6 for all experiments (except in Figure 5.2 where 





Figure 5.1 Full outline of experimental groups used in Figure 5.3-Figure 5.12 
5.3.2 Gene expression response to LPS 
Pups were administered either 1mg/kg of LPS or PBS on P3. After 24 hours (the time point 
which would be the initiation point of MMS for subsequent experiments), pups were killed 
and whole brain tissue removed and snap frozen on dry ice. RNA was then extracted from 
tissue before cDNA synthesis and qPCR analysis of candidate gene expression. 
5.3.3 LPS and MMS experiments 
Pups received 1mg/kg LPS or PBS on P3, 24 hours later MMS was performed and repeated 
on the 2 subsequent days for 1.5 hours (see Figure 5.1). All pups were weighed consecutively 
on each day, immediately prior to MMS. Weights were normalised to the starting weight of 
each pup at the time of LPS or PBS injection. At the end of the paradigm the animals were 
killed, and brains extracted. Brains were then halved down the midline with one half placed 
in 4% PFA for 24 hours before transferring to 70% ethanol and subsequent embedding in 
paraffin wax, from the other half the cortex and hippocampus were dissected and snap 
frozen on dry ice. Tissue was kept at -80° until RNA was extracted. 
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After embedding in wax, the fixed tissue was then cut into 6µm sections using a microtome 
with three consecutive sections per slide. Slides were dewaxed, then antigen retrieval was 
carried out before immunohistochemistry as previously outlined in the materials and 
methods section. Stained slides were imaged using an Axioscan slidescanner and image 
quantification done using Image J. Olig2+ and Iba1+ cells were manually counted and 
normalised to area. GFAP+ cells were analysed by percent area coverage using a universally 
applied threshold 496. For each animal three consecutive brain sections were analysed which 
were then averaged to produce an n of 1. 
5.3.5 3’ mRNA sequencing 
RNA was extracted from frozen tissue before determination of concentration using a Qubit 
Fluorometer. Library preparation was done using 500ng of RNA. Sequencing and analysis 
were done as described previously in the materials and methods section. Briefly, data were 
mapped to the mm10 genome before differential gene expression analysis using the Voom 
sample weights method. This method was chosen to account for variation often seen in 





5.4.1 Candidate gene expression 24 hours after 1mg/kg LPS or PBS 
To ensure the dose of LPS given to pups at P3 produced an inflammatory response in the 
brain, 1mg/kg of LPS was given at P3 and candidate gene expression analysed in whole brain 
tissue 24 hours later. As seen in Figure 5.2, there was a significant upregulation of Iba1, IL1α 
and TNFα 24 hours after LPS administration compared to PBS control. This indicates that at 




Figure 5.2 The expression of candidate inflammatory genes was assessed 24 hours after 1mg/kg of LPS or PBS 
administration. An increase in Iba1 (p=0.002, df=6), IL1α (p=0.009, df=6) and TNFα (p=0.02, df=6) can be seen 
following LPS. Expression was normalised to TBP. Comparisons were made using independent t-tests. ** indicates 
p<0.01. n=4 for all groups. A p-value<0.016 was deemed to be statistically significant following Bonferroni 



































5.4.2 Growth dynamics following LPS and/or MMS 
To examine alterations in growth dynamics following LPS and/or MMS, pups were weighed 
at the same time on consecutive days. Brain weight was also measured in a subset of animals 
after killing.  Figure 5.3A shows the growth trajectories of pups from all 4 groups. The 
associated area under the curve is quantified in Figure 5.3B with a reduction in weight gain 
following LPS with no effect of MMS or an interaction between LPS and MMS. There were no 
differences in brain weight when normalised to body weight among any of the groups, as 




Figure 5.3 In A), the weight gain of pups from the control (solid black line), LPS (dashed dark grey line), MMS 
(dashed light grey line) and LPS and MMS (dashed black line) groups can be seen as a percentage of weight on P3 
(the day of injection with either 1mg/kg LPS or PBS). In B) the area under the curve of the data presented in A) 
shows an effect of LPS (p<0.001, f-statistic=26.136, df=36) with no effect of MMS (p=0.347, f-statistic=0.909, 
df=36) or interaction between LPS and MMS (p=0.866, f-statistic=0.029, df=36). In C) there were no main effects 
for LPS (p=0.736, f-statistic=0.119, df=12) or MMS (p=0.646, f-statistic=0.221, df=12), and no interaction (p=0.963, 
f-statistic=0.002, df=12) in the brain to body weight ratio. In A) and B) n=10 for all groups, and n=4 for all groups 



























































































5.4.3 Investigation of processes related to synaptic pruning in the hippocampus 
Considering the important role of glia in both brain development and the response to LPS, I 
characterised the distribution of several markers associated with glial cells within the 
hippocampus immediately following the paradigm in all 4 groups (control, LPS, MMS and 
LPS+MMS). Representative images for all groups can be seen in Figure 5.4A-L. There was a 
borderline significant decrease (p=0.05) in GFAP (Figure 5.4M) following LPS but no effect of 
MMS or interaction between LPS and MMS. I found no difference in the numbers of Iba+ 
(Figure 5.4N) or Olig2+ (Figure 5.4O) cells in the hippocampus following LPS or MMS and 




Figure 5.4 Assessment of candidate glial populations in the hippocampus in the 4 groups: control (A, E, I), LPS (B, 
F, J), MMS (C, G, K), LPS+MMS (D, H, L). In A-D representative images of hippocampal GFAP staining across the 4 
groups are shown. This is quantified as percent area in M with a borderline effect (p=0.05, f-statistic=4.165, df=22) 
with no effect of MMS (p=0.901, f-statistic=0.016, df=22)  or an interaction between LPS and MMS (p=0.122, f-
statistic=0.73, df=22). In E-H, representative images of Iba1+ cells (green) and DAPI+ cells (blue) from all 4 groups 
are shown. This is quantified as Iba1+ cells/mm2 in N) with no differences seen for an effect of LPS (p=0.889, f-
statistic=0.02, df=22), MMS (p=0.447, f-statistic=0.598, df=22) or an interaction (p=0.772, f-statistic=0.086, df=22) 
between them. Similarly, in I-L representative images for Olig2+ cells (green) and DAPI+ cells (blue) are seen from 
all 4 groups, with this quantified in O) as Olig2+ cells/mm2. No differences were seen for an effect of LPS (p=0.209, 
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df=21) between them. Experiment was analysed using a 2-way ANOVA, n=6-7 for all groups and comparisons. 
Scale bars indicate 100µm. 
Several inflammatory molecules are involved in synaptic pruning within the hippocampus 
during development. Therefore, I examined the effect of LPS and/or MMS on the expression 
of these molecules in the hippocampus immediately following the paradigm, which is shown 
in Figure 5.5. There were no effects of either LPS or MMS and no evidence of an interaction 
between them for any of the genes tested (MEGF10, C4b, CSMD1, TGFβ, CX3CR1 and 
synapsin), as seen in Figure 5.5A-F. As such there was insufficient evidence to pursue the 
investigation of synaptic pruning within the hippocampus following LPS and/or MMS. 
 
Figure 5.5 Candidate gene expression in the hippocampus following control, LPS, MMS or LPS + MMS. In A there 
were no differences found for an effect of MMS (p=0.267, f-statistic=1,28, df=28), LPS (p=0.65, f-statistic=0.211, 


























































































































































































































































































differences found for an effect of MMS (p=0.098, f-statistic=2.922, df=30), LPS (p=0.664, f-statistic=0.192, df=30) 
or an interaction (p=0.293, f-statistic=1.15, df=30) in the expression of C4b. In C there were no differences found 
for an effect of MMS (p=0.238, f-statistic=1.453, df=29), LPS (p=0.241, f-statistic=1.431, df=29) or an interaction 
(p=0.248, f-statistic=1.387, df=29) in the expression of CSMD1. In D there were no differences found for an effect 
of MMS (p=0.065, f-statistic=3.684, df=29), LPS (p=0.538, f-statistic=0.389, df=29) or an interaction (p=0.236, f-
statistic=1.464, df=29) in the expression of TGF-beta. In E there were no differences found for an effect of MMS 
(p=0.567, f-statistic=0.336, df=30), LPS (p=0.317, f-statistic=1.037, df=30) or an interaction (p=0.375, f-
statistic=0.814, df=30) in the expression of CX3CR1. In F there were no differences found for an effect of MMS 
(p=0.161, f-statistic=2.076, df=31), LPS (p=0.322, f-statistic=1.017, df=31) or an interaction (p=0.207, f-
statistic=1.666, df=31) in the expression of Synapsin. Expression was normalised to TBP. Data were analysed using 
a 2-way ANOVA, n=6-9 in all groups shown. Error bars indicate standard error of the mean. 
 
5.4.4 Immunohistochemistry for GFAP, Iba1 and Olig2 in the cortex 
As discussed in the introduction, alterations in Iba1+, Olig2+ and GFAP+ cells in the cortex are 
associated with various perinatal pathologies. I profiled GFAP, Iba1 and Olig2 positive cells 
within the cortex immediately following the paradigm. Representative images of GFAP (A-D), 
Iba1 (E-H) and Olig2 (I-L) can be seen in Figure 5.6. I found no difference in GFAP percentage 
area (Figure 5.6M), Iba1+ cell number (Figure 5.6N) or Olig2+ cell number (Figure 5.6O) 





Figure 5.6 Assessment of candidate glial populations in the cortex in control (A, E, I), LPS (B, F, J), MMS (C, G, K) 
and LPS+MMS (D, H, L) groups. A-D show representative images of cortical GFAP staining across the 4 groups. This 
is quantified as percent area in M with no effect of LPS (p=0.767, f-statistic=0.09, df=22), MMS (p=0.316, f-
statistic=1.048, df=22) or an interaction (p=0.476, f-statistic=0.525, df=22)  between them. In E-H, representative 
images of Iba1+ cells (green) and DAPI+ cells (blue) from all 4 groups are shown. This is quantified as Iba1+ 
cells/mm2 in N) with no difference seen for an effect of LPS (p=0.889, f-statistic=0.02, df=23), MMS (p=0.447, f-
statistic=0.598, df=23) or an interaction (p=0.772, f-statistic=0.086, df=23) between them. Similarly, in I-L 
representative images for Olig2+ cells (green) and DAPI+ cells (blue) are seen from all 4 groups, with this quantified 
in O) as Olig2+ cells/mm2. No differences were seen for an effect of LPS (p=0.857, f-statistic=0.033, df=22), MMS 
(p=0.286, f-statistic=1.203, df=22)  or an interaction (p=0.51, f-statistic=0.451, df=22)  between them. Experiments 
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5.4.5 3’ mRNA sequencing 
The cortical transcriptomes from the LPS, MMS and LPS+MMS groups were compared to the 
control group following 3’ mRNA sequencing. An n of 3 samples/ group were sequenced. 
5.4.5.1 Control vs LPS  
First, as seen in Figure 5.7, I compared the control and LPS groups. Following differential 
expression analysis 28 genes reached an FDR corrected <0.05. The volcano plot shown in 
Figure 5.7A shows all genes analysed for differential expression (all dots), with those with a 
logFC change greater than 1.5 shown in blue (downregulated) or red (upregulated). The 
genes failing to reach this threshold are seen in grey. In Figure 5.7B an MDS plot describes 
the data in 2 dimensions, which explain the vast majority of variance within the dataset. 
See Table 5.1 for a list of genes with an FDR<0.05 from the control vs LPS dataset along with 





Figure 5.7 3’ mRNA sequencing of cortical tissue from the control and LPS group (N=3/group) with differential gene 
expression analysis using VOOM with sample weights. In A) a volcano plot is shown which indicates, in blue and 
red, genes with a logFC of more than 1.5. In B) an MDS plot describes control (blue dots) and LPS (orange dots) 






Table 5.1 Genes with an FDR <0.05, listed alongside their unadjusted p-value and LogFC for the control vs LPS 
dataset 
 
To functionally classify genes which had a logFC in expression of more than 1.5 (indicated by 
blue and red dots in Figure 5.7A), Gene Ontology analysis for cellular component, molecular 
function and biological processes were carried out, as can be seen in Figure 5.8A. To analyse 
over-representation of transcription factor binding sites among genes with a change in 
expression of more than 2-fold, a transcription factor binding enrichment analysis was 
carried out using the Opossum software. The results are listed in Figure 5.8B and are ranked 
by Z-score. 
Gene name FDR Unadjusted p-value LogFC
RP24-468O23.2 0.006775 3.13E-07 1.214946
Col5a1 0.015074 3.93721E-06 1.071448
Gm9968 0.015074 5.89624E-06 -0.62805
Mfap5 0.015074 7.32723E-06 1.597705
RP24-323H7.4 0.015074 3.3439E-06 -1.05004
Hcn1 0.015226 8.09552E-06 -1.29473
Hgfac 0.015226 8.44339E-06 0.764093
H2-Q6 0.015606 9.20014E-06 1.093671
Gm29415 0.023281 1.45236E-05 1.083055
Cdhr3 0.026449 1.73206E-05 1.626322
H2-Oa 0.026449 1.77222E-05 0.768181
Prame 0.027063 1.87592E-05 0.718175
Hmgb1-ps6 0.030084 2.22431E-05 -0.91915
Gm10775 0.038194 3.00043E-05 1.994702





Figure 5.8 Analysis of genes with a greater than 1.5 logFC from the 3’ sequencing dataset of control vs LPS. In A), 
Gene Ontology analysis of genes between control and LPS groups is shown for cellular component (open bars), 
molecular function (grey bars) and biological function (black bars). In B) a transcription factor binding 
enrichment analysis of genes is shown. Transcription factors are ranked by Z-score. 
5.4.5.2 Control vs MMS groups 
Next, I compared the control group to the MMS group as seen in Figure 5.9. Following 
differential expression analysis, a total 61 genes had an FDR corrected <0.05. The volcano 
plot shown in Figure 5.9A shows all genes analysed for differential expression (all dots), and 
those with a logFC of greater than 1.5 are coloured blue (downregulated) or red 
(upregulated) The genes failing to reach this threshold are seen in grey. In Figure 5.9B an 





within the dataset. See Table 5.2 for a list of genes with an FDR<0.05 from the control vs 
MMS dataset along with their unadjusted p-values and LogFC. 
 
Figure 5.9 3’ mRNA sequencing of cortical tissue from the control and MMS group (n=3/group) with differential 





and red, genes with a logFC of more than 1.5. In B) an MDS plot describes control (blue dots) and MMS group 
(green dots) data in 2 dimensions, representing 51% and 20% of the variance within the data respectively. 
Table 5.2 Genes with an FDR <0.05, listed alongside their unadjusted p-value and LogFC for the control vs MMS 
dataset 
 
To functionally classify the genes which had a logFC in expression of more than 1.5 (indicated 
by blue and red dots in Figure 5.9A), Gene Ontology analysis for cellular component, 
molecular function and biological processes were carried out, as seen in Figure 5.10A. To 
analyse the over representation of transcription factor binding sites among genes 
differentially expressed by more than 4-fold, a transcription factor binding enrichment 
analysis was carried out using the Opossum software. The results are listed in Figure 5.10B 
and show enrichment for the NFkB family of transcription factors. 
Gene name FDR Unadjusted p-value LogFC
Gm26884 0.001079064 2.49E-08 0.915564
Zfhx2 0.010467917 1.20933E-06 -0.66157
RP24-323H7.4 0.012627306 2.04231E-06 -1.12375
Gm9968 0.013639318 2.6013E-06 -0.70177
Sult1a1 0.013639318 2.83627E-06 2.050215
C030037D09Rik 0.026857183 9.87355E-06 1.368087
Col5a1 0.026857183 1.17498E-05 0.963867
Gm11895 0.026857183 9.17324E-06 0.824531
Gm20945 0.026857183 9.17324E-06 0.824531
Gm28979 0.026857183 1.17904E-05 0.838962
Samd11 0.026857183 7.82725E-06 1.630807
Tnfrsf18 0.026857183 1.17904E-05 0.838962
Zfp810 0.026857183 9.92458E-06 0.676586
Hmgb1-ps6 0.029911243 1.45133E-05 -0.97942
RP23-247A1.7 0.030061227 1.66698E-05 1.832265
Try5 0.030061227 1.65031E-05 1.082082
Ccdc86 0.039150045 3.25821E-05 0.898725
Erv3 0.039150045 3.32351E-05 1.093053
Gm15982 0.039150045 3.64426E-05 -0.66586
Gm6341 0.039150045 2.80825E-05 1.192692
RP23-240E15.2 0.039150045 3.64426E-05 -0.66586
Ubac2 0.039150045 2.94501E-05 -0.72013
Vax2os 0.039150045 3.57634E-05 -0.67812
Gm5117 0.039387572 4.14167E-05 1.542863
She 0.040802884 4.431E-05 -1.25531
Gm8349 0.044500303 4.97106E-05 0.908804
Rimbp3 0.044500303 5.03816E-05 1.608737
Polr2k 0.048474041 5.71205E-05 0.705397






Figure 5.10 Analysis of genes with a greater than 1.5 logFC from the 3’ sequencing dataset of control vs MMS. In 
A), Gene Ontology analysis of genes between control and MMS groups is shown for cellular component (open 





enrichment analysis of genes with over a 4-fold change in expression is shown, with high representation of the 
NFkB family of transcription factors. Transcription factors are ranked by Z-score. 
5.4.5.3 Control v LPS+MMS groups 
Next, I compared the control group to the LPS+MMS group as seen in Figure 5.11. Following 
differential expression analysis 28 genes in total had an FDR corrected <0.05. The volcano 
plot shown in Figure 5.11A shows all genes analysed for differential expression (all dots), and 
those with a logFC of greater than 1.5 are shown in blue (downregulated) and red 
(upregulated). The genes failing to reach this threshold are seen in grey. In Figure 5.11B an 
MDS plot describes the data in 2 dimensions, which explain the vast majority of variance 
within the dataset. See Table 5.3 for a list of genes with an FDR<0.05 from the control vs 





Figure 5.11 3’m RNA sequencing of cortical tissue from the control and LPS+MMS group (n=3/group) with 
differential gene expression analysis done using VOOM with sample weights. In A) a volcano plot is shown which 
indicates, in blue and red, genes with a logFC of more than 1.5. In B)  an MDS plot describes the control (blue dots) 






Table 5.3 Genes with an FDR <0.05, listed alongside their unadjusted p-value and LogFC for the control vs 
LPS+MMS  dataset 
 
To functionally classify the genes which had a logFC in expression of more than 1.5 (indicated 
by blue and red dots in Figure 5.11A), Gene Ontology analysis for cellular component, 
molecular function and biological processes were carried out, as seen in Figure 5.12A. To 
analyse the over representation of transcription factor binding sites among the genes 
differentially expressed by more than 2-fold, a transcription factor binding enrichment 
analysis was carried out using the Opossum software. The results are listed in Figure 5.12B 
and are not indicative of enhanced or potentiated NFkB signaling. 
 
Gene name FDR Unadjusted p-value LogFC
Gm14335 0.00542 2.50E-07 0.84188
Lemd1 0.006962 6.43E-07 -0.96952
Gm4969 0.020541 2.84761E-06 -1.56267
RP24-323H7.4 0.020541 2.81017E-06 -1.08325
Gm9968 0.023502 4.34411E-06 -0.66127
Gm6341 0.03404 7.16398E-06 1.397551
Ptn 0.036553 9.29016E-06 -0.9929





Figure 5.12 Analysis of genes with a greater than 1.5 logFC from the 3’ sequencing dataset of control vs LPS+MMS. 
In A), Gene Ontology analysis of genes is shown for cellular component (open bars), molecular function (grey bars) 
and biological function (black bars). In B) transcription factor binding enrichment analysis of genes with over a 2-





5.4.6 Comparison of cortical and hypothalamic transcriptome following MMS 
Considering the evidence for NFkB signalling in both the hypothalamic 3’ mRNA sequencing 
dataset presented in the previous chapter and the cortical 3’ sequencing of the MMS group 
presented here in Figure 5.9 and Figure 5.10. I wanted to understand if similar processes 
were driving differential expression of genes in the cortex and hypothalamus. I therefore 
compared these 3’ mRNA sequencing datasets.  
Genes which were differentially expressed in both datasets were identified and are shown in 
Figure 5.13A. Six out of 17 genes (Ccdc158, Sult1a1, Fam180a, 8430408G22Rik, Fam179a and 
Ncf4) were differentially expressed in the same direction i.e. up or down. A Gene Ontology 
analysis of all genes in Figure 5.13A did not identify any enriched terms, likely due to the 
small number of genes. Transcription factor binding enrichment analysis of these genes using 
Opossum, as seen in Figure 5.13B showed an over representation of NFkB motifs among all 





Figure 5.13 Genes which were commonly differentially expressed (greater than logFC 1.5) following MMS in the 
cortex and hypothalamus were identified. In A) these genes are listed along with arrows indicating whether they 
were upregulated (grey box with white arrow) or downregulated (white box and black arrow) in the tissue 
specified. In B) a transcription factor binding enrichment analysis on these genes indicates an over representation 
of NFkB motifs associated with these genes. 
  
Transcription Factor Function Z-Score Fisher Score
NR1H2::RXRA Nuclear receptor 18.942 2.904
REL Inflammatory signalling 9.941 0.641
RELA Inflammatory signalling 9.602 0.65
NFATC2 Inflammatory signalling 6.576 3.296

























In this chapter I tested the hypothesis that the effects of MMS would be potentiated by prior 
exposure to LPS. I show that: 
1. Pups exposed to LPS gained significantly less weight than PBS injected controls during 
the MMS paradigm 
2. There was a significant upregulation of inflammation related gene expression in the 
brain 24 hours after LPS injection (i.e. onset of MMS) 
3. There was no evidence from candidate gene expression or immunohistochemistry to 
suggest an alteration in synaptic pruning in the hippocampus following LPS and/or 
MMS 
4. There were no changes in Iba1+, Olig2+ or GFAP+ cell composition of the cortex in 
any of the groups examined 
5. LPS did not potentiate the effect of MMS with respect to cortical gene expression 
6. There were 17 genes which were changed by more than 1.5 fold in both the 
hypothalamus (described in the previous chapter) and cortex, following MMS 
 
5.5.1 LPS effects 
Here I show a reduction in growth following LPS administration. Similar results have been 
seen in other animal models (i.e. mice 631 and rats 632) and inflammation is also associated 
with poor growth in very preterm infants 633. I did not see any differences in the brain: body 
weight ratio between groups (see Figure 5.3C), which implies there was no brain sparing 
effect as has been described for intrauterine growth restriction in humans 634 and animal 
models 635.  
As shown in Figure 5.4 and Figure 5.6, there were no changes in Iba1+, Olig2+ or GFAP+ cells 
in the hippocampus or cortex respectively, there was also little change associated with LPS 
administration throughout these experiments. This is surprising as LPS is associated with 
profound effects on the brain at various concentrations (see introduction for further details). 
I ruled out poor quality LPS and inaccurate IP injections as the cause of this for the following 
reasons. Firstly, the consistent reduction in growth seen across all animals which received 
LPS is indicative of a physiological response and as outlined earlier in the discussion this result 
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agrees with both clinical and preclinical studies on inflammation. Secondly, using the same 
batch of LPS and injection technique, there were highly significant differences in the 
expression of candidate inflammatory molecules within whole brain tissue 24 hours after 
injection (as seen in Figure 5.2).  
5.5.1.1 LPS dynamics 
I administered LPS systemically through IP injection, through this route LPS is absorbed by 
the mesenteric blood vessels and circulated throughout the body 636. Systemic administration 
of LPS in adult mice results in minimal LPS crossing the BBB. Interestingly when LPS is given 
repeatedly, which results in the opening of the BBB (which more accurately represents the 
neonatal BBB) the vast majority of LPS still does not cross the BBB 637. This implies that LPS 
mediated brain inflammation results from peripheral mediators rather than central LPS 
mediated TLR4 activation. LPS has an extremely short half-life in adult mice (2-4 minutes) 638 
and therefore the peripheral inflammatory mediators driving the central transcriptional 
changes at 24 hours (see Figure 5.2) may have subsided by 73.5 hours (duration of 
experiments described in Figure 5.3-Figure 5.12 from initial LPS administration). This may 
have led to a limited interaction between LPS and the MMS paradigm. This is a central 
limitation to these experiments, as an infant with sepsis would likely experience prolonged 
exposure to these inflammatory mediators. A way to overcome this in the future would be 
to use daily dosing of LPS alongside MMS induction. 
5.5.2 Immunohistochemistry 
5.5.2.1 Iba1 
It was surprising to see no changes in Iba1+ cells within the LPS group but as outlined earlier 
this may be due to the resolution of inflammation by the time of assessment. Iba1 marks all 
myeloid cells and under homeostatic conditions most of these cells consist of microglia. 
However, perinatal insults have been associated with the infiltration of peripheral myeloid 
cells 641. Saavedra et al, using the traditional maternal separation paradigm (3 hours/day for 
2 weeks), saw a decrease in microglial density in the hippocampus. In their study mice 
received 1mg/kg of LPS on P14 (end of the maternal separation paradigm) which also resulted 
in a decreased microglial density within the hippocampus with the largest effect seen when 
maternal separation was combined with LPS 642. Delpech et al, using the same maternal 
separation paradigm as Saavedra et al showed an increase in microglial density within the 
hippocampus at P14 and P28 643. The differences between the findings in these papers and 
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my own could be explained in several ways. Firstly, MMS is distinct from maternal separation 
and as such different effects are not surprising. Secondly, microglial assessment was done at 
P14 in these studies, compared to P6 in this chapter. As described in the introduction 
microglia assume distinct phenotypes during development, therefore at P14 microglia in the 
hippocampus may respond differently to stress and LPS challenge compared to at P6. Finally, 
LPS was given after the stress paradigm in these studies and therefore these studies model a 
different aspect to the interaction between early life stress and inflammation I aimed to 
investigate. 
5.5.2.2 Olig2 
As discussed in the introduction and the first results chapter, oligodendrocytes are 
particularly susceptible to PTB related brain injury 69 and hypomyelination has been seen in 
animal models of perinatal inflammation 250. Also, in my first results chapter I showed a trend 
towards a reduction in mature myelinating oligodendrocytes after LPS exposure in a primary 
mouse OPC culture model. Stress has also been linked to oligodendrocyte alterations, a study 
by Teissier et al using 2 weeks of maternal separation for 3 hours/day showed altered 
myelination within the cortex 644. I used Olig2 to label all cells of the oligodendrocyte lineage, 
therefore, even though I do not see alterations in Olig2 cell number, it is possible there are 
alterations within cellular subtypes of the lineage. For instance, a premature differentiation 
to mature oligodendrocytes would not necessarily reduce Olig2+ cell numbers immediately 
but it would reduce the number of OPCs and increase the number of mature 
oligodendrocytes. Future investigations using specific labels for the entire oligodendrocyte 
lineage would assist with understanding this further.  
5.5.2.3 GFAP 
Astrocytes have recently been described to be much more heterogenous than once thought, 
and the traditional marker GFAP is thought to label only about 5-10% of all astrocytes 645. 
GFAP was used in this study as it is increased during astrogliosis, which is an important 
mechanistic response to inflammation 646. As such it was not intended to be indicative of the 
astrocyte population at large and future work to investigate this could use the marker Sox9 
to more comprehensively assess astrocyte proportions following MMS. 
In adult rats exogenous administration of corticosterone results in a decrease in GFAP 
staining throughout the brain 647. Maternal separation (3 hours/day for 2 weeks from P1) 
studies have also shown a marginal reduction in GFAP staining in the hippocampus at P14 642. 
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However, in my experiments there were no differences in GFAP in the cortex or hippocampus 
following MMS. This discrepancy with the literature may be due to several reasons. Firstly, I 
assessed the presence of GFAP at P6, and the presence of GFAP is known to increase with 
age 648. Secondly, as discussed in the introduction P6 is associated with a hyporesponsive 
period to stress in mice and as such may be associated with differential GFAP responses to 
stress. A marginal reduction in GFAP staining in the hippocampus following LPS in mice at 
P14 has previously been reported 642. This is similar to the trend I report here, of a borderline 
significant decrease in GFAP following LPS. This may be an effect of LPS on astrocytes and 
astrogliosis which is independent of age.  
It should also be noted that the areas which I quantified glial cells were not exhaustive and 
may not be representative of the entire cortex or hippocampus. In the future, studies such 
as this should strongly consider the use of single cell RNA sequencing for deep phenotyping 
of cellular tissue composition. 
5.5.3 Investigation of synaptic pruning 
Using maternal separation for 3 hours/day for 2 weeks (P1-P14), Wei et al show decreased 
synaptic protein levels and an increased number of immature dendritic spines in the 
hippocampus at P28 649. These results imply alterations in synaptic maturation or pruning 
following early life stress, which I provide no evidence for using the MMS model. It is possible 
the time point I used was too early to see functional alterations in synaptic maturation 
associated with MMS.  
Considering I saw no difference in microglial cell number and no expression differences in 
candidate genes, I did not further investigate deficits in synaptic pruning. To do this would 
require a multi-faceted approach using high magnification confocal imaging to look at the co-
localisation of synaptic proteins such as PSD95 or V-GLUT1, Iba1 (or the microglial specific 
marker Tmem119) and a lysosomal marker such as LAMP1. Also, the co-labelling of the pre 
and post-synapse with PSD95 and V-GLUT1 and the optimisation of a Matlab script to 
quantify their co-localisation within a certain distance to assess synapse number in situ as 
per Zhu et al 585. Another option would be whole tissue protein extraction and western 
blotting for these markers, but this lacks spatial specificity. 
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5.5.4 3’ mRNA sequencing 
Here as in the previous chapter, I used 3’ mRNA sequencing to interrogate the cortical 
transcriptome. However, to account for the smaller sample size used here (n=3/group), I used 
the method VOOM with sample weights to analyse differentially expressed genes. This 
consists of a statistical approach to minimize gene expression variation within data groups 
by weighting samples appropriately. Low levels of variation are of particular importance in 
experiments with a low n. This method of variation minimisation results in less false 
discoveries and higher powered experiments (as data removal isn’t necessary) when 
compared to traditional methods 630. 
A study from Delpech et al using 3 hours of maternal separation/day for 2 weeks 
demonstrated widespread changes in the microglial transcriptome at P14 using a Nanostring 
immune panel. In their study, promoter analysis of differentially expressed genes indicated 
an enrichment in NFkB activity 643. I see a similar transcriptional signature across multiple 
brain regions (the hypothalamus and cortex) and among genes which are commonly 
differentially expressed between these two regions following MMS. My data set and that 
from Delpech et al, differ in many ways (i.e. brain region, cellular heterogeneity, age of mice, 
mouse strain, stress paradigm and technique used for transcriptome analysis), this suggests 
that dysregulation of NFkB signaling may be a fundamental mechanism in the acute stress 
response in the developing brain which acts independently of brain region and cellular 
subtype. However, this needs to be validated further in female mice as well as other brain 
regions and cellular subtypes in the future as well as using other techniques such as western 
blotting. 
Due to the unique nature of the transcriptome in specific cell subtypes, a shift in Iba1+, Olig2+ 
or GFAP+ cells would consequently underlie many of the changes seen in any sequencing 
dataset. Even though this is a far from exhaustive list of cell types within the cortex, the lack 
of changes seen here for these markers suggest this is not an explanation for any alterations 
seen in the sequencing dataset. However, with the advent and proliferation of single cell 
sequencing, this method should be the method of choice for the transcriptomic investigation 
of brain areas in the future as it can fully account for subtle changes in cellular composition. 
5.5.5 Interaction between LPS and early life stress 
The results in this chapter do not support my hypothesis that MMS would potentiate and 
prolong a prior inflammatory exposure. As outlined in the introduction to this chapter, I 
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hypothesised this for 2 main reasons. Firstly, in my previous results chapter I saw a strong 
NFkB signature among differentially expressed genes in the hypothalamus and considering 
the canonical role of LPS mediated TLR4 activation I reasoned this would sustain and 
potentiate the effect of LPS. Secondly, sleep deprivation is a central component of the MMS 
paradigm and sleep deprivation has been shown to decrease the clearance of inflammatory 
molecules from the brain and the CSF. As such I considered that the, albeit brief, sleep 
deprivation used here as part of the MMS paradigm would prolong the inflammatory 
response. My ultimate prediction therefore was that there would be more differential 
expression of genes related to inflammation and NFkB signalling in the LPS+MMS group. 
However, as shown in Figure 5.11 and Figure 5.12, there was a slight reduction in 
differentially expressed genes when compared to the MMS alone group with no 
enhancement of NFkB signalling. The reasons discussed above with respect to LPS dosing are 
a possible reason for this result.  
5.5.6 Similar effects of MMS in the cortex and hypothalamus 
In Error! Reference source not found.Figure 5.13 I compare the cortical and hypothalamic 
transcriptome following MMS. Of the genes which were commonly differentially expressed 
between the cortex and hypothalamus, most were not changed in the same direction. This 
may be due to brain region specific differences. Of the 17 genes which were commonly 
altered in both tissue depots, 6 were changed in the same direction. As the criteria used to 
identify commonly differentially expressed genes was not statistically stringent, to promote 
discovery, it would be incorrect to interpret the physiological relevance of these commonly 
dysregulated genes individually, and they are too few to undergo Gene Ontology. 
Gene Ontology terms related to the cilium were enriched in both the hypothalamic and 
cortical MMS datasets. Considering both brain regions have a ventricular surface this could 
indicate altered ciliary function at the ventricular surface and perhaps altered CSF flow as a 
result. This would be an extremely interesting question to address in the future, but it comes 
with significant technical problems. CSF penetration (which relates to metabolite clearance) 
can be measured following fluorophore injection into the CSF via the cisterna magna and 
allowing the animal to recover for a period of time before perfusion and serial brain 
sectioning to measure penetration. However, this is extremely technically difficult in 
neonatal mice and to my knowledge has not been done before. Sophisticated imaging 
techniques such as two-photon microscopy can also be used to image CSF flow in vivo using 
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particle tracking 650. However, to my knowledge this also has not been done in neonatal 
animals. 
5.5.7 Conclusion 
In this chapter I show LPS administration via IP injection, but not MMS, results in decreased 
weight gain, but this does not interact with MMS in neonatal animals. I also provide evidence 
to suggest an inflammatory response is present within the brain 24 hours after the 
administration of LPS, at the onset of MMS. I did not see any specific effects of MMS or any 
interaction with LPS on Iba1, Olig2 or GFAP positive cells in the hippocampus or cortex. I also 
did not see any effect of MMS or interaction with LPS on the expression of candidate genes 
which have previously been implicated in synaptic pruning. I carried out 3’ mRNA sequencing 
and showed an enrichment of NFkB binding motifs among the differentially expressed genes 
in the MMS group, which is not potentiated with prior exposure to LPS. I also show this 
enrichment of NFkB binding motifs is present within the genes commonly differentially 
expressed between MMS in the cortex and hypothalamus. 
 
6 Discussion 
Mechanistic insight into the pathogenic processes associated with PTB is difficult to discern 
in humans. In this thesis, I have examined how insults associated with PTB can affect brain 
development in mice at timepoints with neurodevelopmental relevance to PTB. To do this I 
used several in vitro (organotypic forebrain slice culture and primary cell culture) and in vivo 
(MMS and LPS administration) models, as well as a variety of both candidate (e.g. qPCR, 
immunohistochemistry, ELISAs, etc) and unbiased (3’ mRNA and meDIP sequencing) 
approaches. Using these methods, I investigated the role of LPS and hypoxia on various 
biochemical and physiological outputs, how a novel model of early life stress can affect the 
biochemical and physiological characteristics of the neonatal brain and behaviour in 
adulthood, as well as the interaction between early life inflammation and stress. 
6.1 Heterogeneity of PTB related insults 
PTB can be associated with, among other insults, inflammation, stress, hyperoxia/hypoxia 
and synthetic glucocorticoid exposure. The incidence and/or severity of these vary 
dramatically among preterm infants 651, making it difficult to generalise results. As such, 
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increasing our understanding of these factors and their interactions may be important in 
helping us to elucidate the mechanisms involved in PTB related brain injury.  
In this thesis I investigated the ability of LPS (to model bacterial induced infection) to sensitise 
to subsequent hypoxia and MMS (as described in the first and third results chapters 
respectively). For the investigation of LPS and hypoxia, I focused on candidate gene 
expression and 5hmC in an organotypic forebrain slice culture model, cytokine release in 
primary mouse microglia culture and differentiation in primary mouse OPC culture. Previous 
work has convincingly shown that exposure to LPS can sensitise to the effects of subsequent 
hypoxia in animal models 517,652 with respect to cell death, inflammation and myelination and 
that inflammatory sensitisation might also occur in neonates 612. It is therefore somewhat 
surprising that I saw no effect in the primary OPC and primary microglial culture models. One 
explanation may be that this previous work did not examine the same metrics as I did here. 
A major weakness of my work is that it was performed in vitro, and as discussed previously 
the oxygen saturation used in control conditions may not have be physiologically relevant 
despite its wide use. Future work should investigate these mechanisms in an unbiased 
fashion in vivo and use the culture systems outlined here to investigate the finer mechanisms 
associated with these processes or as an earlier stage screening tool for therapeutics. 
I also hypothesised that LPS would sensitise mice to the subsequent effects of MMS due to 
the NFkB signature seen in the hypothalamic transcriptome. However, I showed that this was 
not the case with respect to gene expression. However, as I demonstrated, MMS is only 
associated with subtle gene expression changes in the first instance and as such any 
potentiation would likely also have a small effect size. Therefore, other methods, such as 
DNA methylation which are associated with many changes following MMS, could be used in 
future studies. I also saw no differences in Iba1, Olig2 or GFAP positive cells following LPS and 
MMS, but this may have been due to the limitations previously discussed. As such, these 
results do not preclude an interaction between LPS and MMS. Future work on this should 
take a more all-encompassing approach by evaluating characteristics which have larger effect 
sizes, such as DNA methylation, as well correlating them to behavioural outcome. 
6.2 Genetics and polygenetics of neurodevelopmental disorders 
Even in instances of monogenic cases of ASD which are inherited in a mendelian fashion, such 
as tuberous sclerosis complex (TSC), there is significant phenotypic heterogeneity. For 
instance, TSC is associated with abnormal DTI (diffusion tensor imaging) findings on MRI, but 
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no one region has been consistently identified as being affected across studies 653,654 
suggesting the involvement of other genetic and/or environmental factors 655. 
As discussed previously, a small proportion of neurodevelopmental disorders are caused by 
a single genetic alteration with a large effect size 656. However, it is now clear that a large 
proportion of neurodevelopmental disorders are characterised by genetic effects with many 
small effect sizes 34. Moreover, most of the heritability of ASD 657 and schizophrenia 658 is due 
to common genetic variation rather than specific mutations, copy number variants or other 
genetic events. Understanding how this normal genetic variation can lead to 
neurodevelopmental disorders is central to understanding their aetiology. 
Normal genetic variation can also contribute to variation in DNA methylation and large scale 
chromatin architecture 659,660, which as discussed previously are changed in many 
neurodevelopmental disorders. However, the effects of other processes such as further 
cytosine modifications, RNA dynamics such as alternative splicing, RNA processing, 
methylation and degradation also need to be assessed. To characterise these features, large 
collaborative efforts such as the PscyhENCODE consortium are required, but it also requires 
a mechanistic understanding of how the environment interacts with these processes. This is 
only currently possible using experimental models whose biochemical and physiological 
processes can be more thoroughly interrogated. 
In most instances the mechanisms by which genetic variation associates with atypical 
development are not fully understood. Previous studies have shown an enrichment for 
hypoxia and vascular related genes among genetic risk factors for schizophrenia 56. Therefore, 
the risk carried by these alleles could potentially be mediated through perinatal exposure to 
hypoxia. Similarly, early life stress has been shown to interact with risk loci for schizophrenia 
and major depressive disorder 530. Polygenic risk may therefore interact with various 
perinatal insults to affect neurodevelopmental trajectories. 
Moreover ASD, schizophrenia, ADHD bi-polar and major depressive disorder share a 
substantial overlap in SNPs 661, and a cross disorder (ADHD, anorexia, affective disorders, 
ASD, bipolar disorder and schizophrenia) GWAS from the iPSYCH study showed several 
significant associations 662, indicating a shared genetic aetiology among neurodevelopmental 
disorders. Therefore, identical environmental exposures may interact with distinct 
polygenetic compositions to result in divergent neurodevelopmental trajectories. 
178 
 
Several neurodevelopmental disorders are associated with altered synaptic characteristics 
663,664. The investigation of early life events which can result in alterations involving synapse 
associated loci, such as my findings of DNA methylation alterations at synapse associated 
genes following MMS, may therefore provide mechanistic insight into this association. This 
may ultimately be useful for the therapeutic facilitation of optimal brain development in the 
neonatal period. 
Even though genetics can explain an increasingly large portion of neurodevelopmental 
disorders, the environment undoubtably also plays a crucial role. Therefore, studies which 
investigate the effect of insults associated with PTB on gene expression and DNA 
methylation, as carried out in this thesis, can contribute to the wider integration of data from 
genetic/epigenetic studies in humans or animal models in an attempt to better understand 
human neurodevelopmental outcomes.  
6.3 Assessment of models used in this thesis 
6.3.1 In vitro models 
In this thesis I use both in vitro and in vivo models to assess the impact of various insults 
associated with PTB on brain development. In vitro models included primary cell culture and 
forebrain organotypic slice cultures. I have previously discussed the practical limitations of 
these models and have recommend they be used in the future to investigate specific 
mechanisms which have been identified through in vivo experimentation. These systems are 
also conducive to a first line screening tool for therapeutics. For instance, the organotypic 
slice culture system would be a good model to investigate the efficacy of SAFit1, SAFit2 and 
CBR1 agonists (which I previously suggested as good candidates to target MMS related 
effects) in response to either Dexamethasone (to induce GR activation) or glutamate (to 
activate hypothalamic neurons), before larger in vivo studies.  
Alternatively therapeutic efficacy could be evaluated in human iPSCs or organoids, however 
as discussed earlier these models are prohibitively expensive to scale up and are associated 
with large heterogeneity, but recent protocols describe more homogenous organoid 
generation 665. 
6.3.1.1 LPS alternatives 
The TLR family is the most well studied family of pathogen recognition receptors (PRR) and 
consists of over 13 characterised members 639, of which many are expressed in the forebrain 
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through development 640. LPS specifically activates TLR4 and as such the experiments 
outlined here fail to account for the dynamic TLR (and wider PRR) activation associated with 
clinical neonatal inflammation 611. 
Poly I:C is a TLR3 agonist and is commonly given to pregnant dams between E14-E18 to model 
viral infection during pregnancy. LPS was used here and it activates canonical NFkB signalling 
through the intracellular MyD88 domain of TLR4. However, TLR3 does not have an 
intracellular MyD88 domain, due to its cytoplasmic localisation, but can activate NFkB 
signalling through the TRIF pathway. As such the NFkB activation dynamics associated with 
TLR3 signalling are different to that of TLR4 signalling 639 and it would be interesting in the 
future to examine the effect of TLR3 stimulation, with Poly I:C, on NFkB signalling before 
and/or during MMS. 
 
6.3.2 Stress associated with PTB in humans 
The ultimate goal of this research is to identify mechanisms which can be targeted during the 
neonatal period to mitigate any adverse effects of stress on brain development. However, 
for now there are many obstacles in this path. First and foremost, to my knowledge there is 
no conclusive human evidence to suggest perinatal stress in preterm infants results in 
atypical brain development. There are a number of reasons why these are difficult 
experiments to carry out. Firstly, there is no logical control group for comparison. Infants 
which will be born at term remain in utero during the time which preterm infants experience 
stress associated with the NICU, which precludes biological sampling. A within subject study 
would, therefore, be needed to identify stress and associate it with neurodevelopmental 
outcome. This design necessitates a biomarker which is responsive to stress. Cortisol only 
begins circadian secretion by 2 months of age 293 but at this point it is responsive to stress 602. 
However, the use of cortisol would require sampling before and after an event such to 
determine associated stress. Aside from the ethical and practical considerations associated 
with frequent blood sampling, the procedure itself would induce stress and thereby render 
the “before” value redundant. Salivary α-amylase has been used as a stress responsive 
biomarker and could be measured non-invasively, but studies suggest stress responsiveness 
in this enzyme only initiates at 2 months 602. Heart rate variation is likely the best candidate 
as it can be measured non-invasively for long periods and is decreased with the use of 
kangaroo care 603. However, this is also a measure of general health and thereby susceptible 
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to the other confounders associated with the use of “painful procedures” as a method to 
quantify stress 604.  
 
6.3.3 Future behavioural tests 
Future work should expand on these behavioural studies outlined here. As mentioned 
previously the EPM and the OF constitute novel stressful environments. It is important to 
understand if this abnormal behaviour is also relevant in novel social or intellectual 
environments. For instance a 3 chamber social approach assay, previously validated for 
abnormal sociability associated with atypical neurodevelopment by Reed et al, 2019 600. A 
test of learning or working memory in a stressful environment such as the Barnes maze would 
also be particularly insightful considering the gene expression changes I show in the 
hippocampus at 4 months of age (see Figure 4.26). 
 
6.4 Epigenetics in PTB related insults 
Throughout this thesis I examined the role of cytosine modifications in response to 
environmental perturbations. However, the importance of these changes is difficult to 
assess. DNA methylation is crucial to brain development; deletion of DNMT1 results in an 
almost 90% loss of DNA methylation and is embryonically lethal in mice669 and DNMT1 is 
comparably important in humans 670. DNA methylation is also crucial for key 
neurodevelopmental processes such as neurogenesis 671, gliogenesis 672 and myelination 673. 
Considering this in combination with the energetic requirements for the generation and 
maintenance of differential methylation 674, it is highly likely the differential methylation seen 
following MMS represents an important component of the response.  
A key aspect to understanding the role of DNA methylation in the pathogenesis of perinatal 
brain injury is to first understand the role of DNA methylation in normal brain development. 
In recent years, many DNA methylation maps of healthy human and mouse brain tissue, of 
various ages, have been generated 110,204,675,676. These are crucial to the fundamental 
understanding of cytosine modifications in the brain, however, more neonatal timepoints are 
needed. Also, many of these maps depict only bulk tissue DNA methylation patterns and not 
within cell lineages. As discussed previously, the technologies for single cell epigenetic 
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analysis are emerging and their use will be central to our future understanding of DNA 
methylation in typical and atypical brain development. 
Currently some therapies which target DNA methylation are used to treat some forms of 
cancer but these are usually associated with many off target effects and are not typically 
front line treatments 677. When the importance of DNA methylation to a range of brain 
processes 671–673 is also considered, it is highly unlikely that DNA methylation is a clinically 
viable target during development. However, the inhibition of DNA methylation using 5-
Azacytidine (intercalates with DNA to inhibit methylation) 678, Procainamide (DNMT1 
inhibitor) 679 or 3-nitroflavones (DNMT3a inhibitor) 680 could provide valuable mechanistic 
insight into the role of DNA methylation following MMS. This could also be achieved through 
genetic means by the conditional deletion of DNMT1 and/ or DNMT3a using Cre-Lox 
recombination in specific cell types or local deletion in the hypothalamus using the injection 
of viral vectors prior to MMS. These methods would allow for the non-specific modulation of 
DNA methylation and thereby allow for inference about the importance of DNA methylation 
in the behavioural effects seen following MMS. 
It is unlikely that changes in DNA methylation occur in isolation, previous work has described 
a close relationship between DNA methylation and chromatin architecture 681 and huge 
efforts to map genome wide epigenetic data in cells such as ENCODE have demonstrated the 
co-localisation of many epigenetic marks 682,683. Moreover, proteins such as MeCP2 can affect 
DNA methylation and chromatin architecture co-operatively 684,685. Future work should focus 
on comprehensively assessing the effect of MMS on the wider epigenetic landscape.   
6.5 Single cell level investigations 
For a more comprehensive understanding of cellular proportions and cell specific 
transcriptomic information, single cell sequencing following MMS could be performed. This 
would also provide information on transcriptional alterations in specific neuronal 
populations, perhaps indicating particular circuits involved in MMS.  
Techniques to analyse DNA methylation at the single cell level are still relatively novel. 
Techniques which use bisulphite conversion followed by sequencing at the single cell level 
have been associated with DNA degradation problems, as well as having prohibitive costs 
due to the depth required for accuracy. Also many non-bisulphite based methods cannot 
assess genome wide methylation 586.  
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Techniques are also emerging for the combined single cell assessment of the transcriptome, 
chromatin accessibility and DNA methylome in a single sample, but these techniques require 
the generation of a large reference data set for accurate cell lineage mapping 587. These large 
datasets are not available for neonatal tissue yet but offer a promising future strategy. 
 
6.6 Conclusions 
Throughout this thesis I have examined how insults associated with PTB affect neonatal 
mouse brain development. Understanding how these processes are involved in atypical 
neurodevelopment is central to better understanding and managing neurodevelopmental 
disorders. The results presented here contribute to the wider body of literature concerning 
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